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  ABSTRACT 
 
 
 
ABSTRACT  
 
 CLL is an incurable B-cell malignancy associated with profound tumour cell-mediated 
immune dysfunction. It therefore represents a challenging disease for the successful 
application of immunotherapeutic strategies aimed at promoting anti-tumour T-cell 
responses. In this study, extensive immunophenotypic analysis of T-cells from the blood of 
CLL patients was performed, in order to better characterise their dysfunctional status within 
the disease. Analysis of CLL patient blood samples revealed a skewing of T-cells towards a 
highly differentiated effector memory phenotype as well as the expression of markers 
associated with exhaustion/senescence (CD28
-
 and CD57
+
) and immunosuppressive 
molecules (PD-1 and CD200). In addition this study revealed the expansion of CD8
+
 T-cells 
in a subset of CLL patients leading to an inversion in the normal CD4:CD8 ratio. The 
presence of an inverted CD4:CD8 ratio was subsequently shown to be associated with a 
shorter time to first treatment and reduced progression-free survival.   
 Characterisation of T-cells identified several molecules that could be targeted 
therapeutically in order to break T-cell tolerance in CLL patients and potentially restore 
normal immune responses. Investigation of the immunosuppressive molecules PD-1 and 
CD200 showed that they are over expressed in CLL patients, suggesting that they may be 
involved in maintaining T-cell tolerance in the disease. However, blockade of PD-1-PDL-1 
and CD200-CD200R signalling pathways failed to enhance T-cell responses from CLL 
patients in vitro. Investigation of an alternative approach to enhance T-cell responses in CLL 
involved the use of a bi-specific antibody targeting CD19 and CD3 called blinatumomab. In 
vitro testing showed that blinatumomab can induce T-cell activation, promoting the release of 
pro-inflammatory cytokines and granzyme B secretion from both CD4
+
 and CD8
+
 T-cells. In 
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addition, blinatumomab was shown to mediate T-cell dependent killing of CLL cells 
requiring the formation of T-cell:CLL cell conjugates. 
  Finally this study provided clear evidence that blinatumomab can break T-cell 
tolerance in CLL and strongly advocates the progression of blinatumomab into clinical trials 
as a novel therapeutic agent in CLL. 
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CHAPTER 1 
Introduction 
 
1.1 Chronic lymphocytic leukaemia 
 Chronic lymphocytic leukaemia (CLL) is the most diagnosed leukaemia in the western 
world representing 30% of all leukaemias in Caucasians (Shvidel et al. 1999). It is 
characterised by the clonal expansion of CD5
+
CD19
+
CD23
+
 B-cells that progressively 
accumulate in the peripheral blood, bone marrow and secondary lymphoid tissues. CLL is a 
remarkably heterogeneous disease where patients who display an indolent disease may live 
for over 30 years post diagnosis, whereas those patients that present with aggressive disease 
may die within 2-3 yrs despite aggressive therapy (Allendorf and Davis 2011, Zenz et al. 
2010). Although standard chemoimmunotherapy has proven success in reducing the tumour 
burden in CLL patients, it does not result in long-term disease-free survival. At present there 
are no curative therapies for CLL, with the possible exception of allogeneic haematopoietic 
stem cell transplantation (allo-HSCT), but this treatment is unsuitable for the vast majority of 
CLL patients (Dreger 2009). Given this backdrop, there is now a surge to better understand 
the pathogenic mechanisms behind this disease with the aim of developing new, widely 
applicable, therapeutic approaches to improve the survival of patients. 
 
1.1.1 Aetiology and Epidemiology 
 CLL is considered to be a disease of the elderly with a median age at diagnosis of 72 
years. Less than 2% of patients are younger than 45, 9.1% between 45 and 54, 19.3% 
between 55 and 64, 26.5% between 65 and 74 and 42.3% greater than 75 (Gribben 2010). 
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Although the frequency of CLL detection has increased since the 1950s, CLL rates are 
thought to be relatively stable with worldwide projection rates ranging from <1 to 5 per 
100,000 people (Redaelli et al. 2004).  
  CLL occurs at higher rates in males than in females with nearly twice as many males 
diagnosed with the disease (Redaelli et al. 2004). Geographic incidence varies widely with 
the highest rates reported in Caucasians and reduced incidences in African and Asian 
populations; incidence rates are 25% and 77% lower in black and Asian/pacific islander 
populations respectively when compared to Caucasians (Dores et al. 2007).  Interestingly 
these lower incidences of CLL were maintained in US Asian populations suggesting racial/ 
hereditary factors in the occurrence of the disease (Groves, Linet and Devesa 1995).  
  Although the first description of CLL was made over 150 years ago, the aetiology of 
CLL remains unknown.  Several environmental determinants including agricultural chemicals 
as well as viruses e.g. Human T-lymphotrophic virus (HTLV), Epstein-Barr virus (EBV) and 
Cytomegalovirus (CMV) have been proposed as causative agents but no direct links have 
been made (Lanasa 2010). By far the most important risk factor for the development of CLL 
is a familial history with between 8 and 10% of newly diagnosed CLL cases having an 
inherited link (Sellick et al. 2007). 
 
1.1.2 CLL pathogenesis 
 CLL is a lymphoproliferative disease with as much as 1% of the entire CLL clone 
turning over each day (Messmer et al. 2005). The expansion and survival of these cells in 
vivo is thought to be influenced by several factors including the presence of cytogenetic 
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abnormalities, microenvironmental signals and tumour immune evasion mechanisms 
(Dighiero 2005). 
 
1.1.3 Genetic aberrations  
 Analysis of the whole CLL population using sensitive cytogenetic techniques such as 
fluorescence in situ hybridisation (FISH), has shown that up to 80% of individuals with CLL 
have cells with 1 or more genetic aberration (Döhner et al. 2000). Five categories of genetic 
aberrations have been defined in CLL patients: a deletion in 13q (55%), a deletion in 11q 
(18%), trisomy of 12q (16%), a deletion in 17p (7%) and a deletion in 6q (6%). 17p deletions 
or deletion 11q22-q23 were shown to be independent prognostic markers, with patients 
carrying these genetic aberrations having rapid disease progression and shorter survival times 
(Döhner et al. 2000). The vast majority of patients with 17p deletions were subsequently 
shown to have a mutation in the p53 gene, with predicted resistance to treatment with 
alkylating agents and a short median treatment-free interval of 9 months (Stilgenbauer et al. 
2002). Patients with deletions of 11q22-q23 commonly have a mutation in the ataxia 
telangiectasia mutated (ATM) gene, which is also associated with the autosomal recessive 
disorder ataxia telangiectasia (A-T). Individuals with this disease have a predisposition to 
cancer including hypersensitivity to ionizing radiation, genomic instability and disruption of 
cell cycle checkpoints (Lavin and Shiloh 1997). Candidate genes responsible for the 
pathogenesis of other genetic aberrations in CLL are yet to be determined.  
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1.1.4 IGHV mutational status 
   During B-cell responses to antigen, B-cells readily undergo proliferation in germinal 
centres followed by a phase of somatic hypermutation whereby mutations are introduced into 
the immunoglobulin variable region genes (Liu et al. 2008). B-cells then enter a phase of 
affinity maturation where B-cells with high affinity for the specified antigen are selected for 
survival. In CLL two subsets of patients exist, those with mutated and those with unmutated 
immunoglobulin variable region genes. Variable region gene sequences with less than 98% 
homology to germline are considered to have undergone somatic hypermutation and therefore 
considered mutated (Gribben 2010). The incidence of unmutated IGHV genes can vary 
between 20-50% depending on the patients’ chromosomal abnormalities and  has been 
subsequently shown to have prognostic significance (Oscier et al. 1997). The median survival 
time of stage A patients with mutated IGHV genes was 3 times longer than that of the 
corresponding patient group with unmutated IGHV genes (Hamblin et al. 1999). Interestingly 
a higher incidence of mutated IGHV genes was found in familial CLL cases than sporadic 
cases (Houlston, Catovsky and Yuille 2002). 
   Generally the IGHV genes expressed by B-cell leukaemias do not tend to develop 
additional somatic mutations over time. The presence of two groups of CLL patients based on 
mutated or unmutated IGHV genes was therefore thought to represent two subtypes of CLL 
with different cytogenetics and different maturation states (Schettino et al. 1998). CLL cells 
with unmutated IGHV regions were considered to be derived from a pre-germinal centre 
naїve B-cell and those with mutated IGHV regions from an antigen experienced post-
germinal central memory cell (Kröber et al. 2002).  
 However, gene expression profiling using micro-array technology has cast doubt on 
these findings showing that all CLL cells display a common and characteristic gene 
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expression profile that is largely independent of IGHV mutational status. Comparison of CLL 
gene expression profiles with those from healthy B-cells points to CLL cells being more 
related to memory B-cells than naїve B-cells (Klein et al. 2001). Moreover recent 
transcriptome analyses of CLL cells has indicated that they are derived from a normal 
CD19
+
CD5
+
 B-cell counterpart (Seifert et al. 2012).     
 CLL cells use a biased repertoire of V genes with the most frequently used rearranged 
genes being VH1-69, VH4-34, VH3-21 and VH3-7 (Mauerer et al. 2005). VH1-69 was found 
exclusively in unmutated CLL representing the most frequently detected IGHV gene in this 
group (25%). The VH3-21 gene was mainly used in the mutated (87%) compared to the 
unmutated (13%) group. The use of the VH3-21 gene was subsequently shown to be 
associated with poor prognosis regardless of mutational status (Tobin et al. 2002).  
 
1.1.5 Antigenic stimulation  
 The role of antigenic stimulation in the pathogenesis of CLL has been widely debated 
with no candidate antigen as yet identified. The presence of mutated IGHV genes in a subset 
of CLL patients suggests that the CLL cell B-cell receptor (BCR) is functional and able to 
recognize antigen. Antibody gene sequencing has shown that CLL patients have a restricted 
use of IGHV genes (VH, D and JH) with a bias in antibody repertoires found in these 
leukaemic expansions. In patients with mutated IGHV genes, approximately 20% of the 
mutated IGHV genes display replacement mutations in a pattern indicating antigen 
recognition (Fais et al. 1998). 30% of CLL patients carry quasi-identical (stereotyped) 
receptors with 1% of CLL patients identified expressing virtually identical Immunoglobulin 
(Ig) (Darzentas et al. 2010). The likelihood of two CLL cells carrying identical BCRs is 
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extremely remote (10
-9
-10
-12
) suggesting that CLL B-cell development and progression may 
by driven by a common antigen.  
     Proteins derived from infectious pathogens including EBV and CMV as well as self-
proteins, have all been put forward as potential antigens capable of stimulating CLL cells. An 
auto-antigen non muscle myosin chain IIA (MYHIIA) found on apoptotic cells was shown to 
be capable of binding CLL monoclonal antibodies (Stamatopoulos 2010). More recently 
CMV and EBV infection has been linked with CLL cases expressing the VH4-34 and CLL 
recombinant antibodies encoded by IGHV 1-69 or IGVH 3-21 have been shown to react with 
a phosphoprotein pUL32 derived from CMV (Kostareli et al. 2009, Steininger et al. 2012). 
 
1.1.6 The lymph node microenvironment  
 CLL cells recovered from the blood of CLL patients and cultured in vitro, rapidly 
undergo spontaneous apoptosis, yet in the body they have the ability to proliferate and resist 
apoptosis (Collins et al. 1989). In vivo, CLL cells preferentially localise to the lymph nodes 
and bone marrow, where microenvironmental niches aid their survival and proliferation 
(Figure 1.1). CLL cells possess a variety of surface adhesion molecules including selectins, 
integrins and immunoglobulin which facilitate interactions between CLL cells, accessory 
cells and the extracellular matrix (ECM). These interactions ultimately promote the 
migration, localisation and survival of CLL cells at these sites (Vincent, Cawley and Burthem 
1996).          
   Accessory cells present in lymphoid compartments are thought to play an important 
role in maintaining the CLL clone (Buggins et al. 2010). Bone marrow-derived endothelial 
cells (BMECs) and follicular dendritic cells (FDC) provide pro-survival signals to CLL cells 
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(Jewell and Yong 1997). The peripheral blood of CLL patients also contains cells capable of 
differentiating into nurse-like cells (NLC) in vitro that protect CLL cells from apoptosis 
(Burger et al. 2000). T-lymphocyte numbers are also elevated in CLL patients with evidence 
of extensive T-cell expansions in patients with poor prognostic markers (Röth et al. 2008). 
Furthermore, CD4
+
 T-cells were shown to be essential for the proliferation and engraftment 
of CLL cells in mouse models (Bagnara et al. 2011) with activated CD4
+
 T-cells also shown 
to co- localise with proliferating CLL cells in lymph node (LN) pseudofollicles (Patten et al. 
2008). Activation of CD4
+
 T-cells induces the upregulation of CD40L, which delivers 
activation signals to CLL cells by binding CD40 present on the CLL cell surface. T-cell 
derived cytokines including IL-4, IFN-γ and TNF-α have also been shown to inhibit CLL 
apoptosis in vitro (Tangye and Raison 1997).  
 
1.1.7 Symptoms and diagnosis of CLL 
 The presence of small monomorphic B-lymphocytes expressing CD19, CD5 and CD23 
in the peripheral blood, bone marrow or lymph nodes is used to diagnose CLL with positive 
samples requiring the presence of at least 5000 B-cells per µl (Gribben 2010). Most patients 
present with few symptoms at diagnosis but these increase during disease progression. The 
progression of disease is marked by an acceleration in lymphocyte doubling times, leading to 
the accumulation of leukaemic cells and the development of lymphadenopathy, splenomegaly 
and heptamegaly (Hallek and Group 2005). In a small minority of patients autoreactive 
antibodies to blood components have been shown to develop, which can result in anaemia 
and thrombocytopenia. Other symptoms of CLL include unintentional weight loss, fever, 
night sweats, extreme fatigue and infections (Binet et al. 1981). Infections remain a major 
issue in CLL patients, primarily due to immune dysfunction induced by the tumour and 
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therapy related immunosuppression. Patients are at risk of developing infections caused by 
bacterial pathogens such as streptococcus or staphylococcus, fungal pathogens such as 
candida and aspergillus, and viruses such as herpes viruses (Morrison 2007).  
 
 
Figure 1.1 The CLL tumour microenvironment (Fecteau and Kipps 2012). Accessory 
cells within the tumour microenvironment provide signals in the form of chemokines, 
cytokines and receptor-ligand interactions to CLL cells. These interactions are crucial in 
supporting CLL cell survival and proliferation.  
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1.1.8 Staging and prognostic markers in CLL patients 
 The standard system for estimating prognosis in CLL is the clinical staging systems 
developed by Binet (Binet et al. 1981) and Rai (Rai et al. 1975). These systems are used to 
define early (Binet stage A, Rai 0), intermediate (Binet stage B, Rai 1 and 2) and advanced 
(Binet stage C, Rai 3 and 4) disease. At the time of diagnosis patients are 25% stage 0, 50% 
stage 1 to 2 and 25% stage 3 or 4 (Gribben 2010). Although these staging systems assess risk, 
they are unable to predict an individual’s risk of disease progression when diagnosed with 
early stage disease (Herishanu and Polliack 2005). 
 In order to get a clearer prediction of a patient’s clinical course, additional prognostic 
markers can be used. Several prognostic markers have been defined in CLL including 
lymphocyte doubling time (Viñolas et al. 1987), IGHV mutational status, CD38 expression 
(Damle et al. 1999), ZAP-70 expression (Dürig et al. 2003), bone marrow histological pattern 
(Rozman et al. 1984), serum soluble CD23 levels (Sarfati et al. 1996), serum beta-2 
microglobulin (Di Giovanni et al. 1989) and cytogenetic aberrations including 17p deletions 
(Furman 2010). 
 
1.1.9 Treatments 
 Current treatment strategies for CLL include the use of chemotherapeutic agents and 
immunotherapy in the form of monoclonal antibodies. In rare cases radiotherapy or surgery 
are used to debulk or remove tissues with extensive CLL cell infiltration e.g. lymph nodes or 
spleen. The clinical management of CLL patients is usually based on the ‘watch and wait’ 
approach, whereby treatment is only administered upon the development of symptoms 
(Gribben 2010). 
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1.1.9.1Chemotherapy 
Alkylating agents 
 Chlorambucil and cyclophosphamide are the most widely used alkylating agents in 
CLL. The precise mode of action through which these drugs work remains unclear. 
Chlorambucil is however capable of binding to several cellular structures including 
membranes, proteins, RNA and DNA with DNA cross-linking thought to be the most 
important factor for its anti-leukaemic activity (Begleiter et al. 1996). Clinical trials of 
chlorambucil, administered with or without prednisone, showed initial response rates of 
between 60% and 70% but no significant complete responses (Byrd, Stilgenbauer and Flinn 
2004). Furthermore, chlorambucil did not prolong the survival of stage A CLL patients 
(Dighiero et al. 1998). When the clinical effect of chlorambucil was assessed against 
cyclophosphamide there was no significant difference in overall survival, complete response 
rates or duration of responses (Raphael et al. 1991). 
 
Purine analogues 
 Several purine anologues are currently used as treatments in CLL including 
fludarabine, cladribine and pentostatin. The incorporation of nucleotide phosphates from 
these compounds into the DNA of proliferating tumour cells induces cell death by apoptosis 
(Johnson and Thomas 2000). Fludarabine has been shown to inhibit enzymes involved in 
DNA synthesis including, DNA polymerase, DNA primase and DNA ligase. The enzyme 
ribonuclease, responsible for maintaining the cellular deoxynucleotide pool is also inhibited 
which increases the likelihood of fludarabine phosphate being incorporated into cellular DNA 
(Parker et al. 1988). Separate studies have shown that fludarabine and cladribine used as 
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single agents had similar clinical activity in CLL, whilst pentostatin showed less activity in 
this disease (Ricci et al. 2009). Several studies have also evaluated the effect of fludarabine in 
comparison to alkylator-based regimes in CLL. Patients treated with fludarabine had 
significantly higher complete response rates than alkylator-based chemotherapy (Zhu et al. 
2004). 
 
1.1.9.2 Monoclonal antibody therapy 
 Despite encouraging response rates with chemotherapy there are still several challenges 
to treating CLL patients. Chemotherapy alone has not led to an improvement in overall 
survival in CLL patients. The introduction of the monoclonal antibodies (mAbs) has 
revolutionised the treatment of CLL as well as other human malignancies (Held, Schubert 
and Pfreundschuh 2008). Rituximab and alemtuzumab are mAbs that target antigens on the 
surface of the CLL cells, inducing apoptosis through mechanisms including antibody directed 
cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). mAbs are 
considered to have lower toxicity than chemotherapeutics, probably due to the targeted nature 
of the antibodies which avoids damage to healthy tissue (Adams and Weiner 2005). 
Rituximab is a chimeric murine-derived mAb, capable of highly specific associations with its 
target antigen CD20. Although expressed weakly, CD20 can be found on virtually all CLL 
cells. Clinical trials using rituximab as a single agent showed higher response rates in 
untreated patients compared to relapsed or refractory patients. Furthermore, complete 
response rates remained low at 9% (Hainsworth et al. 2003).  
   Alemtuzumab is an antibody directed against CD52 found on a variety of 
haematopoietic cells including monocytes, macrophages, a small subset of granulocytes as 
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well as normal and malignant T- and B-lymphocytes (Fraser et al. 2007). The ubiquitous 
expression of CD52 means alemtuzumab usage is associated with increased toxicity when 
compared with other monoclonal antibodies such as rituximab. Common side effects include 
neutropenia, lymphopenia and infectious complications e.g CMV reactivation (Christian and 
Lin 2008). Clinical trials with alemtuzumab showed an overall response rate of 33% in 
fludarabine-refractory CLL patients and a 40% clinical response rate in patients with p53 
mutations and deletions (Keating et al. 2002). These studies suggest that alemtuzumab may 
be effective in subgroups of CLL patients with high-risk cytogenetic markers and may induce 
CLL cell death through a p53-independent mechanism. Alemtuzumab is now approved for 
the treatment of fludarabine refractory CLL patients (Montillo et al. 2008). 
 Novel antibodies that are currently in development for CLL include two anti-CD20 
antibodies, GA101 and ofatumumab which have shown improved efficacy when compared to 
rituximab (Robak 2008). In addition antibodies designed to block CLL cell migration to 
secondary lymphoid organs; which is necessary for CLL cell survival and proliferation are 
now being tested. These include natalizumab which targets the alpha 4 integrin CD49d and 
plerixafor which blocks the chemokine receptor CXCR4 (Burger et al. 2009).  
 
1.1.9.3 Combination therapies in CLL 
 Currently most patients receive intermittent treatment with periods of stable and 
progressive disease, however very little is known about when to start treatment or what 
combinations of drugs result in the best clinical outcome. Combining monoclonal antibodies 
with chemotherapy has been actively investigated, with the aim of improving treatment of 
CLL patients. Several studies have investigated the synergistic effect of fludarabine with 
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monoclonal antibodies including rituximab and alemtuzumab, with both found to have a 
synergistic effect with fludarabine in killing CLL cells (Di Gaetano et al. 2001). A recent 
study has also shown that the combination of fludarabine, cyclophosphamide and rituximab 
(FCR), induced an overall response rate of 74% in relapsed CLL patients including those 
with chromosome 17 abnormalities (Badoux et al. 2011). Furthermore a recent clinical trial 
showed that FCR treatment increased progression-free survival (PFS) and overall survival 
(OS) in symptomatic patients (Molica 2011). Currently FCR is regarded as the ‘gold 
standard’ for CLL treatment, but with new studies combining current therapeutic drugs as 
well as the advent of new novel therapies, future changes to the way CLL patients are treated 
seems inevitable.   
 Novel therapeutic agents in development include monoclonal antibodies as mentioned 
previously as well as BCR signalling antagonists including Bruton’s tyrosine kinase (BTK) 
inhibitors and PI3 kinase inhibitors. Both have shown promising and ongoing clinical 
responses in early phase І/ІІ clinical trials in CLL and have shown efficacy even in ‘high risk’ 
CLL patients (Woyach, Johnson and Byrd 2012). Blockade of BCR signalling may prevent 
upregulation of anti-apoptotic proteins such as BCL-2 necessary for CLL cell survival in vivo 
as well as interfering with signalling through chemokine receptors such as CXCR4 (Burger 
2011). Future clinical trials will help to establish whether remissions with such therapies can 
be maintained long-term of whether resistance mechanisms will develop. 
 
1.1.9.4 Stem cell transplantation 
 Haematopoietic stem cell transplantation (HSCT) is not a suitable treatment option for 
most CLL patients, in particular the frail and elderly due to the high treatment related 
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morbidity and mortality (Gribben 2009). It does however remain a potential treatment for 
high-risk CLL patients who are younger and likely to die from their disease (Mauro et al. 
1999). High-risk patients are defined as those with p53 mutations, purine analogue 
refractoriness or have early relapse after purine analogue combination therapy. There are two 
types of stem cell transplant available autologous (auto-SCT) and allogeneic (allo-SCT). 
Auto-SCT requires the infusion of haematopoietic stem cells derived from the patient’s blood 
or bone marrow, with the cytotoxicity seen in patients thought to be due to the accompanying 
high-dose chemotherapeutic regimen (Böttcher, Ritgen and Dreger 2011). Allo-SCT involves 
the transfer of stem cells from an HLA-matched donor and relies on an immune-mediated 
anti-host response or graft versus leukaemia (GVL) effect to kill CLL cells (Dreger and 
Montserrat 2002). Although allo-SCT is characterised by high treatment-related mortality 
compared to auto-SCT, it does have some significant advantages. Unlike auto-SCT, allo-SCT 
can overcome poor prognostic markers (e.g. p53 mutations) and has a lower incidence of 
relapse, with survival curves plateauing in the long-term suggesting a potential curative effect 
(Esteve et al. 2002). A recent study also showed that there was no difference in overall 
survival between patients receiving auto-SCT as first-line therapy compared to chemotherapy 
(Sutton et al. 2011). Further work is needed to try and identify prognostic markers that 
identify patients at sufficiently high risk as to warrant the use of allo-SCT, and to investigate 
the use of reduced intensity conditioning (RIC) allo-SCT in patients with poor performance 
status (Gribben 2009).  
 
1.1.9.5 The clinical efficacy of therapeutic treatments in CLL  
 In the past decade significant improvements in the way clinicians treat CLL has led to 
increased response rates and durations of responses in patients. This has included clinical 
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trials looking at the effects of combination drug treatments, at when to start treatment and at 
which patient groups are likely to benefit for such treatments (Byrd et al. 2004). Despite this 
CLL remains a largely incurable disease for the majority of patients, where almost 70% of 
CLL patients will die from causes related to CLL, with older patients (>80 years) nearly 
twice as likely to die than those between 40 and 59 (Diehl, Karnell and Menck 1999). The 
future development of novel agents to treat CLL is therefore warranted. 
   
1.2 The immune system 
 The immune systems’ central role is to protect the body from invasion by infectious 
pathogens. It is made-up of two separate arms, innate immunity and adaptive immunity. 
Innate immunity provides a rapid, non-specific, response to infection by pathogens that does 
not result in immunological memory. Alternatively, adaptive immunity is initiated in 
instances where the innate immune system is unable to resolve infection, resulting in the 
expansion of pathogen-specific effector cells. After pathogen clearance, a subset of these 
effector cells will persist in the body capable of responding to pathogen re-challenge 
(Janeway et al. 2008). 
 
1.2.1 Innate Immunity 
 The innate immune system is an evolutionary ancient part of the host defence system, 
which is made up of several components including anatomical barriers, secreted molecules 
and effector cells. Initial infection is prevented by the skin epithelium that provides a physical 
barrier to infectious agents. This barrier is aided by mucus and cilia found in such areas as the 
respiratory and gastrointestinal tract, which helps to trap and remove pathogens before they 
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cause damage. Furthermore secreted factors found in sweat, saliva and tears including 
lysozyme, phospholipase and defensins also have antimicrobial activity (Janeway et al. 
2008). 
      Once a pathogen penetrates into the tissues, humoral factors play an essential role in 
inducing acute inflammation characterised by oedema and the recruitment of innate immune 
effector cells. Components of the coagulation and complement systems aid the removal of the 
pathogen by increasing vascular permeability and attracting phagocytic cells to the site of 
infection. Activated complement can also lysis bacteria directly or facilitate opsonisation of 
antibody-bound pathogens by phagocytic cells.  
    Whereas the adaptive immune response relies on receptors encoded by rearranged gene 
segments, innate immune cells use germ-line encoded receptors capable of recognising 
molecular structures essential for microbe survival (Janeway 1989). These molecular 
structures or pattern-associated molecular patterns (PAMPs) are conserved by a number of 
pathogens e.g. Lipid A of Lipopolysaccharide (LPS) and are recognised by receptors termed 
pattern recognition receptors (PRRs) (Janeway and Medzhitov 2002). Several PRRs have 
been identified including mannose receptors (bacterial and viral carbohydrate), scavenger 
receptors (anionic polymers and acetylated low-density lipoproteins) and Toll-like receptors 
(various bacterial and viral components). Binding of infectious agents via PRRs can result in 
phagocytosis and the release of pro-inflammatory cytokines including IL-1, TNF-α and IL-6 
by phagocytes (Janeway et al. 2008). 
     Innate immune cells include natural killer (NK) cells, eosinophils, mast cells, 
neutrophils, macrophages and dendritic cells. These cells can differentiate into short-lived 
effector cells in response to inflammation and usually clear the infection without the need for 
an adaptive immune response (Medzhitov and Janeway 1997). Macrophages are mononuclear 
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phagocytes that mature from monocytes in the blood before moving to the tissues. They are 
the first cell to encounter antigen, after which short-lived neutrophils are recruited from the 
blood to the site of infection. Both cell types are important phagocytic cells able to recognise, 
ingest and destroy pathogens.  
      NK cells play an important role in the detection of stressed, infected or malignant cells. 
NK cells receive signals through surface activating receptors such as (NKG2D) or inhibitory 
receptors (Killer cell immunoglobulin-like receptors (KIRs), which can bind to Major 
histocompatibility complex (MHC) class I molecules (Pegram et al. 2011). During infection 
the balance of these signals can become disrupted in favour of activation, inducing 
proliferation, IFN-γ production and release of cytotoxic granules from NK cells 
(Lakshmikanth et al. 2009).  
 
1.2.2 Adaptive immunity 
 Unlike the innate immune system, the adaptive immune response requires some time to 
react to antigen, is antigen specific and demonstrates immunological memory, capable of 
rapid responses to subsequent re-challenge with the same antigen. The adaptive immune 
system is composed of two components, antibody-producing B-cells forming the humoral 
component and T-lymphocytes the cell-mediated component. Both T- and B-lymphocytes 
differentiate from a common lymphoid progenitor in the bone marrow with T-cells then 
migrating to the thymus to complete their maturation process. Following maturation, both T- 
and B-cells enter the circulation with functional maturation of B-cells occurring in the 
secondary lymphoid organs (e.g. lymph nodes and spleen) (LeBien and Tedder 2008).   
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1.2.2.1 Humoral responses 
 B-cells are lymphoid cells that are produced in the bone marrow and develop in 
lymphoid tissues such as the LNs and spleen. They are characterised by their expression of 
surface markers including CD19 and CD20. CD19 is expressed on virtually all B-cell lineage 
cells and is a regulator of intercellular signal transduction, whilst CD20 is expressed on 
mature B-cells and functions as a membrane calcium channel. CD5 is found on a subset of 
IgM-secreting B-cells in healthy individuals and has been shown to be highly expressed on 
tumour B-cells in CLL patients (LeBien and Tedder 2008).  
     The protection of extracellular spaces is mediated by B-cell derived antibodies, which 
contribute to the destruction of extracellular pathogens, and prevent the spread of intracellular 
pathogens. Antigens activate B-cells through their engagement with surface BCR causing B- 
cell differentiation into antibody-secreting plasma cells and memory B-cells. The process of 
B-cell activation usually requires additional signals provided by T helper cells in the form of 
CD40-CD40L interactions and cytokines.              
      Antibodies act through multiple mechanisms in order to facilitate the destruction of 
pathogens. They can bind toxins and antigens on the surface of pathogens preventing their 
spread and entry to cells or facilitate opsonisation of the antigen by phagocytic cells 
possessing FC receptors, which are capable of recognizing the antibody C-region. 
Alternatively pathogen-bound antibodies can activate proteins of the complement system 
which can lyse microorganisms directly or facilitate opsonisation of the pathogen by binding 
to complement receptors on phagocytic cells (Janeway et al. 2008).    
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1.2.2.2 Cell mediated immune responses 
 The main cellular subset that mediates adaptive cellular immunity are T-lymphocytes 
which express αβ T-cell receptors (TCRs) on their surface, capable of recognising antigens in 
the form of short peptides presented on the surface of cells. These foreign peptides are 
delivered and presented onto the surface of cells by glycoproteins called major 
histocompatibility complex (MHC) molecules. There are two classes of MHC molecules, 
MHC class I molecules are presented on all nucleated cells whereas MHC class II molecules 
are normally only expressed on antigen presenting cells (APCs).  
 Generally T-cells can be categorised into two groups based upon their surface 
expression of CD4 or CD8. Peptides derived from intracellular pathogens present in the 
cytosol are carried to the cell surface and presented on MHC class I molecules to CD8
+
 T-
cells. Peptide antigens from pathogens that multiply in intracellular vesicles or are ingested 
from an extracellular source are processed and presented to CD4
+
 T-cells on MHC class II 
molecules (Janeway et al. 2008).    
 
Priming T-cell responses 
 Upon activation, professional APCs including macrophages, dendritic cells (DC) and 
B-cells are all capable of activating naїve T-cells to produce armed effector cells. The most 
important APCs for T-cell priming are the DCs that reside in peripheral tissues, which are 
common sites of infection (e.g. skin, mucosal surfaces). In peripheral tissues, DCs are 
constantly sampling the environment, taking up both self and non-self-antigens, degrading 
and processing and presenting them on MHC class I and II molecules (Banchereau et al. 
2000). Upon infection inflammatory cytokines help activate DCs, whilst PAMP recognition 
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by DC surface PRRs induce expression of the co-stimulatory molecules CD80/CD86. 
Activated DCs expressing co-stimulatory (CD80/CD86) and adhesion molecules 
(Intercellular Adhesion Molecule 1(ICAM-1, ICAM-3) and Lymphocyte function-associated 
antigen (LFA-3)) migrate to lymph nodes, where they fully mature into highly effective 
APCs capable of interacting with and activating naїve T-cells (Guermonprez et al. 2002). 
Both macrophages and B-cells can be similarly induced by PRRs on their surface to 
upregulate co-stimulatory molecules and act as APCs. Thus the initiation of an innate 
immune response hastens the movement of APCs to the LNs where they can interact with T-
cells.  
   Upon arrival in the LNs, DCs lose their ability to capture new antigen and distribute 
throughout the cortex in the T-cell areas. Naїve T-cells circulate continuously from the blood 
to the lymphoid organs directed by the chemokine CCL21 (Flanagan et al. 2004), where they 
come into contact with thousands of APCs allowing sampling of MHC:peptide ligands 
(signal 1). The recognition of a specific MHC:peptide by the naїve T-cell TCR is by itself not 
sufficient for T-cell activation. Activation is dependent on a secondary signals (signal 2) 
provided through CD28 ligation on the T-cells to CD80/CD86 on the activated DCs. Naїve 
T-cells that receive both signal 1 and signal 2 then cease to migrate and undergo several 
rounds of expansions before becoming armed effector cells capable of leaving the lymph 
node and migrating to the site of infection (Janeway et al. 2008).    
 
CD4
+
 T-cells 
 CD4
+
 T-cells are a heterogeneous population of cells including effector T-cells 
important in protection against pathogens, and regulatory T-cells (Tregs, TH3, TR1) that 
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protect against autoimmunity (Parish and Liew 1972, Jonuleit and Schmitt 2003). In 1986 
Mosmann et al, identified the existence of two main subsets of effector CD4
+
 T-cells, Th type 
1 (Th1) and Th type 2 (Th2), from which several subgroups including Th0, Th17, Th9 and 
Th22 have been subsequently identified (Mosmann et al. 1986, Jutel et al. 2001). The 
polarisation towards a Th1 or Th2 response was found to be dependent on environmental 
cytokines, with Th1 responses critical for immunity to intracellular microorganisms favoured 
by the presence of IFN-γ and IL-12 and Th2 responses important for immunity to 
extracellular pathogens favoured by IL-4 and IL-25 (Paul and Seder 1994).     
     Th1 cells produce several pro-inflammatory cytokines such as IFN-γ, TNF-α and IL-2. 
Initial production of IL-12 from APCs in response to specific activation signals acts on NK 
cells inducing the production of IFN-γ. In turn IFN-γ acts on CD4+ T-cells inducing the 
expression of IL-12Rβ2 and later IL-18Rα on Th1 cells. This allows Th1 cells to respond 
directly to IL-12, which can synergise with IL-18 to induce IFN-γ production from Th1 cells 
even in the absence of TCR stimulation (Yang et al. 2001). Th1 cells activate macrophages 
enabling destruction of intracellular organisms and on B-cells to promote the production of 
strongly opsonising antibodies (IgG1 and IgG3) (Herbst, Schaible and Schneider 2011). Th2 
cells can produce cytokines such as IL-4, IL-5, IL-9 and IL-13. Th2 cells also aid the 
activation of B-cells promoting IgE class switching in the presence of IL-4 whilst Th2 cell 
derived IL-5 is a major eosinophil-differentiation factor promoting proliferation and survival 
(Zhu and Paul 2008). 
       CD4
+
 T-cells also play a crucial role in the initiation of CD8
+
 T-cell responses. 
Activation of CD4
+
 T-cells induces the upregulation of CD40L, which can bind to CD40 on 
APCs promoting their activation and upregulation of co-stimulatory molecules including 
CD80/CD86. This process facilitates the activation/licensing of DCs allowing them to present 
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already captured antigens to CD8
+ 
T-cells. Activated CD8
+
 T-cells can then synthesise IL-2, 
which acts in an autocrine fashion by binding to surface IL-2R to drive proliferation and 
differentiation. Moreover, the presence of IL-2 during CD8
+
 T-cell priming has been shown 
to be crucial for CD8
+
 memory T-cell development (Williams, Tyznik and Bevan 2006). 
CD4
+
 T-cell are also able to produce their own cytokines such as IL-2 and IFN-γ as well as 
stimulating DCs to produce IL-12 and IL-15. Together these cytokines can promote CD8
+ 
T-
cell proliferation, survival and enhance CTL cytotoxicity (Zhang, Zhang and Zhao 2009b). 
 
Regulatory T-cells 
 Regulatory T-cells (Tregs) play an important role in maintaining peripheral tolerance 
including; prevention of autoimmunity, modulating immune responses to pathogens or 
environmental stimuli, and maintaining immune homeostasis (Sakaguchi et al. 2009). They 
may however have a negative role in preventing immune responses to tumours, with 
increased Tregs cells found in several solid cancers (lung, breast, pancreatic, liver) and 
haematological malignancies (Hodgkin’s lymphoma, CLL) (Beyer and Schultze 2006). 
Subsequent studies have identified correlations between increased Tregs and poor prognosis 
in several cancers (Zhou et al. 2009). Tregs are defined by their expression of surface CD4, 
CD25, CTLA-4, glucocorticoid-induced TNF receptor (GITR) and intracellular expression of 
FOXP3. This transcription factor is essential for the function, maintenance and development 
of regulatory T-cells, but its presence does not necessary indicate a regulatory phenotype 
(Hori, Nomura and Sakaguchi 2003). Two types of regulatory cells have been identified; 
those that originate in the thymus called natural Tregs cells (nTreg) and those that are 
generated in the periphery named adaptive or induced Treg cells (iTreg). No markers have 
yet been identified to differentiate between both types, but iTreg development has been 
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shown to require TCR stimulation as well as the cytokines TGF-β and IL-2 (Curotto de 
Lafaille and Lafaille 2009).   
     The exact mechanism of Treg mediated suppression of immune responses is still 
unknown but is thought to occur in a contact-dependent manner with soluble mediators also 
contributing. Tregs produce inhibitory cytokines IL-10, IL-35 and TGF-β, with IL-10 and 
TGF-β production shown to be crucial in Treg regulation in asthma and allergy models 
(Joetham et al. 2007). Tregs may also disrupt normal effector T-cell development by 
sequestering IL-2 and inhibiting IL-6 expression responsible for promoting pro-inflammatory 
Th17 cell development (Oukka 2007). Human Tregs also have cytotoxic activity and are able 
to induce apoptosis of effector T-cell and NK cells through both granzyme-dependent and 
TRAIL-DR5-dependent pathways (Cao et al. 2007). Other surface markers including the 
immunosuppressive molecule CTLA-4, are constitutively expressed on Tregs and may play a 
role in suppressing not only T-cells but also important activators of effector T-cells including 
DCs (Read, Malmström and Powrie 2000).  
 
NK T-cells and Gamma delta (γδ) T-cells 
NK T-cells and γδ T-cells play a crucial role in bridging the gap between the innate and 
adaptive immune responses. NK T-cells are a population of T-cells that share properties of 
NK cells and are thought to have a regulatory role in controlling immune responses to 
infections and tumours (Guven et al. 2003). They express an invariant TCR composed of an α 
and β chain which recognises CD1d in conjunction with hydrophobic ligands. Upon TCR 
ligation NK T-cells have been shown to secrete several cytokines including IL-4, IL-10 and 
IFN-γ (Godfrey et al. 2000). 
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    Gamma delta T-cells express γδ T-cell receptors and typically represent between 1-10% 
of human T-lymphocytes (Kunzmann and Wilhelm 2005).  In contrast to αβ T-cells, γδ T-
cells recognize small non-peptidic phospohorylated metabolites which do not require 
processing and presentation by MHC class molecules. These metabolites are produced by a 
broad range of microorganisms including bacteria and parasites. Several functions have been 
described for γδ T-cells including elimination of intracellular microorganisms (bacteria, 
parasites and viruses) and tumour cells, as well as roles in regulating immune homeostasis. 
Upon activation γδ T-cells can also act in a similar fashion to APCs, presenting antigens and 
providing co-stimulatory signals to CD8
+
 T-cells (Brandes et al. 2009).   
 
CD8
+
 T-cells 
The detection of cells infected with intracellular pathogens e.g. viruses, bacteria and 
parasites is mediated by cytotoxic CD8
+
 T-cells through the recognition of foreign peptide 
bound to surface MHC class I molecules on APCs. Peptides derived from pathogens are 
generated in the cytosol through degradation by the proteasome. These peptides translocate 
into the endoplasmic reticulum (ER) through the transporter associated with antigen 
processing (TAP), where they associate with newly formed MHC class I molecules. These 
peptides: MHC class I complexes can then be transported to the cell surface, where the short 
8-10 amino acid peptides are presented to CD8
+
 T-cells (Pamer and Cresswell 1998).  
   The initial binding of CD8
+
 T-cells to an APC is a non-specific interaction mediated by 
adhesion molecules LFA-2 and CD2. Levels of the molecules are up to four-fold higher on 
armed effector T-cells compared to naїve T-cells, allowing efficient binding to cells 
expressing low levels of ICAMs and CD58. Upon recognition of antigen-specific peptide: 
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MHC class I complexes, CD8
+
 T-cells form an immunological synapse. The T-cell receptor 
and associated co-receptor cluster at the point of contact called the central supramolecular 
adhesion complex (SMAC) and are flanked by adhesion molecules including LFA-1 making 
up the peripheral SMAC (Ramsay et al. 2008). Clustering of the TCR at the contact point 
initiates reorganisation of the cell’s actin cytoskeleton, aligning the effector cell’s secretory 
apparatus towards the target cell (Valitutti et al. 1995).    
       Activation of CD8
+
 T-cells induces 2 key effector functions; the release of cytokines 
and the induction of target cell death. Cell killing can be mediated through the release of 
cytolytic granules containing perforin, serine proteases (granzymes) and granulysin. Perforin 
disrupts the target cell’s membrane integrity whilst granzymes activate caspases, which 
ultimately lead to DNA degradation and cell apoptosis. Granulysin causes direct target cell 
membrane damage as well as mitochondrial depolarisation, resulting in caspase-3 activation 
(Kaspar et al. 2001). CD8
+
 T-cell expression of these granule components requires specific 
cytokine signals delivered through the upregulation of IL-2 and IL-6R expression upon TCR-
stimulation (Russell and Ley 2002).    
     The existence of an alternative CD8
+
 T-cell killing mechanism was made upon 
discovery that effector T-cells from perforin knockout mice still retained the ability to lyse 
target cells (Kägi et al. 1994). This pathway is widely thought to be mediated by the calcium 
independent Fas/FasL pathway with other apoptotic pathways such as TNF-related apoptosis 
inducing ligand (TRAIL) playing a lesser role in target cell elimination (Johnstone, Frew and 
Smyth 2008). The Fas/FasL pathway is responsible for clearance of T-cell clones after 
antigen elimination, inactivation of autoreactive peripheral T-cells, allograft rejection and 
clearance of damaged or abnormal cells (Henkart 1994). Upon T-cell activation, FasL is up 
regulated onto the surface which can engage Fas expressed on target cells leading to 
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activation of caspase-8 and the subsequent downstream activation of caspase-3 (Waring and 
Müllbacher 1999).  
    Activated CD8
+
 T-cells are also capable of secreting several cytokines including IFN-γ, 
TNF-α and TNF-β, that act to enhance pathogen recognition and destruction. IFN-γ can 
inhibit viral replication directly as well as enhancing antigen presentation by increasing MHC 
class I expression on the surface of target cells. TNF-α and TNF-β have also been shown to 
synergise with IFN-γ to promote macrophage activation allowing them to move to sites of 
infection and increase their antigen presenting capability (Janeway et al. 2008).    
 
Memory T-cell responses  
Following the resolution of infection, T-cells that have been activated and expanded 
undergo apoptosis, with a small population of antigen-specific T-cells known as memory 
cells persisting and forming the basis of immunological memory. These memory cells show a 
low activation threshold and are capable of proliferating and acquiring effector function in 
response to a second encounter with a pathogen, resulting in long-term protective host 
immunity. Unlike naïve T-cells, memory T-cells are capable of proliferating in an antigen-
independent manner in the presence of IL-7 and IL-15, which is crucial in the maintenance of 
both memory CD4
+
 and CD8
+
 T-cells (Seddon, Tomlinson and Zamoyska 2003). 
     Two types of memory T-cell have been defined based on their ability to mount effector 
function and their expression of homing receptors to secondary lymphoid organs (Sallusto et 
al. 1999). Central memory T-cells (TCM) express CD45RO, as well as CCR7 and CD62L, 
which are required for migration into secondary lymphoid organs. TCMs can be stimulated 
by mature DCs present in the LNs, where upon activation they produce mainly IL-2 before 
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differentiating into CCR7
-
 effector cells capable of secreting IFN-γ or IL-4. Effector memory 
T-cells (TEM), express CD45RO but unlike TCM cells have lost the expression of CCR7. 
These cells display chemokine receptors and adhesion molecules facilitating migration to 
inflamed tissue (gut, lungs and liver) where upon activation, they have rapid effector function 
(Campbell et al. 2001). Highly differentiated effector memory cells or TEMRA are closely 
related to TEM cells but have lost their expression of CD45RO and instead re-express 
CD45RA. Both TEM and TEMRA have a lower proliferative potential than TCM and are 
characterised by increased levels of senescent T-cells. Analysis of TEM cells showed they 
carry large amounts of perforin with TEMRA shown to carry the highest levels. CD4
+
 and 
CD8
+
 TEM also secrete a broader spectrum of cytokines than naïve T-cells including IFN-γ, 
IL-4 and IL-5.   
     Both TEM and TCM cells are thought to represent different states of memory T-cell 
activation. TCM cells closely resemble naïve T-cells which are maintained in a state of low-
level activation with low relative turnover and expression of activation markers (Sallusto et 
al. 1999). In comparison TEM resemble effector cells, overtly activated with the expression 
of integrins and chemokine receptors necessary for entry to non-lymphoid organs. There is 
also evidence to suggest that the cytokine milieu and site of T-cell activation can influence 
the expression of homing receptors on memory T-cells (Baron et al. 1993).    
          The lineage of memory T-cell development has not yet been fully characterised. Three 
pathways have been proposed, the first being the linear pathway of memory T-cell 
development whereby memory T-cells develop from effector cells generated in response to 
infection (Figure 1.2). Several studies have subsequently supported this theory with one 
identifying a population of effector cells with high expression of CD127 and IL-7Rα as 
precursors for CD8
+
 memory T-cells (Kaech et al. 2003). The second, named the divergent 
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pathway suggests naïve T-cells can give rise to daughter cells capable of differentiating into 
both effector and memory T-cells (Kaech, Wherry and Ahmed 2002). This direct process of 
memory T-cell development may occur during the end of an infection when T-cells still 
receive antigen and co-stimulatory signals but there is an absence of inflammatory milieu e.g. 
IL-12, IFN-γ and IL-21 (Kalia et al. 2006). The last model suggests that memory T-cell 
development can be dictated by the length of antigen stimulation on effector cells with short 
periods of stimulation favouring central memory T-cells and longer periods favouring 
effector memory T-cell development.   
     During periods of extended antigenic stimulation, T-cells can become dysfunctional 
and enter a state of exhaustion. T-cell exhaustion is defined by loss of proliferative capacity, 
expression of inhibitory receptors (e.g. PD-1, TIM-3 and LAG-3) and poor effector function 
(Freeman et al. 2006, Sakuishi et al. 2010). Exhaustion has been demonstrated in various 
mouse models as well as during chronic infections and in cancer. It effects both CD8
+
 and 
CD4
+
 T-cells and represents a distinct state of T-cell differentiation different from effector or 
memory T-cells (Yi, Cox and Zajac 2010). The cause of T-cell exhaustion remains unclear 
but it is believed, the persistence of antigen, presence of suppressive cytokines IL-10 and 
TGF-β and inhibitory receptor signals have a role in promoting T-cell exhaustion (Wherry 
2011). 
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Figure 1.2 Models of memory T-cell development (Adapted from Kaech et al. 2002). The 
first model represents a divergent pathway whereby antigen stimulation gives rise to both 
effector and memory cells (a). The second model represents the linear pathway with antigen 
stimulation of naїve cells initially giving rise to effector cells which may develop into 
memory cells once the antigenic stimulation has gone (b). In the last model the generation of 
a memory phenotype is dictated by the length of antigen stimulation: short stimulation 
favours central memory T-cells and longer stimulation favours effector memory T-cell 
development.  
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1.3 Cancer immunology 
The concept of the immune system playing a role in the recognition and destruction of 
tumours was first conceived by Ehrlich et al in the early 20th century and later developed by 
Thomas and Burnet into the hypothesis of cancer immunosurveillance (BURNET 1957). This 
hypothesis suggested that the development and accumulation of tumour cells with new 
antigenic markers may induce an effective immunological reaction which clears the tumour 
before symptoms become apparent. In mouse models protection from tumour formation was 
found to be dependent on IFN-γ and perforin, with both contributing independently towards 
the anti-tumour effector function (Kaplan et al. 1998). IFN-γ and perforin are secreted by 
several lymphocytes including CD8
+
 T-cells and NK cells which pointed to specific cell 
types being important in tumour surveillance. Using genetic, immunochemical and functional 
ablation methods to deplete cell subtypes in mouse models, both innate (γδ T-cells) and 
adaptive (NK and αβ T-cells) cellular responses were subsequently found to be important in 
tumour surveillance (Shankaran et al. 2001). 
Whether this theory of immunosurveillance can be directly applied to humans remains 
to be determined. Early follow up studies of immunosuppressed individuals including 
transplant and AIDS patients as well as those with immunodeficencies show a significantly 
higher risk of tumour development, however these are often virus associated malignancies 
(Dunn et al. 2002). There is however little evidence of immunosurveillance for non-viral 
cancers such as melanoma and pancreatic cancer. 
The fact that tumours can develop in individuals with intact immune systems 
demonstrates that immunosurveillance is not 100% effective. In 2002 Dunn et al, put forward 
the idea of immunoediting, which suggested that tumour development is shaped by three 
phases; elimination, equilibrium and escape. Tumour cells that are not initially eliminated by 
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the immune system enter a second phase of equilibrium where they are immunologically 
shaped to produce new tumour variants able to escape immune recognition. The malignant 
cells can then grow out and become detectable in the escape phase which is associated with 
immunological anergy and tolerance towards the tumour (Dunn, Old and Schreiber 2004). If 
these series of events are correct they pose several key questions for immunologists a) what is 
the cause of this switch between host protection and no protection and b) can we reverse this 
immunological anergy and tolerance in order to restore host protection?   
 
1.3.1 Immune responses to cancer cells 
In mammals several cell types including B, T, NK cells and macrophages have proven 
to have tumouricidal effects. B-cells are capable of binding auto-antigens expressed on 
apoptotic tumour cells and have been shown to infiltrate tumour sites. Naturally occurring 
anti-tumour antibody responses are associated with improved survival in breast cancer and 
may be enhanced after chemotherapy (Karanikas et al. 2009). Macrophages are capable of 
direct cytotoxic responses either through the release of lytic factors such as serine proteases 
and reactive nitrogen intermediates into the neoplastic cell or through antibody dependent 
cellular cytotoxicity (ADCC). They can also influence immune responses indirectly through 
the release of pro-inflammatory cytokines (IFN-γ, TNF-β and IL-1β) which can help 
stimulate the anti-tumour activity of NK and T-cells (Gough et al. 2001).  
NK cells as well as T-cells play a crucial role in the defence against tumour cells, 
virally infected and some bacterially infected cells. NK cells possess both activating and 
inhibitory receptors, which synergise to help NK cells respond to changes in MHC class 1 
molecules found on most somatic cells. MHC class 1 receptor: ligand interactions can induce 
   INTRODUCTION 
32 
 
inhibitory signals to be sent to NK cells, blocking activation through the recruitment of 
tyrosine phosphatase SHP-1 to the ITIM in the receptor’s cytoplasmic tail (Rajagopalan and 
Long 2010). Down regulation of MHC class 1 molecules during viral infection and 
carcinogenesis leads to the removal of this inhibitory signal and allows the activation of the 
NK cell (Adam, Odhav and Bhoola 2003). NK cells also possess natural killer receptors 
(natural cytotoxicity receptors (NCR) or DNAX assessory molecule-1 (DNAM-1)), which 
bind ligands expressed on the surface of tumour cells (Lakshmikanth et al. 2009). They can 
also release pro-inflammatory cytokines such as IFN-γ and TNF-α that promote the 
development of Th1 type responses.  
 
1.3.1.1 T-cells in tumour surveillance 
T-cells play a crucial role in preventing the development and progression of neoplastic 
cells. T-cell surveillance of tumour development and growth depends on T-cell recognition of 
tumour-associated antigens (TAA) in the form of peptides, processed and presented by 
neoplastic cells on MHC molecules. These TAAs can be self-antigens or modified self-
antigens, which are over expressed on tumour cells but are barely detected on healthy tissue. 
There are 3 different classes of TAA: the first are neoantigens which are peptides derived 
from mutations in tumour cells, the second are self-antigens which are mainly proliferation 
and differentiation markers over expressed by tumour cells and the third group are modified 
self-antigens due to tumour-specific post translational modifications (Palena and Schlom 
2010). In cases where tumour formation is associated with infection with DNA or RNA 
oncogenic viruses, (10-15% of cancers worldwide) viral protein can act as TAAs if broken 
down and presented on MHC molecules (Martin and Gutkind 2008). 
   INTRODUCTION 
33 
 
     T-cells with high affinity receptors for MHC:self-peptides are normally deleted during 
T-cell development in the thymus with T-cells in the periphery that are reactive to TAAs 
restricted to those with low affinity T-cell receptors that may be tolerant to the tumour  
(Töpfer et al. 2011). T-cell responses to TAAs have however been identified in solid tumours 
(Melanoma: MAGE-1 and MART-1) as well as blood borne tumours (CLL: MDM2, 
Fibromodulin) (Traversari et al. 1992). Interestingly the frequency of these TAA specific T-
cells are higher in cancer patients than in healthy donors; where they are generally of a naïve 
phenotype. However both T-cells from patients and healthy donors have the potential to kill 
tumour cells (Marincola et al. 1996). In vitro priming of T-cells from melanoma patients 
using peptide loaded DCs revealed a subset of T-cells capable of killing autologous tumour 
cells (Yee et al. 2002). T-cell tolerance to tumours may therefore be relative but not absolute, 
with even low affinity T-cells capable of discharging effector function if properly activated 
(Pardoll 2002).  
     Both CD4
+
 and CD8
+
 T-cells play an important role in anti-tumour immune responses. 
CD8
+
 T-cells however are thought to be more important in the detection of tumour cells due 
to the fact that most non-haematopoietic tumours express MHC class I and the activation of 
CD8
+
 T-cells results in a direct cytotoxic response towards the target cell. CD4
+
 T-cells are 
thought to support CD8
+
 T-cell anti-tumour responses. CD40L present on CD4
+
 T-cells can 
engage CD40 on APCs helping activate tumour-specific CD8
+
 T-cells through cross priming. 
CD4
+
 T-cells were also shown in mouse tumour models, to produce both Th1 type cytokines 
such as IFN-γ; which can activate macrophages and Th2 cytokines e.g. IL-4; which recruits 
anti-tumour effector cells such as tumourcidal eosinophils. CD4
+
 T-cells can also recognize 
tumour antigens presented by MHC class ІІ molecules on macrophages (Hung et al. 1998). It 
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is however important to point out certain subsets of CD4
+
 T-cells can have a negative effect 
on anti-tumour immune responses as highlighted by FOXP3
+
 Tregs.        
      
1.3.2 Tumour evasion of T-cell responses  
As discussed previously, selective pressures put on tumour cells by the immune system 
may select for tumour variants able to escape immune recognition. Tumour cells display 
multiple immunosuppressive mechanisms that can directly or indirectly suppress T-cell 
responses. This includes; creation of a tumour microenvironment that promotes Treg 
production, increased surface expression of immunosuppressive molecules and reduced 
expression of molecules involved in antigen presentation. All of these mechanisms could in 
isolation or combination facilitate immune escape (Zou 2005) (Figure 1.3). The tumour 
microenvironment has been shown to induce the tolerance of both tumour specific CD4
+
 and 
CD8
+
 T-cells including skewing cytotoxic T-lymphocyte (CTL) maturation towards a 
preterminally differentiated state preventing effective CTL responses (Staveley-O'Carroll et 
al. 1998). Tumour suppressive mechanisms are also thought to co-operate in both early and 
advanced stages of cancer leading to a loss of immunological control and tumour progression. 
 
 
   INTRODUCTION 
35 
 
 
Figure 1.3 Suppression of T-cells mediated by CLL cells (Riches, Ramsay and Gribben 
2010). Tumour cells display a reduced level of surface co-stimulatory molecules and increase 
surface expression of immunosuppressive molecules to block T-cell activation. Contact-
dependent changes in genes involved in cytoskeleton rearrangements and cytotoxicity in T-
cells can inhibit anti-tumour immune responses. Tumour cells also secrete suppressive 
cytokines such as IL-10 that promote the development of a Th2 phenotype.  
 
 
1.3.2.1 Reduction in tumour antigen presentation capacity  
One of the best-studied immune evasion strategies deployed by tumours is the 
impairment of antigen presentation (Rivoltini et al. 2002). Complete loss and/or down 
regulation of surface MHC class I expression has been observed in several cancers including 
colorectal, prostate, cervical carcinoma and melanoma. This down regulation can inhibit 
CD8
+
 T-cell recognition of the tumour. The genetic instability of cancer cells can lead to a 
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loss of MHC class I expression through the accumulation of genetic abnormalities including 
mutations in the HLA class I genes and beta 2-microglobulin gene (Hicklin, Marincola and 
Ferrone 1999). Defects in cytokine signalling pathways in cancer lines have also been shown 
to reduce MHC class I upregulation upon IFN-γ stimulation (Respa et al. 2011).    
     Antigen presentation in tumour cells can also be effected by abnormal peptide 
processing which has been observed in lung and renal cancer and lymphoma (Hicklin et al. 
1999). Defects in proteosome subunits LMP2/LMP7 and TAP can affect the spectrum of 
peptides presented on MHC class I allowing the preferential expression of peptides which 
disfavour CTL recognition and activation.  
       For optimal T-cell activation T-cells not only require antigen-specific triggering of 
their TCR but also additional co-stimulatory signals through CD28:CD80/CD86 ligation. In 
the absence of co-stimulation T-cells undergo anergy and become tolerised to the tumour.  
Down regulation of CD80 and CD86 molecules have been described in several solid and 
haematological malignancies including CLL that may inhibit T-cell recognition and 
activation (Fujiwara et al. 2004, Dai et al. 2009, Grzywnowicz et al. 2012). Furthermore 
CD80/CD86 expression has been associated with better overall survival in nasopharyngeal 
carcinoma (Chang et al. 2007). 
 
1.3.2.2 Expression of immunosuppressive molecules  
As well as co-stimulatory signals, the B7 family can provide negative signals that 
control and suppress immune responses. B7-H1 (PDL-1) is expressed on several human 
cancers where upon binding to its counter-receptor PD-1 can induce apoptosis, anergy or 
exhaustion of T-cells (Rabinovich, Gabrilovich and Sotomayor 2007). PD-1 belongs to a 
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family of proteins that negatively regulate T-cell responses including CTLA-4 and BTLA. 
PD-1 ligation on T-cells leads to the recruitment the protein tyrosine phosphatase SHP-2 
which interfere with TCR signalling by dephosphorylating downstream effector molecules 
syk, ZAP70 and PI3K (Keir et al. 2008). Tumour cells can also release soluble forms of PDL-
1 with high serum levels associated with worse prognosis in renal cell carcinoma (Frigola et 
al. 2011).  
    CD200 is the ligand for the inhibitory immune receptor CD200R which is highly 
expressed on a variety of cancer cells including solid tumours e.g. melanoma and ovarian 
cancer and haematological malignancies e.g. acute myeloid leukaemia (AML),  multiple 
myeloma (MM) and CLL (Rygiel et al. 2011, El Desoukey et al. 2012, Palumbo et al. 2009). 
Although the role of CD200-CD200R interactions in tumour immunology remains unclear, 
CD200 expressed on tumour cells has been shown to inhibit anti-tumour T-cell responses. 
This inhibition may occur through direct interaction of CD200 with CD200R expressed on T-
cells or through the inhibition of CD200R expressing cells of the macrophage lineage, which 
is associated with Th2 cytokine production and Treg induction (Hoek et al. 2000). 
 
1.3.2.3 Secretion of immunosuppressive cytokines and soluble inhibitory factors 
Tumour cells are known to secrete an array of immunosuppressive cytokines capable of 
inhibiting T-cell responses and favouring tumour progression. Analysis of cytokines present 
in the tumour microenvironment identified low levels of GM-CSF, IL-4, IL-12 and IFN-γ 
that are essential for DC maturation and T-cell priming, and an abundance of IL-6, IL-10, 
TGF-β that have suppressive properties (Freedman et al. 2004, Buggins et al. 2008). IL-10 
and TGF-β secreted by tumour cells can act in an autocrine fashion promoting tumour cell 
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growth, whilst inducing the differentiation of tumour reactive CD4
+
 T-cells to become 
regulatory FOXP3
+
 T-cells (Chen, Benoist and Mathis 2005). TGF-β is also known to inhibit 
T-cell activation, proliferation and transcription of genes encoding perforin and granzyme A 
and B necessary for cytotoxic T-cell responses (Thomas and Massagué 2005). Elevated levels 
of TGF-β have been associated with poor prognosis in breast and lung cancer (Walker and 
Dearing 1992).  
 
1.3.2.4 Resistance to T-cell killing mechanisms 
Tumour cells possess a series of mechanisms aimed at preventing and protecting them 
from cytotoxic T-cells. The loss of FAS and TRAIL receptors due to tumour-associated 
mutations and the secretion of soluble decoy receptors (sCD95) and TRAIL-R4/R5, help 
tumour cells avoid CTL death receptor-mediated killing (Park et al. 2001, Shin et al. 2001). 
Resistance mechanisms to granzyme/perforin mediated CTL attack have also been described 
including the expression of serine protease inhibitor PI-9/SPI-6 in murine and human cancers 
resulting in resistance of tumour cells to granzymes (Bird et al. 1998). 
   The over expression of anti-apoptotic proteins including members of the BCL-2 family 
BCL-X and MCL-1 in tumours as well as reduced expression of pro-apoptotic proteins have 
been described in several cancers including CLL (Findley et al. 1997, Pepper et al. 2008). A 
high level of the anti-apoptotic regulator FLICE inhibitory protein (C-Flip) in melanoma cells 
is associated with resistance to TRAIL-mediated but not perforin/granzyme-mediated killing 
(Griffith et al. 1998). In addition, increased levels of serine protease inhibitor (serpins) have 
also been shown in haematological malignancies which may protect them from granzyme B 
mediated killing (Riewald et al. 1998). 
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1.3.2.5 Contact dependent inhibition of T-cells 
Direct suppression of T-cells upon contact with tumour cells has been described in 
CLL. T-cells/tumour cell contact in CLL led to defective actin polymerisation and impaired 
immunological synapse formation between T-cells and tumour cells. Furthermore differential 
gene expression was seen in both CD4
+
 and CD8
+
 T-cells including genes involved in 
cytotoxicity (Ramsay et al. 2008). Increased surface expression and secretion of FAS-L and 
TRAIL by tumour cells may also induce T-cell death by interacting with the corresponding 
receptor on T-cells (Shiraki et al. 2005). 
 
1.3.2.6 Stimulation of regulatory and suppressive cell populations 
Elevated numbers of Tregs have been found in both solid tumour as well as 
haematological malignancies (Ustun et al. 2011). Stage-dependent increases in Tregs have 
been shown in CLL (Giannopoulos et al. 2008), whilst in solid tumours the appearance of 
Tregs at the tumour site has been linked to worse prognosis (Beyer and Schultze 2006). 
Although the precise mechanism of inhibition is unclear, Tregs inhibit T-cell, DC and NK 
cell function in a contact and dose-dependent manner (Trzonkowski et al. 2004). At least part 
of Treg suppressive activity is thought to be due to the surface expression of inhibitory 
molecules PD-1 and CTLA-4 and the secretion of IL-10 and TGF-β. Both activated natural 
Tregs as well as induced Tregs; derived from tumour-specific CD4
+
 T-cells at the tumour site 
are believed to mediate suppression (Linehan and Goedegebuure 2005). Tregs express CCR4 
allowing them to migrate towards CCL22 secreting tumour cells and local macrophages 
whilst in lymphoid tissues they can be found in close proximity to CD11c
+
 DCs, CD4 and 
CD8
+
 T-cells (Ishida et al. 2006).  
   INTRODUCTION 
40 
 
       A group of myeloid suppressor cells (MSC) have been identified in pancreatic, colon 
and breast cancer, which are found in the lymph node and also at the tumour site where they 
inhibit naїve T-cell responses. MSCs are a heterogeneous cell population including immature 
DCs, granulocytes and macrophages. MSCs deplete the milieu of L-arginine, which is 
essential for T-cell function including responses to IL-2 and development of T-cell memory 
phenotypes (Rodriguez et al. 2004).   
 
1.3.2.7 Accessory cell dysfunction 
BM-derived APCs, particularly DCs have been shown to play an important role in the 
development of tumour antigen-specific CD4
+
 T-cell tolerance (Sotomayor et al. 2001). The 
tumour microenvironment contains increased levels of IL-10, vascular endothelial growth 
factor (VEGF) and prostaglandin E2 (PGE2) which are known to inhibit DC maturation 
(Gabrilovich et al. 1996). Without DC maturation and the upregulation of co-stimulatory 
molecules, presentation of tumour antigens to T-cells may result in T-cell tolerance. Although 
DC levels are reduced in cancer patients, there is an increase in DCs with a regulatory 
phenotype inducing T-cell defects through the production of IL-10 and indoleamine 2,3-
dioxygenase (IDO)-mediated tryptophan depletion (Liu et al. 2009).  
 
1.4 Cancer Treatment   
1.4.1 Cancer immunotherapy 
Cancer immunotherapy covers a broad range of strategies aimed at generating anti-
tumour responses in patients. These include the transfer of tumour-targeting antibodies or 
   INTRODUCTION 
41 
 
tumour reactive lymphocytes to cancer patients,  cancer vaccines, adjuvants and pro-
inflammatory molecules (Brody et al. 2011). 
 
1.4.1.1 Therapeutic Cancer Vaccines 
Vaccines aimed at preventing or treating malignancies provide an attractive model for 
cancer prevention. These vaccines aim to treat patients with existing cancers by stimulating 
the body’s immune system to recognise and target the malignant cells. Therapeutic cancer 
vaccines tested in clinical trials include peptide vaccines, whole cell vaccines, DC vaccines 
and heat shock protein vaccines. So far results of these trials have being relatively poor with 
an overall objective response rate of 3.3% seen in 1306 vaccine treatments tested for 
metastatic cancer (Itoh et al. 2009).  
 
Peptide-based and whole cell vaccines 
     Cancer vaccines incorporating tumour specific antigens could lead to the induction of 
both effector and memory immune responses capable of targeting malignant cells. Several 
groups of candidate tumour antigens have been identified on the surface of cancer cells 
including cancer testis antigens (MAGE-A1, NY-ESO-1), differentiation antigens (Melan-A, 
Mart-1), and over expressed antigens (survivin, hTERT). So far only a limited number of 
peptide vaccines have been tested in clinical trials, most of which contain antigens recognised 
by CD8
+
 T-cells in melanoma patients. Melanoma peptides MART-1 and gp100 were the 
first to be tested in phase І and ІІ studies as a vaccine in metastatic melanoma resulting in 
clinical responses in between 10-30% of patients (Rosenberg et al. 1998). Although peptide 
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vaccines have been shown to induce tumour specific T-cell responses in vivo this has not 
translated into significant clinical responses.  
       The relative failure of peptide vaccines to induce clinical responses in cancer patients 
may be due to several factors. The use of vaccines targeting a single antigen may result in the 
expansion of tumour variants that have lost that antigen and are resistant to vaccine-induced 
immune responses. Consequently improved vaccines incorporating multiple immunogenic 
epitopes have been investigated (Perez et al. 2010). Whole tumour cells have the potential to 
present multiple tumour antigens on their surface to T-cells. Vaccination using whole tumour 
cells derived from autologous or allogenic sources has been tested in several cancer types 
including colorectal and prostate cancer and melanoma (Simons et al. 2006). Alternatively 
polyepitope peptide vaccines including vaccines using long peptides; generated by the 
chemical linkage of multiple immunogenic epitopes have been tested in clinical trials in 
colon and non-small cell lung cancer (NSCLC) (Perez et al. 2010). A report by Neller et al 
published the combined results of 177 clinical trials for patients with a wide range of solid 
cancers receiving either molecular defined synthetic antigens or autologous or allogeneic 
tumour cell vaccines. They found that 8.1% (138 of 1711 patients) receiving immunotherapy 
with whole tumour or tumour extracts had an objective clinical response compared to 3.6% 
(63 of 1733 patients) that received molecularly defined antigen vaccines (Neller, López and 
Schmidt 2008).  
 Collectively these studies suggest that whole tumour vaccines can generate superior 
clinical responses compared to molecularly defined antigen vaccines but overall clinical 
responses remain low.  
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Dendritic cell-based vaccines 
New technologies have allowed for the generation of high numbers of DCs from CD34
+
 
progenitor cells derived from patient bone marrow or peripheral blood (Bai et al. 2002). 
Mature DCs can be loaded with tumour peptides or pulsed with tumour cell lysates or 
apoptotic debris, which theoretically may contain multiple tumour antigens. These DCs can 
then be transferred back into the patient where they can present tumour antigens on both 
MHC class I and class II molecules.  
     Patients with metastatic cancer vaccinated with autologous DCs loaded with 4 class 1 
HLA-restricted melanoma peptides resulted in enhanced immune responses to one or more 
melanoma antigens in 16 out of 18 patients, with tumour regression evident in 7 patients 
(Banchereau et al. 2001). The ability of DC vaccines to induce CTL production and induce 
anti-tumour responses is dependent on multiple factors including the site of vaccination and 
the origin of the DCs used. In addition, using a mixture of CD8
+
 and CD4
+
 T-cell epitopes 
and including cytokines such as IL-12 can improve DC vaccine efficacy (Parmiani et al. 
2002).  
     Although DC-vaccines appear to generate stronger CTL responses than standard 
tumour-peptide vaccines only a small proportion of patients show clinical responses. That 
said there has been some success for a DC based vaccine called ‘Dendreon’ which became 
the first licensed cancer vaccine in the US, after it showed a 4 month median survival 
advantage in advanced prostate cancer. It is composed of autologous DC cells cultured in 
vitro and pulsed with a prostatic acid phosphatase (PAP) antigen present on 95% of prostate 
cancer cells (Kantoff et al. 2010). Efforts to improve the efficacy of DC-based vaccines in 
prostate cancer as well as other cancers is ongoing including combining DC vaccines with 
TLR-ligands and cytokines to enhance DC presentation of antigens in vivo. 
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  1.4.1.2 Improving the immunogenicity of cancer vaccines  
Cancer vaccines have been shown to induce increased frequencies of tumour specific 
T-cells in vivo but this has not always correlated with clinical responses in patients. Novel 
strategies of improving the immunogenicity of cancer vaccines including the use of cytokines 
and adjuvants are now being considered. Indeed it is likely that combinatorial approaches 
using vaccines that allow for improved T-cell priming and antigen presentation as well as 
therapies that block the suppressive effects of the tumour microenvironment may be 
necessary for optimally and effective cancer immunotherapy.  
 
Enhancing Antigen presentation  
As discussed previously, tumour cells are poor antigen presenting cells, expressing 
reduced levels of MHC and co-stimulatory molecules necessary for T-cell activation.  Several 
strategies aimed at improving the antigen presentation capacity of tumour cells are now being 
considered. Tumour cells genetically modified to express co-stimulatory molecules such as 
CD80, CD70 and LIGHT have been shown to induce cytotoxic anti-tumour responses in vitro 
(Douin-Echinard et al. 2000). Alternatively, presentation of tumour antigens can be enhanced 
using CD40L and TLR-agonists such as cytosine-phosphate-guanine (CPG) DNA. CD40L 
and CPG DNA are potent stimulators of B-cells and DCs, inducing the upregulation of MHC 
and B7 co-stimulatory molecules as well as the release of Th1-type cytokines (Teleshova et 
al. 2006). Both soluble forms of CD40L and tumour cells genetically modified to express 
CD40L have been tested in clinical trials. CLL patients infused with genetically modified 
CLL cells expressing CD40L resulted in significant drops in tumour cells in vivo, however no 
   INTRODUCTION 
45 
 
complete responses were observed  (Wierda et al. 2000). CPG DNA is being investigated in 
animal models and clinical trials as a vaccine adjuvant (Klinman 2004, Bode et al. 2011).  
 
Blocking immunoinhibitory molecules 
Increased expression of immunoinhibitory molecules known to inhibit T-cell activation 
including PD-1, CTLA-4 and TIM-3 have been identified on the surface of T-cells from 
cancer patients (Fourcade et al. 2010, Curran et al. 2010). Immunotherapeutic approaches 
using blocking antibodies to disrupt the interaction of the molecules with their respective 
ligands are being investigated in clinical trials to try and enhance anti-tumour T-cell 
responses. The FDA recently approved a CTLA-4-targeted antibody ipilimumab, which 
improved the median overall survival of metastatic melanoma patients by 3.7 months (Hodi 
et al. 2010). Synergistic effects of blocking multiple immunoinhibitory molecules have been 
shown in mouse models where combining CTLA-4 and PD-1 blocking antibodies increased 
circulating CD107a
+
 CD8
+
 T-cells compared to either antibody alone (Mangsbo et al. 2010).  
Clinical trials are ongoing to assess the clinical benefit of blocking antibodies including the 
kinetics of clinical responses, potential side effects e.g. autoimmunity and potential for 
combination with radiotherapy and hormone therapy (Sharma et al. 2011).  
 
Cytokines as vaccine adjuvants 
Since cytokines play an important role in shaping immune responses in the tumour 
microenvironment, it is possible that cytokine therapy may break immune tolerance to cancer 
cells. Several cytokines including IFN-α, IL-2, IL-12 and GM-CSF have been evaluated in 
clinical trials (Dranoff 2004). Administration of high dose IL-2 was shown to have an 
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antitumour effect in 20% of metastatic melanoma and renal cancer patients (Fyfe et al. 1995). 
The clinical benefit of cytokine therapy is however limited by significant systemic toxicity 
associated with high dose of cytokines administered. Thus investigators have focused on 
directly modifying the cytokine microenvironment at the tumour site through local infusions 
of cytokines. Localised injection of cytokines, particular IL-2, can have therapeutic benefit 
coordinating innate and adaptive immune responses at the tumour site in mouse models 
(Dranoff 2004). In humans, cytokine linked antibodies (Immunocytokines) are now in 
clinical trials designed to direct cytokines to the tumour site. In a study of neuroblastoma 
patients, 22% had a complete response after receiving an antibody targeting GD2 
disialoganglioside on neuroblastoma cells combined with IL-2 (Shusterman et al. 2010).  
        The application of gene-transfer techniques has also allowed tumour cells to be 
directly modified to express particular cytokines. Several cytokine secreting tumour vaccines 
are being investigated to determine whether they can augment immune responses towards 
wild-type tumours. GM-CSF vaccines have been tested in multiple cancers including 
metastatic melanoma, where localised infusion induced both T-cell and B-cell accumulation 
in resected lesions and extensive tumour necrosis in 3 out of 6 patients (Salgia et al. 2003).  
 
1.4.1.3 Adoptive T-cell transfer 
The anti-tumour effect seen in patients successfully treated with allo-HSCT has 
encouraged the use of adoptive immunotherapy as a tool for treating cancer. Adoptive T-cell 
transfer is a type of transfusion therapy whereby T-cells pre-selected for reactivity to the 
tumour are infused into a patient. Ideally these T-cells should be able to proliferate, home and 
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persist at the tumour site and maintain effector function capable of eliminating the tumour 
and preventing its reoccurrence (June 2007).  
       Two approaches have been identified for isolating tumour reactive T-cells from  
cancer patients. The first relies on identification and isolation of tumour specific T-cells 
before expansion in vitro. The second relies on the assumption that tumour specific T-cells 
exist in the patient’s body which are already primed, thus polyclonal T-cell activation in vitro 
will also result in expansion of these T-cells. Tumour specific T-cells can be expanded using 
irradiated allogeneic PBMC (feeder cells) acting as APCs or by creating artificial APCs using 
anti-CD3 and anti-CD28 antibodies (Powell and Levine 2008). MHC class I molecules 
loaded with viral or tumour-specific peptides have also been used to generate antigen-specific 
T-cell expansions. MHC tetramers presenting peptides for tumour antigens MART1, gp100 
and virus (EBV) have been used to isolate high avidity T-cells which can be expanded in 
vitro (Dunbar et al. 1999).  
      Adoptive transfer of virus specific T-cells has already proved successful in 
reconstituting viral responses following allo-HSCT and can induce clinical responses against 
virally transformed tumours (Riddell et al. 1992). Treatment of EBV-positive type ІІ latency 
tumours with autologous EBV-specific T-cells resulted in 2 complete and 1 partial remission 
out of 6 patients (Straathof et al. 2005).  
       The investigation of TAA-reactive T-cells in adoptive therapy has been limited by the 
low number of identified tumour-associated antigens and the difficulty in expanding known 
TAA-reactive T-cells from the blood of cancer patients. However adoptive transfer of T-cells 
targeting MART-1/Melan A and gp100 were shown to migrate to tumour sites and eliminate 
antigen positive tumour cells in metastatic melanoma (Yee et al. 2002). In myeloma, adoptive 
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T-cell transfer combined with vaccination with tumour antigens hTERT and survivin, 
resulted in immune responses to the tumour antigen vaccine (Rapoport et al. 2011).  
Despite the promising results in a few studies, the majority of early clinical trials with 
adoptively transferred T-cells showed only modest and often transient responses (Rosenberg 
et al. 1994). Successful application of ACT is hampered by several factors including the 
limited knowledge of how to culture T-cells which are likely to traffic to the tumour site, 
persist and exert effector function in vivo and the tolerising effects of the tumour 
microenvironment exerted on T-cells.  
Currently there are no FDA-approved T-cell therapies for cancer despite over 60 years 
of research. However lessons learned from adoptive transfer in lymph depleted hosts, in Treg 
depleted patients and the use of improved culturing techniques may help to improve ACT 
efficacy and bring it into routine practice in clinical medicine (June 2007). Indeed 
Rosenberg’s group reported response rates of 52% and 72% in patients with metastatic 
melanoma receiving chemotherapy or total body irradiation prior to ACT (Dudley et al. 
2008).   
 
 Engineering T-cells to recognise tumour cells 
One current limitation of ACT is that many tumours are poorly immunogenic, so 
naturally occurring tumour specific T-cells occur at very low frequencies. This makes it 
difficult to expand high avidity tumour-specific T-cells in sufficient numbers for transfusion. 
Using gene transfer techniques, T-cells of any specificity can be reprogrammed to target 
tumour antigens. In particular molecular determinants on the surface of malignant cells which 
are over expressed and crucial for tumour cell survival, would be attractive targets. This 
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would overcome tumour escape mechanisms designed to avoid surveillance by the patient’s 
own T-cells. Furthermore tumour-specific T-cells obtained from the blood of patients for 
ACT are often tolerised and after several rounds of expansion may be driven to a terminally 
differentiated phenotype with a replicative senescence phenotype (June 2007). By genetically 
engineering T-cells, tumour specificity can be conferred to selected T-cells, preferably with 
high proliferative capacity (long telomere length), a TCM phenotype and lacking markers 
associated with a senescent/exhausted phenotype. 
 
Chimeric Antigen Receptor T-cells (CAR-Ts) 
One approach is to manipulate T-cells to express chimeric antigen receptors on their 
surface conferring new antigen specificity. These CAR-Ts consist of the antigen recognition 
domain of the antibody combined with the intracellular domain of the CD3 zeta chain or 
FCγR1 protein allowing the T-cell, upon recognition of the appropriate antigen, to become 
activated (Porter et al. 2011). These constructs allow T-cells to target tumour cells in an 
antigen specific but MHC-independent manner via the intracellular signalling pathway of the 
endogenous TCR. Previous in vivo studies using adoptive transfer of CAR-Ts in 
neuroblastoma and ovarian cancer have reported poor clinical activity with rapid clearance of 
CAR-Ts from the body (Jena, Dotti and Cooper 2010). Several factors are thought to prevent 
the persistence of CAR-Ts in vivo including the presence of host humoral and cellular 
immune responses, the immunotoxic effects of the tumour microenvironment and the lack of 
co-stimulatory signals necessary for long-term T-cell survival upon tumour recognition 
(Lamers et al. 2011). 
 
   INTRODUCTION 
50 
 
TCR gene transfer 
T-cells can be genetically engineered to express natural αβ TCRs heterodimers with 
known specificity for tumour antigens (Schumacher 2002). Killing of leukaemia cells has 
been observed in vitro and in mouse models with T-cells genetically modified to express 
TCRs (Tsuji et al. 2005). CD8
+
 T-cells genetically engineered to express TCRs reactive to 
tumour peptides including MART, gp100, NY-ESO-1 and p53 were shown to be capable of 
recognizing HLA-A2-matched tumours in melanoma, lung and breast cancer. Furthermore 
adoptive transfer of genetically engineered lymphocytes transduced with a TCR recognising 
gp100 in metastatic melanoma patients resulted in durable engraftment and objective 
regression of metastatic lesions in two patients (Morgan et al. 2006).  
       Limitations of TCR engineering technology include the potential pairing of the 
transgenes with the endogenous TCR chains leading to novel TCR specificities and increased 
risk of autoreactivity, low cell surface expression of tumour specific TCRs, and the 
transduction efficacy of the retroviral delivery system.   
 
1.4.1.4 Antibody therapy 
Monoclonal antibodies 
Monoclonal antibodies are used at several stages in cancer therapy including diagnosis, 
treatment and monitoring of patients. In terms of treatment, monoclonal antibodies can be 
used to target specific antigens on the tumour cell surface, which are absent or have reduced 
expression on normal tissue. Upon binding monoclonal antibody can induce indirect killing 
of tumour cells through ADCC by recruiting phagocytic cells including monocytes and 
macrophages or can directly bind complement-inducing tumour cell death through CDC. 
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MAbs can also function to inhibit cell signalling pathways. In the case of trastuzumab it can 
block HER2-mediated signalling in breast cancer cells leading to an upregulation of p27kip1 
protein resulting in cell cycle arrest (Le, Pruefer and Bast 2005). Multiple mAbs have been 
approved or in clinical trials for use in solid cancers (trastuzumab: HER-2/neu antigen, 
Edrecolomab: 17-1A antigen) as well as haematological malignancies (Rituximab: CD20, 
Alemtuzumab CD52, Gemtuzumab CD33 and anti-idiotype antibodies). Solid cancers have 
however proved harder to treat than haematological malignancies due to the lack of identified 
tumour specific antigen targets and the difficulty of mAbs penetrating into solid tumours 
(Oldham and Dillman 2008).  
      The potential for mAbs to block molecules important in tumour cell survival are also 
being investigated in clinical trials. mAbs capable of blocking growth factor receptors on the 
tumour surface including Epidermal growth factor (EGF) receptors has been shown to induce 
proliferative arrest, apoptosis and inhibition of angiogenesis in tumour cells (Sharkey and 
Goldenberg 2006). Several blocking mAbs to immune-modulatory molecules are also being 
tested in clinical trials with the aim of promoting immune responses to tumours cells. These 
includes blocking antibodies to CTLA-4, which has been found to antagonize early T-cell 
activation and IL-2 production and PD-1 which has been shown to promote T-cell anergy 
upon binding to the ligand PDL-1 (Fife et al. 2009).    
       Alternative approaches include conjugating monoclonal antibodies to anti-cancer 
drugs, radioisotopes or toxins that has allowed treatments to be delivered to the surface of the 
tumour cells. This ensures that treatments are concentrated towards tumour cells whilst 
limiting toxic effects on surrounding tissue. A randomised trial comparing rituximab (anti-
CD20) mAb to an anti-CD20 mAb conjugated to yttium-90, showed enhanced overall 
response rates in those patients treated with the antibody conjugate (Witzig et al. 2002).  
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 There are several obstacles to the implementation of monoclonal antibodies in the 
clinic. Firstly generating high yields of antibodies necessary for infusion can be laborious and 
expensive. Secondly murine monoclonal antibodies induce the production of anti-mouse 
antibodies in vivo, which limits the half-life of any therapeutic mAb. This problem has been 
somewhat reduced through the development of chimeric and fully humanised antibodies 
(Oldham and Dillman 2008).  
 
Bi-specific antibodies     
The successful application of monoclonal antibodies as cancer treatments has resulted 
in a drive to enhance the efficacy of these molecules through new antibody engineering 
approaches. Engineering of mAb FC fragments has been used to try and improve the efficacy 
of existing mAbs by enhancing ADCC or CDC killing mechanisms. Other research has 
focussed on the development of a new class of antibodies termed bi-specific antibodies 
capable of dual specificity. Such molecules can induce the retargeting of immune effector 
cells towards target cancer cells by binding surface antigens expressed on both cell types 
resulting in the killing of the tumour cells. Bi-specific antibodies capable of retargeting innate 
immune cells (e.g. macrophages, neutrophils) as well as acquired immune cells (e.g. T-cells 
and NK cells) have been described (Chames and Baty 2009). Importantly bi-specific antibody 
mediated cytotoxicity does not require MHC:peptide presentation by tumour cells. Such 
antibodies have also shown anti-tumour activity both in vivo and in animal models.   
      Early bi-specific antibodies were formed using chemical cross-linking or quadromas 
but clinical application was limited by the difficulty of producing large homogeneous batches 
of mAbs. Furthermore patients often developed anti-mouse Ab responses, preventing 
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repeated mAb administration. Subsequent advances in antibody engineering led to a 
reduction in the size of bi-specific antibodies by producing small antibody fragment 
representing the entire recognition region of the parent molecule. These single chain variable 
fragments (scFv) include the variable domains of the antibody heavy and light chains which 
can be fused to another scFv through a peptide linker to form a single polypeptide chain 
(Wolf et al. 2005) (Figure 1.4). 
     The efficacy of bi-specific antibodies has been demonstrated in clinical trials in 
patients with solid cancers and haematological malignancies. Bi-specific antibodies targeting 
CD3 and HER2/neu (Ertumaxomab) or EpCAM (Catumaxomab) have shown clinical activity 
in breast and ovarian cancer (Kiewe et al. 2006). In 2009 Catumaxomab became the first bi-
specific antibody approved by the European commission for treatment of malignant ascites in 
patients with EpCAM-positive cancers. In haematological malignancies bi-specific antibodies 
targeting the B-cell antigen CD19 have been tested in clinical trials of acute lymphoblastic 
leukaemia and non-Hodgkin’s lymphoma (NHL) patients. Seven patients with NHL treated 
with a bi-specific antibody targeting CD19 showed tumour regression and elimination of 
tumour cells from the bone marrow and liver (Bargou et al. 2008). Bi-specific antibodies are 
also being evaluated in myeloid leukaemias targeting surface antigens such as CD33 (Aigner 
et al. 2012).  
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Figure 1.4 Schematic diagram detailing the formation of a bi-specific antibody and its 
mode of action on effector cells and target cells (Adapted from Baeuerle and Reinhardt 
2009). Bi-specific T-cell engager (BiTE) antibodies are formed by the fusion of two single 
chain variable fragments from two different antibodies using by a short peptide linker. The 
BiTE antibody binds both the effector cell (T-cell) and tumour cell triggering a cytotoxic 
killing mechanism to be directed towards the tumour cell.  
 
 
1.5 Aims of this project  
The use of alkylating agents and purine analogs has proven highly successful in 
inducing remissions but therapy does not result in long-term disease free survival in CLL 
patients. Novel therapeutics aimed at improving the treatment and overall survival of CLL 
patients is therefore warranted.  
Immunotherapy has emerged as an exciting tool in the treatment of CLL, with a recent 
study showing for the first time that immunotherapy alongside chemotherapy can increase 
progression free survival (PFS) and overall survival (OS) of CLL patients (Molica 2011). The 
objectives of this project were to characterise T-cell abnormalities in CLL patients with the 
aim of using this information to develop immunotherapeutic strategies capable of breaking T-
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cell tolerance within the disease. Such therapeutic strategies will subsequently be investigated 
to determine whether they can improve T-cell immune response in vitro and potentially 
restore anti-tumour immunity.   
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CHAPTER 2 
Materials and Methods 
 
2.1 Tissue culture basics 
2.1.1 Media and Buffers 
AB MEDIA 
Roswell Park Memorial Institute (RPMI) 1640 (Sigma) was supplemented with 2mM L-
Glutamine (Invitrogen), 25mM Hepes buffer (Sigma), 100units/ml Penicillin and 100µg/ml 
streptomycin (Invitrogen) and 5% AB serum (Welsh blood service).   
FIBROBLAST MEDIA 
Dulbecco's Modified Eagle Medium (DMEM, Sigma) was supplemented with 10% foetal 
calf serum (FCS), 100units/ml Penicillin and 100µg/ml streptomycin (Invitrogen), 2mM L-
Glutamine (Invitrogen) and 1mM Sodium pyruvate (Invitrogen).  
FREEZING MEDIA AND FREEZING MIX 
MEDIA- 2mM L-Glutamine (Invitrogen), 100units/ml Penicillin and 100µg/ml streptomycin 
(Invitrogen) was added to RPMI.  
MIX- 40% Freezing media, 50% FCS and 10% Dimethyl Sulfoxide (DMSO, Sigma).  
FACS BUFFER 
1% FCS was added to Phosphate buffered saline (PBS, Invitrogen) 
  CHAPTER 2: MATERIALS AND METHODS  
57 
 
MACS BUFFER FOR IMMUNOMAGNETIC CELL ENRICHMENT 
 0.5% Bovine serum albumin (BSA-Sigma) and 2mM Ethylenediaminetetraacetic acid 
(EDTA, Sigma) was added to 100ml of PBS. The buffer was then sterile filtered using a 
0.2µm bottle top filter (Millipore).  
FIX/PERM BUFFER  
3 parts Fix/Perm diluent + 1 part Fix/Perm Concentrate (Ebiosciences) 
PERMEABILISATION BUFFER 
1 part perm wash concentrate (Ebiosciences) was diluted in 9 parts distilled water.  
RED BLOOD CELL LYSIS BUFFER 
Red blood lysis solution (Miltenyi Biotec) was diluted 1/10 in distilled water.   
10% NP40 
10g Tergitol-type NP40 (nonyl phenoxypolyethoxylethanol) (Sigma) was dissolved in 100ml 
of water. 
 
2.1.2 Tissue culture plastics 
Culture Flasks (T25, T75 and T225) ( Nunc), Pipettes and Falcon tubes (15ml, 50ml) 
(Corning Incorporated), Tips (1000, 200, 20, and 2µl) (Star lab), plates (98, 48, 24, 12 well) 
(Nunc and Greiner bio-one). FACS tubes (BD biosciences).   
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2.1.3 Cell viability staining  
Trypan blue staining 
Cell viability was assessed using the live cell exclusion dye trypan blue. Dead cells take 
up the dye giving them a distinct blue colour under the microscope. Live cells, which appear 
white, can then be counted allowing the total number of viable cells in suspension to be 
measured. Cell counting was performed using the Beckman Coulter Vi-cell or a 
Haemocytometer (Immune systems).  
Beckman Coulter Vi-cell counting- Briefly 50µl of sample was added to 450 µl of PBS (1/10 
dilution) in a cell counting container and placed into the Vi-cell carousel. The cell type, 
dilution and name of sample were entered into the machine. The machine was then set to run, 
allowing the sample to be mixed with trypan blue and the number of viable cells per µl 
calculated.  
Haemocytometer- Twelve microlitres of cell suspension was mixed with an equal volume of 
trypan blue in a 96 well plate. Twelve microlitres was then pipetted under the grid of a 
disposable haemocytometer. The total numbers of viable cells were counted in 3 squares 
divided by 3 and then multiplied by 20,000 to give the number of cells per ml. 
 
Aqua staining 
Exclusion of dead cells during flow cytometric analysis was performed using the 
amine-reactive fluorescent dye aqua. Cells were washed twice in 1ml of PBS by 
centrifugation at 756 x g for 2 minutes. The aqua dye (Invitrogen) was diluted 1/40 in PBS 
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and 4µl added to each sample. The cells were incubated at 4°C for 15 minutes in the dark 
before being washed twice in 1ml of FACS buffer to neutralise the reaction.  
 
2.2 CLL patient blood samples  
Professor Chris Fegan obtained blood samples from CLL patients attending clinics at 
the University Hospital Wales and Llandough hospital. Additional samples were obtained 
from Birmingham University in collaboration with Dr Guy Pratt. All samples were taken with 
informed consent from patients and the appropriate ethical approval obtained. Healthy, age- 
matched control samples were obtained by Professor Chris Fegan with informed consent, or 
from volunteers from within the department.   
 
2.3 Cell lines 
Non-transfected mouse fibroblasts (NTLs) and CD40 ligand transfected mouse 
fibroblasts TL(CD40L) were kindly donated by Dr Aneela Majid (University of Leicester). 
 
2.3.1 Growing cell lines in culture  
NTL and TL(CD40L) cell lines were cultured in 20ml of fibroblast media in a T175 
flask. 2-4x10
6
 fibroblast cells were used for the initial seeding of the flasks and allowed to 
grow for 3 days until a confluent monolayer was formed. The cells were then washed in PBS 
and incubated for 5 minutes at 37°C in the presence of 5ml EDTA-trypsin (Invitrogen). Once 
the cells had detached from the flask surface, the cells were washed in 15ml of fibroblast 
media and spun down at 272 x g for 5 minutes. The supernatant was removed and the cells 
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re-suspended in 10ml of fibroblast media. 1ml was used to reseed the flask and the rest of the 
cells were used for co–culture experiments or frozen down. 
 
2.3.2 Cell line and PBMC cryopreservation 
Between 1-5x10
6
 fibroblast cells or PBMCs were suspended in 1ml of freezing mix and 
stored in cryovials overnight at -80ºC. The cells were then transferred and stored in liquid 
nitrogen until required.  
 
2.3.3 Co-culture of cell lines with CLL PBMC  
TL (CD40L) and NTL cell lines were suspended in 5ml of fibroblast media and 
irradiated (8000 RADs). 5x10
4
 irradiated NTL or TL (CD40L) cells were then seeded into a 
48-well plate in 1ml of AB media. The plate was then incubated for 24 hours at 37°C to allow 
the fibroblast cells to adhere to the well surface. 1x10
6
 CLL patient PBMCs were suspended 
in 500μl of AB media and added to the surface of the irradiated NTL and TL (CD40L) cells 
and incubated for 3 or 7 days.  
 
2.4 Cell separation 
2.4.1 Peripheral blood mononuclear cell (PBMC) separation 
Blood samples were collected and immediately processed for PBMC extraction. Whole 
blood was layered onto a lymphoprep (Axis-shield) gradient at a 1:1 ratio and centrifuged at 
756 x g for 20 minutes without the use of the brake. The buffy coat interface containing 
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PBMCs was carefully collected and the cells washed in 15ml of PBS by centrifugation at 272 
x g for 10 minutes.  The supernatant was discarded and any red blood cell contamination 
removed by re-suspension of the pellet in 1ml of red blood cell lysis buffer and incubation at 
room temperature for 10 minutes. Cells were washed again in 15ml of PBS and pelleted by 
centrifugation at 272 x g for 5 minutes. The supernatant was removed and the cells re-
suspended in 10ml of fresh PBS and counted by trypan blue staining. 
 
2.4.2 CD3
+
 T-cell isolation 
CD3
+
 T-cells were enriched using an indirect magnetic bead labelling system designed 
to deplete non T-cells (Miltenyi Biotec). Cells were washed in PBS and spun down at 272 x g 
for 10 minutes. The supernatant was removed and the cell pellet re-suspended in 40µl of 
MACS buffer per 10
7
 cells. 10µl of a Biotin-Antibody Cocktail against CD14, CD16, CD19, 
CD36, CD56, CD123 and CD235a (Glycophorin A) was then added per 10
7
 cells. The cell 
suspension was vortexed and incubated at 4-8°C for 15 minutes. 30µl of additional MACS 
buffer and 20µl of anti-biotin microbeads per 10
7
 cells was then added. The cell suspension 
was again incubated for 15 minutes at 4-8°C before being washed in 6ml of MACS buffer. 
The cells were centrifuged at 272 x g for 10 minutes, the supernatant removed and the pellet 
re-suspended in 500µl of cold (4°C) MACS buffer ready for magnetic column separation 
(See section 2.4.4). 
 
2.4.3 CD19
+
 B-cells isolation  
CLL cells were isolated by depleting non B-cells (Miltenyi Biotec). Cells were washed 
in PBS and spun down at 272 x g for 10 minutes. The supernatant was removed and the cell 
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pellet re-suspended in 40µl of buffer per 10
7
 cells. 10µl of B-CLL biotin-antibody cocktail 
against CD2, CD4, CD16, CD36, Anti-IgE, and CD235a (Glycophorin A) was added and the 
cell suspension, vortexed and incubated for 10 minutes at 2-8°C. The cells were then washed 
by adding 1-2ml of buffer and centrifuged at 272 x g for 10 minutes. The supernatant was 
removed and the pellet re-suspended in 80µl of MACS buffer. 20µl of anti-biotin microbeads 
was added and the cells again incubated for 15 minutes at 4-8°C. Cells were then washed in 
PBS, centrifuged at 272 x g for 10 minutes and the supernatant removed. The pellet was re-
suspended in 500µl of MACS buffer ready for loading onto a magnetic column.  
 
2.4.4 Magnetic column separation of cell fractions 
The cells were suspended in 500µl of MACS buffer and loaded onto a magnetic MS 
column or LS columns (Miltenyi) in the presence of a strong magnetic field (MiniMacs 
Separators). The cell suspension was allowed to run through the column until the column 
reservoir was empty. The column was then washed by adding 500µl of MACS buffer to the 
top of the column, allowing it to completely run through the column. This wash step was 
repeated 3 times. In cases of negative selection the effluent was collected in a 15ml falcon 
tube. The number of viable cells was counted by trypan blue staining and the purity of the 
collected cells determined using single colour flow cytometry. 
 
2.4.5 Measuring the purity of collected cell fractions 
1x10
5
 viable cells were taken from the collected effluent and stained with a FITC-
conjugated anti-CD3 or PE cy-7-conjugated anti-CD19 antibody. A purity of >95% CD3
+
 T-
cells within the viable gate was used as the threshold for a pure CD3
+
 T-cell population. 
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Samples with a CD3 purity less than 95% were put back through a MS column and the purity 
of the effluent fraction tested again using the CD3 staining protocol. For CD19
+
 B-cells, a 
purity of 99% or greater was used as the threshold for CLL cell purity. 
 
2.5 Antibody staining and flow cytometric analysis  
2.5.1 Flow cytometric compensation set-up 
Cells were analysed using a BD FACS Canto II or an Accuri C6 flow cytometer (BD 
Accuri). For analysis on the BD FACS Canto II, compensation between the fluorochrome 
emission spectra was done automatically using anti-mouse Ig/negative control compensation 
beads and FACSDiva software. Briefly 3 drops of anti-mouse Ig and Negative control comp 
beads were added to 700µl of FACS buffer. The beads were vortexed for 3 seconds and then 
100µl was added to 1 FACS tube. Fluorochrome conjugated antibodies were then added at 
optimised concentrations (1 antibody per tube) and incubated for 5 minutes at room 
temperature (RT). A further 900µl of FACS buffer was then added to each tube. These 
antibodies were used as single-colour compensation controls. Each tube was analysed using 
the BD FACS Canto II by gating on the single bead population using forward side scatter, 
then gating both the positive and negatively stained populations on a histogram plot. These 
populations were then used to automatically calculate the compensation between antibodies 
using FACSDiva software. 
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2.5.2 Single and multi-colour immunofluorescence staining 
Fluorochrome conjugated antibodies were directly incubated with 1-1.5x10
6
 PBMC 
from CLL patients. Antibody concentrations used in this study were optimised by testing 
neat, ½ dilution and ¼ dilutions of the manufacturers’ recommendations. The antibodies were 
incubated with the cells for 15 minutes at 4°C. Cells were then washed twice in FACS buffer 
by centrifuging at 756 x g for 2 minutes and discarding the supernatant. Cell pellets were re-
suspended in 200-300µl of FACS buffer and analysed using a BD FACS Canto II or an 
Accuri C6 flow cytometer (BD Accuri). 
 
2.5.3 FOXP3 staining 
Intracellular FOXP3 staining was used in the identification of regulatory T-cells. 1x10
6
 
CLL PBMC were suspended in 100µl of FACS buffer and surface stained for 30 minutes on 
ice with antibodies to CD3-(AM Cyan), CD4-(Pacific Blue), CD25-(PE) and CD45RA-
(APC). Cells were then washed twice in 1ml of FACS buffer and re-suspended in 500µl of 
Fix/Perm buffer (Ebiosciences). In order to fix the cells the samples were incubated on ice for 
40-60 minutes. After incubation, the cells were washed twice in 2ml of permeabilisation 
buffer (Ebiosciences) and re-suspended in 30µl of permeabilisation buffer containing 2% 
normal rat serum. The cells were then incubated on ice for a further 15 minutes to allow 
permeabilisation of the cell membranes. Without washing, 15µl of a FOXP3-FITC 
conjugated antibody was added to the cells and the incubation continued for a further 30 
minutes on ice in the dark. The cells were then washed twice in 1ml permeabilisation buffer 
and once in 1ml FACS buffer before being re-suspended in 300µl of FACS buffer.      
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2.5.4 Ki-67 proliferation assay 
Intracellular Ki-67 staining was used to identify cells in active phases of cell cycle. 
1x10
6
 CLL PBMC were washed once in 1ml of FAC buffer and surface stained with 
antibodies to CD4-(Pacific Blue), CD8-(APC-CY7), CD45RA-(APC) and CCR7-(PE). Cells 
were incubated at 4°C for 15 minutes before being washed twice in 1ml of FACS buffer. 50µl 
of Reagent A (Fixation Medium, Invitrogen) was added and the cells, incubated again for 15 
minutes at 4°C to fix the cells, before being washed twice in 1ml of FACS buffer. Fifty 
microlitres of reagent B (Permeabilisation Medium, Invitrogen), 0.5µl of 1% NP40 and 3µl 
of an anti-Ki-67-(FITC) antibody were then added to the cells. The cells were incubated at 
4°C for 15 minutes, then washed twice in 1ml of FACS buffer and re-suspended in 300µl 
FACS buffer.  
 
2.5.5 CFSE proliferation assay 
Carboxyfluorescein succinimidyl ester (CFSE) was reconstituted in DMSO to a 
concentration of 5mM. 1x10
6
 PBMCs were suspended in 1ml of RPMI containing 1% FCS 
and CFSE to a final concentration of 2μM. The cells were then incubated at 37ºC in the dark 
for 5 minutes before being washed in 10ml of ice cold RPMI containing 10% FCS. The cells 
were centrifuged at 272 x g for 5 minutes and the wash step repeated before being counted. 
1.5x10
6
 PBMCs were added to separate sterile 5ml FACS tubes in 1ml of AB media. 
CD3/CD28 beads were then added at a ratio of one bead to one T-cell. The cells were then 
incubated for 3 or 7 days with the addition of blocking antibodies (PDL-1, 10μg/ml, 
Ebioscience, Clone MIH1), CD200 (20μg/ml, BD Pharmingen, Clone MRC OX-104) and an 
isotype control (20μg/ml, Ebioscience, Clone P.3.6.2.8.1) at day 0, 2 and 4 time points.  
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2.5.6 Intracellular cytokine, CD107 and Granzyme B staining  
T-cell intracellular cytokine and granzyme B expression and surface CD107 were used 
to determine the activation status and cytotoxic potential of T-cells from CLL patients. 3x10
6
 
CLL PBMCs were seeded per well in a 24-well plate in 2ml of AB media. Each well received 
PBS, 10ng/ml blinatumomab (Amgen) or 7.5µl of Human T-Activator CD3/CD28 
Dynabeads (Invitrogen). The cells were then incubated for 7 days before being removed into 
15ml falcon tubes and washed in 1ml of fresh AB media. The number of viable cells in each 
tube was determined using trypan blue staining and ≤1x106 viable cells were added to two 
FACS tubes. One FACS tube would be later stained for IFN-γ and TNF-α and the other tube 
for granzyme B and CD107. The cells were then centrifuged at 756 x g for 2 minutes, the 
supernatant removed and the pellet re-suspended in 190µl of AB media. 1μl of golgi plug and 
0.7μl golgi stop (BD biosciences) was added to 198.3μl of PBS and 20µl was added to each 
FACS tube. 10µl of CD107-(FITC) was added to those tube measuring CD107 and granzyme 
B, and all the tube were incubated for 5 hours at 37°C. 
  After the incubation, human T-activator CD3/CD28 beads were removed with a magnet 
and 1ml of PBS added to each tube. The cells were centrifuged at 756 x g for 2 minutes, the 
supernatant removed and the cells stained with the fluorescent dye aqua. The cells were then 
surface stained with antibodies to CD5-(PERCP-Cy5.5), CD4-(Pacific Blue) and CD8-(AM 
Cyan) followed by incubation at 4°C for 15 minutes. Cells were again washed twice with 1ml 
of FACS buffer then incubated for 20 minutes in the dark in 200µl of 
fixation/permeabilisation solution (BD biosciences). Perm/Wash Buffer (BD biosciences) 
was diluted 1/40 in PBS and 2x 200µl used to wash the cells before re-suspension in 50µl of 
the Perm/wash buffer. Each tube then received antibodies to IFN-γ-(PE) and TNF-α-(APC) or 
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CD107-(FITC) and Granzyme B-(PE). Cells were again incubated at 4°C for 15 minutes, 
washed twice in FACS buffer and re-suspended in 300µl of FACS buffer.  
 
2.6 Cytokine assays 
2.6.1 Supernatant transfer assay 
PBMCs were incubated for three days in the presence or absence of CD3/CD28 beads 
(7.5μl). One ml of media was then carefully removed and stored at -20°C. Purified B-cells 
were isolated from CLL patients using a CLL isolation kit using the procedure outlined 
previously. B-cells (1x10
6
 aliquots) were added to FACS tubes in 250µl of AB media. The 
supernatants were then thawed with 1 tube receiving 250µl of supernatant from the untreated 
culture, 1 tube receiving 250µl of supernatant from the CD3/CD28 bead treated culture and 
the last tube receiving 250µl of fresh AB media. The cells were then incubated at 37°C for 24 
hours and the CLL cells measured for activation markers (HLA-DR and CD69) and PDL-1 
expression by flow cytometry. 
 
2.6.2 B-cell Cytokine Assay  
Purified CLL cells were incubated in the presence or absence of 7 cytokines IFN-γ 
(10ng/ml), TNF-α (5ng/ml), IL-2 (10 IU/ml), IL-8 (10ng/ml), IL-4 (5ng/ml), IL-10 (5ng/ml) 
and IL-12 (5ng/ml). Briefly, 1x10
6
 CLL cells were suspended in 500µl of AB media in sterile 
FACS tubes and single cytokines added to separate tubes at the final concentrations indicated. 
The cells were then incubated at 37°C for 24 hours and the CLL cells measured for activation 
markers (HLA-DR and CD69) and PDL-1 expression by flow cytometry.  
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2.6.3 Cytokine bead array 
This assay was used to determine the type of cytokines secreted by CLL PBMC after 
incubation for 3 days in the presence of blinatumomab. One ml of supernatant from 10 CLL 
patient PBMC cultures treated with or without 10ng/ml blinatumomab for 3 days was stored 
at -20°C.  
 
Standards and sample preparation  
Lyophilised cytokine standards were reconstituted in distilled water according to the 
label on the standard vial. Ten microlitres of each cytokine standard was added to a vial 
labelled standard 1 and filled up to a final volume of 200µl with 1x assay buffer (50ml of 10x 
assay buffer concentrate (Ebiosciences) diluted in 450ml distilled water). One hundred 
microlitres of assay buffer was added to 6 separate tubes labelled standard 2 to 7 and 50µl of 
standard 1 used to serial dilute the initial standard mixture. Twenty five microlitres of each 
standard mixture dilutions 1 to 7 was then added to 7 separate tubes. Meanwhile the 
supernatants from the 3 day PBMC cultures were thawed and 25µl of supernatant from the 
untreated and treated cultures added to separate labelled tubes. 
 
Cytokine Bead mixture 
Beads that would bind the cytokines in the supernatant were prepared by calculating the 
final bead mixture volume required for all samples (25µl x number of tests for standard 
curves, blank and samples). The individual cytokine bead vials were then vortexed and 1/20 
of the total bead mixture volume required of each bead set added to a vial labelled ‘bead 
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mix’. Reagent dilution buffer (Ebiosciences) was then added to the vial labelled ‘bead mix’ to 
make up to the total bead mixture volume. The vial was then centrifuged at 3000 x g for 5 
minutes and the supernatant removed leaving 50µl of liquid in the vial. The volume of liquid 
removed was replaced with the same volume of fresh reagent dilution buffer. Twenty-five 
microlitres of the bead mixture was then added to all the standard and sample tubes including 
a blank tube.   
 
Preparation of Biotin-conjugate and strepavidin-PE solution 
A biotin-conjugated second antibody mixture was made up in order to bind cytokines 
that had been capture by the cytokine bead mixture. Briefly each biotin conjugated antibody 
was added to a vial labelled biotin-conjugate mix at 1/20 of the final volume required (final 
volume= 50µl x number of tests for standard curve, blank and samples). The vial was then 
made up to the final volume by adding reagent dilution buffer. 50µl of the biotin-conjugate 
mixture was added to all tubes including standards, samples and the blank and the tubes left 
at RT for 2 hours in the dark.  
      After the incubation the tubes were washed twice by centrifugation at 200 x g for 5 
minutes in 1ml of assay buffer. The streptavidin-PE solution was diluted in assay buffer and 
50µl added to each tube. The tubes were then incubated for 1h at RT in the dark followed by 
two wash steps with assay buffer as outlined previously. Five hundred microlitres was added 
to each tube and the samples analysed by flow cytometry (BD FACS Canto II). Cytokine 
concentrations were calculated using FlowCytomix Pro 2.2 Software (Ebiosciences).  
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2.7 FACS-based cytotoxicity assay 
2.7.1 Measuring absolute counts of cells 
The absolute number of viable T-cells and CLL cells was assessed after incubation in 
the presence or absence of blinatumomab (10ng/ml). An agonistic anti-CD3 antibody 
(27.7ng/ml) or CD3/CD28 beads (7.5μl) were used as controls. CLL PBMC (3x106) were 
incubated in 2mls of AB media in the presence of BiTE, anti-CD3 antibody or CD3/CD28 
beads for 7 days at 37°C. The cells were then resuspended by repetitive pipetting and 1ml of 
the cell suspension added to a 5ml FACS tube. The cells were then centrifuged at 756 x g for 
2 minutes and 900µl of the supernatant carefully removed from each tube. Two hundred 
microlitres of binding buffer was then added to each tube and the cells surface stained with 
antibodies to Annexin V-(FITC), CD5-(Percp-cy5.5), CD8-(APC-CY-7) and CD4-(Pacific-
blue) before being incubated for 15 minutes at  4°C. After incubation, 100µl of cytocount 
beads (Dako) was added to each tube and analysed by flow cytometry. In total 3x10
6
 events 
were recorded and the absolute number of cells was determined using the following 
equation:-  
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2.7.2 T-cell cytotoxicity assay in co-culture with TL (CD40L) 
CLL PBMCs were incubated in the presence or absence of NTLs or TL (CD40L). Each 
well containing NTLs received PBS (untreated control) or blinatumomab (10ng/ml or 
100ng/ml). The procedure was repeated for the wells containing CD40L cells and the wells 
containing media only. The plate was then incubated at 37°C for 7 days. On day 7, CLL 
PBMCs were carefully removed from the surface of the fibroblast monolayer, washed twice 
in PBS and surface stained with the dead cell stain aqua. The cells were re-suspended in 
200µl of binding buffer (Ebiosciences) and labelled with antibodies against Annexin V, 
CD20, CD5, CD8 and CD4 for 15 minutes before analysis by flow cytometry. CLL cell death 
based on 2-4x10
5
 events, was determined by measuring the percentage of Annexin V
+
 CLL 
cells in each sample. 
 
2.8 T-cell and CLL cell imaging 
2.8.1 Immunofluorescence labelling of T-cells and CLL cells 
Purified T-cells were labelled with 15mM red CFSE (Invitrogen) and purified CLL 
cells labelled with 10mM Green CFSE (Invitrogen) in 1ml of RPMI supplemented with 1% 
FCS. Cells were incubated at 37°C for 10 minutes before being washed twice in RPMI 
supplemented with 10% FCS. Labelled cells were then added to a 48 well plate in a total of 
1ml of AB media at a ratio of 1 T-cell to 10 CLL cells. The cells were incubated in the 
presence or absence of blinatumomab (10 or 100ng/ml) for 12 hours.   
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2.8.2 Preparation of cells for phase contrast imaging 
1.5x10
6
 CLL PBMC were incubated in the presence or absence of blinatumomab (10, 
100ng/ml), CD3 (27.7ng/ml, 277.7ng/ml) or CD3/CD28 beads (7.5μl). Cells were incubated 
for 12hours in a 48-well plate in 1ml of AB media 
 
2.8.3 Phase contrast and confocal microscopy 
Phase contrast and confocal microscopy were performed using a Leica RS2 microscope 
and analyzed using Leica confocal software (Leica Microsystems, Milton Keynes, UK) and 
Image J software (National institutes of Health (NIH) USA). For 3-D image reconstruction of 
clusters, 50 confocal sections were taken and assembled using Imaris imaging software 
(BITPLANE scientific software Zurich Switzerland). 
 
2.9 Statistical analysis  
All statistical analysis was performed using Graphpad Prism 5.0 software (Graphpad 
Inc.). For variables between independent groups a non-parametric Mann-Whitney U test was 
used. For statistical analysis between 1 group measuring two nominal variables, a paired t-
test was used when the data were shown to conform to a Gaussian distribution. Correlations 
between CD4:CD8 ratios and other prognostic markers were determined using a Fisher’s 
exact test or Chi-squared test. Time to first treatment and progression-free survival were 
calculated from the patients’ date of diagnosis and curves constructed using Kaplan and 
Meier methodology. 
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CHAPTER 3 
 Immunophenotypic characterisation of T-cells from CLL patients 
 
 CLL is a disease characterised by profound immune dysfunction whereby CLL cells 
exert immunosuppressive mechanisms in order to avoid immune recognition (Ramsay and 
Gribben 2009). Furthermore, the relative failure to mount effective immune responses in CLL 
patients likely contributes to the pathogenesis of the disease including the progressive 
accumulation of tumour cells and the increased susceptibility to infection (Ravandi and 
O'Brien 2006). As yet the mechanisms behind CLL cell subversion of immune effector cells 
in particular T-cells, has not fully been characterised. 
    Flow cytometry is an established tool in the diagnosis, characterisation and monitoring 
of haematological malignancies and in viral infections including HIV (Barnett et al. 2008, 
Craig and Foon 2008). The objectives of this chapter were to use multi-colour flow cytometry 
to undertake phenotypic analysis of T-cells from the peripheral blood of 50 CLL patients, in 
order to identify any disease-associated T-cell abnormalities. Data generated from the 
analysis of these 50 CLL patients was subsequently pooled with a series generated by Dr 
Claudia Nunes, to obtain a cohort of over 100 CLL patients and a smaller cohort of 22 
healthy age-matched normal controls.  
    There is growing evidence to suggest T-cells play a key role in CLL pathogenesis.  
Increased numbers of activated T-cells have been documented in CLL, particularly in those 
patients with advanced disease (Tötterman et al. 1989). Furthermore, a recent report showed 
that the telomere length of T-cells was shortened in advanced stage CLL patients suggesting 
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that T-cells may indeed be proliferating in response to the growth of the CLL clone (Röth et 
al. 2008). In this study, an in-depth retrospective analysis was performed on T-cells using 
immunophenotyping data collected from over 100 CLL patients with the aim of identifying 
poor prognostic patients based on T-cell abnormalities. The identification of T-cell 
abnormalities which affect prognosis may be crucial in directing the development of future 
therapies in CLL.  
 
3.1 Lymphocyte populations in CLL patients 
To confirm the findings of previous studies, the frequency of lymphocyte populations 
including CD19
+
CD5
+ 
B-cells, T-cells (CD4
+
 and CD8
+
) and NK cells were enumerated in 
the peripheral blood of CLL patients and healthy age-matched donors (Figure 3.1 and 3.2). 
As expected the frequency of CD19
+
CD5
+
B-cells were significantly increased in the blood of 
CLL patients, when compared to healthy controls (Mean: 77.2% vs. 4.4%, P<0.0001). In 
contrast the percentage of CD3
+
 T-cells was decreased in CLL patient lymphocytes compared 
to control samples (Mean: 12.1% vs. 61.1%, P<0.0001). Within the CD3
+
 T-cell 
compartment, CLL patients had a significantly lower percentage of CD4
+
 T-cells when 
compared to healthy donors (Mean 40.3% vs. 57.2%, P=0.002). Conversely the percentage of 
CD8
+
 T-cells in the CLL cohort was significantly higher than the healthy donors (Mean 
41.6% vs. 30.9%, P=0.03). Measurement of absolute T-cell counts for 50 CLL patients and 
10 healthy donors revealed increased numbers of CD4
+
 and CD8
+
 in CLL patients (Figure 
3.11). 
  NK cells are another population of lymphocytes capable of recognising and targeting 
tumour cells. Analysis of the NK population in CLL patients showed that there was a 
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significantly lower percentage of NK cells within the CLL samples compared to the healthy 
control group (Mean 1.5% vs. 6.7%, P<0.0001). 
  Overall these results show that CD19
+
CD5
+
 B-cells dominate the lymphocyte 
population in CLL patients. In addition, they show that the frequency of both NK cells and 
CD3
+
 T-cells are significantly reduced in CLL patients with a trend towards increased CD8
+
 
T-cells and reduced CD4
+
 T-cells.  
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(A) CLL PATIENT 
               
                 B-cells                                            NK cells                            CD4+ and CD8+ T-cells 
 
(B) HEALTHY DONOR                   
                        
                     B-cells                                              NK cells                            CD4
+ 
and CD8
+ 
T-cells
                  
Figure 3.1. Gating strategy for the identification of B, T and NK cells from CLL 
patients (A) and healthy age-matched controls (B) The number of positive cells was 
measured using 8-colour flow cytometry (FACS Canto ІІ). Lymphocytes were gated based on 
forward and side scatter and separated on the cell surface expression of CD3. Within the CD3 
negative population both CD19
+
CD5
+
 B-cells and CD56
+
CD16
+
 were defined. In the CD3 
positive population both CD4
+
 and CD8
+
 T-cells were gated.     
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Figure 3.2. The frequency of peripheral blood lymphocyte populations in CLL patients 
(n=51-58) and healthy donors (n=12). The number of positive cells was measured using 8-
colour flow cytometry (FAC Canto ІІ). Lymphocytes were gated based on forward and side 
scatter profiles. The percentages of CD19
+
CD5
+ 
(CLL patients) and CD19
+ 
(Healthy donors) 
B-cells, CD3
+ 
T-cells and CD56
+
CD16
+
CD3
-
 (NK cells) within the lymphocyte gate are 
shown. CD4
+ 
and CD8
+ 
T-cells are measured within the lymphocyte/CD3 gate. The mean 
within each group is shown. Statistical analysis (Mann-Whitney U test) was carried out using 
GraphPad Prism. 
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3.2 T-cell subsets in CLL patients 
In order to gain new insights into why CLL patients respond so poorly to 
immunological challenge, a comprehensive analysis of CD4
+
 and CD8
+
 T-cell subsets was 
performed comparing healthy donors (age range 44-77 yrs, mean: 64yrs) and CLL patients. 
In ageing and during persistent viral infections, studies have shown there is a decline in naїve 
T-cell numbers and a skewing of T-cells towards a memory phenotype with limited T-cell 
repertoire diversity (Nikolich-Zugich 2008). This process is coupled with the down regulation 
of the co-stimulatory receptor CD28 on the surface of T-cells and an increase in the 
expression of CD57, a marker associated with a senescent/exhausted phenotype (Brenchley et 
al. 2003, Joshi and Kaech 2008). High levels of CD57
+
 T-cells have been observed in chronic 
viral infections such as HIV and have been associated with poor prognosis in solid cancers 
(Weekes et al. 1999, Focosi et al. 2010). 
  Using flow cytometry, T-cell subsets from CLL patients were separated based on their 
expression of the chemokine receptor CCR7; responsible for migration of T-cells to the 
lymph nodes from the peripheral blood and the surface marker CD45RO. T-cells were 
separated into naїve (CCR7+CD45RO-), central memory (CCR7+CD45RO+), effector 
memory (CCR7
-
CD45RO
+
) and highly differentiated effector cells (EMRA) (CCR7
-
CD45RO
-
). Within each subset CD28 and CD57 expression were analysed to identify cells 
with an antigen experienced/exhausted phenotype (Figure 3.3). 
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         A                                                              B 
         
 
         C    
                                    
Figure 3.3. Gating strategy for the measurement of CD28 and CD57 expression within 
CD4
+
 and CD8
+
 T-cell subsets. The number of positive cells was measured using 8-colour 
flow cytometry (FACS Canto ІІ). Lymphocytes were gated based on forward and side scatter 
profiles. (A) Separation of CD4
+
 T-cells into CD45RO
+
 and CD45RO
-
 subsets (B) Gating of 
Naїve, Central memory (CM), Effector memory (EM) and EMRA T-cells using both CCR7 
and CD45RO markers within the CD4
+
 T-cell population. (C) Within T-cell subsets the 
gating strategy for defining CD28
-
 and CD57
+
 cells.  
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3.2.1 CD8
+
 T-cells 
Within the CD8
+
 population, T-cells were separated based on their expression of 
CD45RO (Figure 3.4). The CD45RO
+
 population had a significantly higher percentage of 
CD28
-
 (P=0.004) and CD28
-
CD57
+
 (P=0.009) T-cells in CLL patients compared to healthy 
controls. In contrast, analysis of the CD45RO
-
 population showed no statistically 
significantly difference in CD28
-
 or CD28
-
CD57
+
 T-cells between the CLL and healthy 
cohorts. Using CCR7 and CD45RO, CD8
+
 T-cells were further sub-categorised into naїve, 
CM, EM and EMRA subsets (Figure 3.5). There was a significant decrease in naїve CD8+ T-
cells (P=0.004) in CLL patients when compared to healthy donors. The percentage of CD8
+
 
T-cells displaying a CM, EM and EMRA phenotype however were not statistically different 
in CLL patients compared to controls. Analysis of CD28
-
 and CD57
+
 T-cells within each 
CD8
+
 T-cell subset showed there was a significant increase in CD28
-
 (P=0.008) and CD57
+
 
(P=0.004) CD8
+
 T-cells within the EM compartment of CLL patients compared to healthy 
donors. Increased percentages of CD28
-
 and CD57
+
 T-cells were also seen in the CD8
+
 
EMRA subset but this did not reach significance (Figure 3.6).  
    These results showed that there is a significant decrease in naїve CD8+ T-cells and a 
trend towards increased EM CD8
+
 T-cells in CLL patients compared to healthy-age matched 
controls. Analysis of CD8
+
 T-cells revealed a significantly increase in CD28
-
 and CD57
+
  
within the EM subset of CLL patients a phenotype previously associated with replicative 
senescence. 
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 A 
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Figure 3.4. The expression of CD57, CD28 and CD45RO in CD8
+ 
T-cells from CLL 
patients (n= 49) and healthy donors (n=11). The number of positive cells was measured 
using 8-colour flow cytometry (FACS Canto ІІ). Lymphocytes were gated based on forward 
and side scatter profiles. (A) The percentage of CD28
-
 cells in the CD45RO
+
 and CD45RO
-
 
subsets within the CD8
+
 T-cell gate. (B) The percentage of cells negative for CD28 but 
positive for CD57 within both the CD45RO
+
 and CD45RO
-
 subsets in the CD8
+
 T-cell gate. 
The mean within each group is shown. Statistical analysis (Mann-Whitney test) was carried 
out using GraphPad Prism. 
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Figure 3.5. The expression of Naїve, Central memory, Effector memory, and Effector 
(EMRA) CD8
+
 T-cells in CLL patients (n=49) and healthy donors (n=11). The number of 
positive cells was measured using 8-colour flow cytometry (FACS Canto ІІ). Lymphocytes 
were gated based on forward and side scatter profiles. CD8
+
 T-cell subsets were gated based 
on their expression of CCR7 and CD45RO, Naїve (CCR7+CD45RO-), Central memory (CM) 
(CCR7
+
CD45RO
+
), Effector memory (EM) (CCR7
-
CD45RO
+
) and Effector (EMRA) (CCR7
-
 
CD45RO
-
). CLL=CLL Patient, HD=Healthy age-matched donor. The mean within each 
group is shown. Statistical analysis (Mann-Whitney test) was carried out using GraphPad 
Prism. 
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CD28
- 
   
 
 CD57
+ 
  
Figure 3.6. The frequency of CD28
-
 and CD57
+
 cells within CD8
+
 T-cell subsets from 
CLL patients (n=49) and healthy donors (n=11). The number of positive cells was 
measured using 8-colour flow cytometry (FACS Canto ІІ). Lymphocytes were gated based on 
forward and side scatter profiles. CD8
+
 T-cell subsets were gated based on their expression of 
CCR7 and CD45RO, Naїve (CCR7+CD45RO-), Central memory (CM) (CCR7+CD45RO+), 
Effector memory (EM) (CCR7
-
CD45RO
+
) and Effector (EMRA) (CCR7
-
 CD45RO
-
). 
CLL=CLL Patient, HD=Healthy age-matched donor. The mean within each group is shown. 
Statistical analysis (Mann-Whitney U test) was carried out using GraphPad Prism. 
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3.2.2 CD4
+
 T-cells 
Within the CD4
+
 T-cell population both CD45RO
+
 and CD45RO
-
 subsets were 
analysed from their expression of CD28 and CD57 (Figure 3.7). There was a significant 
increase in both CD45RO
+
CD28
- 
(P=0.04) and CD45RO
+
CD28
-
CD57
+
 (P =0.04) cells within 
the CD4
+
 compartment of CLL patients compared to healthy controls. Analysis of the 
CD45RO
- 
CD4
+ 
T-cell compartment showed no significant difference in the percentage of 
CD28
-
 or CD28
-
CD57
+
 cells. When the CD4
+
 T-cells compartment was separated into naїve, 
CM, EM and EMRA subsets based on CCR7 and CD45RO expression a significant increase 
in the percentage of EM CD4
+
 T-cells was observed in CLL patients compared to controls 
(P=0.04). In contrast a significant decrease in CM CD4
+
 T-cells was seen in CLL patients 
(P=0.04, Figure 3.8). Analysis of CD4
+
 T-cell subset revealed an increase in CD28
-
 (P=0.02) 
and CD57
+
 (P=0.008) cells within the EM CD4
+
 T-cell compartment of CLL patients 
compared to healthy controls whilst the other compartments showed no statistically 
significant differences (Figure 3.9). 
    These results revealed a significant decrease in CM and a trend towards a decrease in 
naïve CD4
+ 
T-cells within CLL patients when compared to healthy age-matched controls. In 
contrast there was a significant increase in EM CD4
+ 
T-cells in CLL patients. In a similar 
fashion to the CD8
+
 T-cell compartment, analysis of CD57
+
 and CD28
-
 cells revealed a 
significant increase in the EM compartment of CD4
+ 
T-cells in CLL patients.  
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Figure 3.7. The expression of CD57, CD28 and CD45RO in CD4
+ 
T-cells in CLL 
patients (n= 49) and healthy donors (n=11). The number of positive cells was measured 
using 8-colour flow cytometry (FACS Canto ІІ). Lymphocytes were gated based on forward 
and side scatter profiles. (A) The percentage of CD28
-
 cells in the CD45RO
+
 and CD45RO
-
 
subsets within the CD4
+ 
T-cell gate. (B) The percentage of cells negative for CD28 but 
positive for CD57 within both the CD45RO
+
 and CD45RO
-
 subsets in the CD4
+
 T-cell gate. 
The mean within each group is shown. Statistical analysis (Mann-Whitney U test) was carried 
out using GraphPad Prism. 
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Figure 3.8. The expression of Naїve, Central memory, Effector memory, and Effector 
(EMRA) CD4
+
 T-cells in CLL patients (n=49) compared to healthy controls (n=12). The 
number of positive cells was measured using 8-colour flow cytometry (FAC Canto ІІ). 
Lymphocytes were gated based on forward and side scatter profiles. CD8
+
 T-cell subsets 
were gated based on their expression of CCR7 and CD45RO: Naїve (CCR7+CD45RO-), 
Central memory (CM) (CCR7
+
 CD45RO
+
), Effector memory (EM) (CCR7
-
CD45RO
+
) and 
Effector (EMRA) (CCR7
-
CD45RO
-
). The mean within each group is shown. Statistical 
analysis (Mann-Whitney U test) was carried out using GraphPad Prism. CLL=CLL Patient, 
HD=Healthy age-matched donor.  
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Figure 3.9. The frequency of CD28
-
 and CD57
+
 cells within the CD4
+
 T-cell subsets from 
CLL patients (n=49) and healthy donors (n=12). The number of positive cells was 
measured using 8-colour flow cytometry (FACS Canto ІІ). Lymphocytes were gated based on 
forward and side scatter profiles. CD4
+
 T-cell subsets were gated based on their expression of 
CCR7 and CD45RO, Naїve (CCR7+CD45RO-), Central memory (CM) (CCR7+CD45RO+), 
Effector memory (EM) (CCR7
-
CD45RO
+
) and Effector (EMRA) (CCR7
-
CD45RO
-
). CLL= 
CLL Patient, HD= Healthy age-matched donor. The mean within each group is shown. 
Statistical analysis (Mann-Whitney U test) was carried out using GraphPad Prism. 
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3.3 The prognostic significance of T-cell subsets in CLL 
Phenotypic markers identified on the malignant B-cell clone have proven highly successful in 
classifying patients likely to undertake rapid disease progression (Van Bockstaele, Verhasselt 
and Philippé 2009), yet little is known about the prognostic power of other immune cells 
including T-cells. In this study retrospective analysis was performed on T-cells using 
immunophenotyping data collected from over 100 CLL patients with the aim of identifying 
poor prognostic patients based on the presence of T-cell abnormalities. 
 
3.3.1 Inversion of the CD4:CD8 ratio in a subset of CLL patients  
Phenotypic analysis of the CD3
+
 T-cell populations revealed that 47% of patients had a 
preferential expansion of CD8
+ 
T-cells compared to the CD4
+
 T-cells (Figure 3.10A). 
Therefore the patient cohort was divided into patients with an inverted CD4:CD8 ratio 
(CLL
IR
) and normal (non-inverted) ratio (CLL
NR
) based on a CD4:CD8 ratio threshold of 1.0. 
This threshold was based on the median CD4:CD8 ratio of the whole patient cohort and also 
represented the ratio at which the percentage of CD8
+
 T-cells outnumbered that of the CD4
+
 
T-cells (Figure 3.10B).  
Absolute numbers of T-cells were measured in 25 CLL
IR
 and 25 CLL
NR 
patients and 10 
healthy age-matched controls (Figure 3.11). Both CLL
IR
 and CLL
NR 
patients had increased 
numbers of CD4
+ 
and CD8
+ 
T-cells compared to healthy controls. Comparison CLL
IR
 and 
CLL
NR 
patients showed similar numbers of CD4
+ 
T-cells in both cohorts (CLL
IR
 1289 vs 
CLL
NR 
1317) but increased numbers of CD8
+ 
T-cells in the CLL
IR 
group (CLL
IR
 1524 vs 
CLL
NR 
842). 
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Figure 3.10. The incidence of normal and inverted CD4:CD8 ratios in CLL patients. (A) 
The number of patients within the cohort that had an inverted ratio (CD4:CD8 <1) and 
normal ratio (CD4:CD8 ≥1) of CD4+ and CD8+ T-cells. (B) The CD4:CD8 ratio was 
determined for the cohort of 110 CLL patients with a median ratio of 1.0. (C) The median age 
of CLL patients in the CLL
IR
 and CLL
NR 
groups. Statistical analysis (Mann-Whitney U test) 
was carried out using GraphPad Prism. 
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T lymphocyte 
subsets 
CLL patient samples 
 
Normal CD4:CD8       Inverted CD4:CD8 
        (n=25)                          (n=25) 
    
Age-matched 
healthy donors 
(n=10) 
CD4+ T-cells in CD3 1317± 564 1289 ± 441 713 ± 342 
CD8+ T-cells in CD3 842 ± 332 1524 ± 303 308 ± 183 
 
Figure 3.11. Absolute numbers of CD4
+
 and CD8
+ 
T-cells from normal and inverted 
ratio CLL patients and healthy age-matched controls. 
   
 
3.3.2 Patients with an inversion of the CD4:CD8 ratio have an inferior prognosis  
In order to determine whether like other cancers (Markowska et al. 1995, Sheu et al. 
1999) the ratio of CD4:CD8 ratio had prognostic significance in CLL, the time to first 
treatment (TTFT) and progression-free survival of both the CLL
IR 
and CLL
NR 
patient groups 
were compared. Patients with an inverted ratio of CD4:CD8 were found to have a 
significantly shorter time to first treatment (P=0.03, Figure 3.11A) and progression-free 
survival (P= 0.005, Figure 3.11B) when compared to those patients with a normal CD4:CD8 
ratio. Importantly the inferior prognosis seen in the CLL
IR 
group was independent of the age 
of patients as there was no significant difference between the median ages of both groups at 
the date of testing (Figure 3.10C) 
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3.3.3 T-cell subset analysis of CLL
IR 
and CLL
NR 
patient groups  
In order to rationalise the poor prognosis associated with the inverted CD4:CD8 ratio 
group, detailed phenotypic analysis of T-cell subsets in both the CLL
IR 
and CLL
NR 
groups 
was performed. Using the markers CCR7 and CD45RO, T-cell subsets from both the CLL
IR 
and
 
CLL
NR group were separated into naїve (CCR7+CD45RO-), central memory 
(CCR7
+
CD45RO
+
), effector memory (CCR7
-
CD45RO
+
) and highly differentiated effector 
cells (EMRA) (CCR7
-
CD45RO
-
). An increased frequency of CD57
+
CD27
-
CD28
-
 T-cells has 
been shown during normal aging and in individuals with chronic viral infections and cancer 
(Merino et al. 1998). These CD57
+
CD27
-
CD28
-
 T-cells have also been associated with a 
replicative senescence phenotype with an enhanced tendency to undergo apoptosis 
(Brenchley et al. 2003, Van den Hove et al. 1998). Therefore differences in the frequency of 
these CD57
+
CD27
-
CD28
-
 T-cells within memory subsets of T-cells from CLL
IR
 and CLL
NR 
patient groups were examined, as well as for healthy age-matched donors.  
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Figure 3.12. Kaplan-Meier curves for time to first treatment and progression-free 
survival for CLL
IR 
(n= 41)
 
and CLL
NR 
patients (n=43). Kaplan-Meier analysis was used to 
assess the effect of a CLL patient’s CD4:CD8 ratio on (A) time to first treatment (TTFT) and 
(B) progression-free survival (PFS). A log-rank test was used to test the difference between 
the two curves. (HR=Hazard ratio) 
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 A 
 
 B 
 
Figure 3.13. The percentage of Naїve, CM, EM and EMRA within the (A) CD8+ and (B) 
CD4
+ 
T-cells populations of CLL
IR
 (n=43), CLL
NR
(n=43) and healthy donors (n=19). 
The number of positive cells was measured using 8-colour flow cytometry (FACA Canto ІІ). 
Lymphocytes were gated based on forward and side scatter profiles. CD8
+
 and CD4
+
 T-cell 
subsets were gated based on their expression of CCR7 and CD45RO: Naїve 
(CCR7
+
CD45RO
-
), Central memory (CM) (CCR7
+
 CD45RO
+
), Effector memory (EM) 
(CCR7
-
CD45RO
+
) and Effector (EMRA) (CCR7
-
CD45RO
-
). The mean within each group is 
shown. Statistical analysis (Mann-Whitney U test) was carried out using GraphPad Prism. 
CLL
IR
 = CLL Patient (CD4:CD8 ratio <1) CLL
NR
 = CLL patient (CD4:CD8 ratio 1) and HD 
= Healthy age-matched donor. 
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3.3.4 Patients with an inverted CD4:CD8 ratio have an expansion of CD8
+
 T-cells with a             
         highly differentiated effector phenotype 
Analysis of T-cell subsets revealed a significant decrease in both naїve (P=0.002) and 
CM (P=0.004) CD8
+
 T-cells in the CLL
IR
 group compared to the CLL
NR 
group. In contrast, 
there was a significant increase in EMRA CD8
+
 T-cells in the CLL
IR 
group (P=0.03). Within 
the CD4
+
 T-cell population there was also a significant decrease in naїve T-cells (P=0.0007) 
with a concomitant increase in EM T-cells (P=0.0005) but not EMRA T-cells (P=0.32) within 
the CLL
IR 
group in comparison to the CLL
NR 
group (Figure 3.13). 
    Overall these results identified a preferential decrease of naïve CD4
+ 
and CD8
+ 
T-cells 
in the CLL
IR 
group in comparison to the CLL
NR 
group. This change in naïve T-cells was 
associated with a significant increase in EMRA CD8
+ 
T-cells and EM CD4
+ 
T-cells in the 
CLL
IR 
group.   
 
3.3.5 Increased frequency of CD57
+
 CD27
-
CD28
-
 T-cells within the CLL
IR 
patient group 
Within the CD8
+
 T-cell compartment CD57
+
CD27
-
CD28
-
 T-cells were significantly 
increased in the EM (P=0.019) subset and progressing towards significance in the EMRA 
subset (P=0.06) of CLL patients compared to healthy controls (Figure 3.14A). When the CLL 
patient cohort was separated into the CLL
IR
 and CLL
NR 
groups, significantly higher 
percentages of CD8
+
CD57
+
CD27
-
CD28
-
 T-cells were seen in the EM (P=0.0005) and EMRA 
(P=0.002) subsets in the CLL
IR
 compared to healthy donors. No significant difference in 
CD8
+
CD57
+
CD27
-
CD28
-
 T-cells was seen between the CLL
NR 
group and healthy group in 
both the EM and EMRA subsets (Figure 3.14B). The presence of CD57
+
CD27
-
CD28
-
 T-cells 
was also assessed in the EM subset within CD4
+
 T-cell population. There was a significant 
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increase in CD4
+
CD57
+
CD27
-
CD28
-
 T-cells within the EM subset from CLL patients 
compared to healthy controls (Figure 3.14C). When assessing both the CLL
IR
 and CLL
NR 
groups compared to healthy controls, only the CLL
IR 
patient group had a significantly higher 
percentage of CD4
+
CD57
+
CD27
-
CD28
-
 T-cells in the EM subset (P=0.01, Figure 3.14D). 
Due to the low frequency of CD4
+
 T-cells displaying an EMRA phenotype in CLL patients, 
no comparative analysis was made of this population between the CLL
IR
 and CLL
NR 
groups.            
    Overall these results show an increase in CD57
+
CD27
-
CD28
-
 T-cells within the EM/ 
EMRA CD8
+ 
T-cell compartment and EM CD4
+ 
T-cell compartment of CLL patients 
compared to healthy donors. These CD57
+
CD27
-
CD28
-
 T-cells were preferential expanded in 
CLL patients from the CLL
IR
 group compared to the CLL
NR
 group.  
 
3.3.6 CD8
+
CD57
+
 CD27
-
CD28
-
 T-cell expansions in the CLL
IR
 group are independent of                   
         patient CMV serostatus 
 
A previous study reported the expansion of CMV-specific CD8
+
CD45RA
+
CD27
-
 T-
cells in CMV-seropositive CLL patients (Mackus et al. 2003). In order to determine whether 
CMV infection could be driving the CD8
+
CD57
+
 CD27
-
CD28
-
 T-cell expansions in the 
CLL
IR
 group, the CMV serostatus of 20 CLL
IR
 and 20 CLL
NR
 patients was determined by the 
local Health Laboratory Service, Cardiff, Wales. 17 out of 20 CLL
IR 
patients and 15 out of 20 
CLL
NR 
patients were seropositive for CMV. Separation of CLL patients based on CMV 
serostatus revealed no significant differences in the percentage of CD8
+ 
T-cells or 
CD57
+
CD27
-
CD28
-
 T-cells between both groups (Figure 3.14E).  
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These results suggest that CMV cannot be solely responsible for the inversion of the 
CD4:CD8 ratio or the increase in CD57
+
CD28
-
CD27
-
 EM and EMRA T-cells observed in the 
CLL
IR 
group. 
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A                                                                B 
      
 
      C                                                D                                              E 
   
 
 
Figure 3.14. Expression of CD57
+
CD27
-
CD28
-
 cells within the EM and EMRA T-cells 
from CLL
IR
 (n=40), CLL
NR 
(n=43) and healthy donors (n=19). (A) Percentage of 
CD57
+
CD27
-
CD28
-
 EM and EMRA CD8
+ 
T-cells of the CLL patient cohort and age-matched 
healthy donors. (B) Percentage of CD57
+
CD27
-
CD28
-
 EM and EMRA CD8
+
 T-cells in the 
CLL
IR
, CLL
NR
 patient cohorts and healthy donors. (C) Percentage of CD57
+
CD27
-
CD28
- 
EM 
CD4
+
 T-cells in CLL patients and healthy donors. (D) Percentage of CD57
+
CD27
-
CD28
-
 EM 
in the CLL
IR
, CLL
NR
 patient cohorts and healthy donors. The EMRA subset was not included 
for CD4
+
 T-cells due to the low prevalence of this subset within the total CD4
+
 T-cell subset. 
(E) The effect of CMV serostatus on the percentage of CD8
+
 T-cells or the percentage of 
CD57
+
CD27
-
CD28
- 
T-cells in the CLL patient cohort. The mean within each group is shown. 
Statistical analysis (Mann-Whitney U test) was carried out using GraphPad Prism.   
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3.3.7 Inversion of the CD4:CD8 ratio associated with increased CD8
+
PD-1
+
 expression  
 
PD-1 is a negative regulator of TCR signalling which, like CD57
+
 has been associated 
with replicative senescence (Miles et al. 2010, D'Souza et al. 2007). The expression of PD-1 
in 77 out of 110 (70%) patients was investigated with the aim of determining whether this 
marker was differentially expressed between the CLL
IR 
and CLL
NR 
groups. There was a 
significant increase in the percentage of PD-1 expressing CD8
+ 
T-cells in the CLL
IR 
group 
when compared to the CLL
NR 
group (P=0.027, Figure 3.15A). This increase in PD-1 
expression within the CD8
+
 T-cell compartment was found to be independent of CMV 
serostatus (Figure 3.15B). 
    These results suggest that there is a preferential expansion of PD-1
+
 CD8
+
 T-cells 
within the CLL
IR
 group which is independent of patient CMV serostatus.  
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A                                                                         B 
 
   Figure 3.15. PD-1
+
 expression on CD8
+
 T-cells from CLL patients. (A) The percentage 
of CD8
+
PD-1
+
 T-cells in CLL patients with an inverted CD4:CD8 ratio and those with a 
normal CD4:CD8 ratio. (B) The percentage of CD8
+
PD-1
+
 T-cells in CMV-seronegative and 
CMV-seropositive CLL patient groups. The mean within each group is shown. Statistical 
analysis (Mann-Whitney U test) was carried out using GraphPad Prism. 
 
3.3.8 CLL
IR
 is not associated with the percentage of regulatory T-cells within the CD4
+  
              
compartment
 
A recent study showed an association between high levels of Tregs and shorter time to 
first treatment in CLL (Weiss et al. 2011). This study therefore looked at the frequency of 
regulatory T-cells within the CLL
IR
 group in order to determine if this could be responsible 
for the poor prognosis of this group (Figure 3.16). Within the total CLL cohort there was a 
significant increase in Tregs compared to healthy age matched controls (P=0.02, Fig. 3.16). 
However, upon separating the CLL patient cohort into CLL
IR 
and CLL
NR 
groups, there was 
no significant difference found in the percentage of Tregs between the CLL
IR 
group and  
healthy age-matched controls (P=0.07). 
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A                                                                       B   
                        
    
    C                                                                       D 
 
 
 
  
 
 
 
Figure 3.16. Gating strategy for the detection of CD4
+
CD25
HIGH
FOXP3
+ 
regulatory T-
cells from the blood of CLL patients. The number of positive cells was measured using 8-
colour flow cytometry (FACS Canto ІІ). Lymphocytes were gated based on forward and side 
scatter profiles. (A) CD3
+
 cells were gated within the lymphocyte population, (B) CD4
+
 cells 
within CD3
+
 gate, (C) Gating of CD4
+
CD25
HIGH
 cells within CD4
+
 gate and (D) FOXP3
+
 
cells within CD4
+
CD25
HIGH
 gate. 
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Figure 3.17. The frequency of CD4
+
CD25
HIGH
FOXP3
+ 
regulatory T-cells within the 
whole CLL patient cohort, the CLL
IR
 and CLL
NR 
subsets and healthy age-matched 
donors. Treg percentages were measured within the CD4
+ 
T-cell population of CLL patients 
and healthy age-matched donors. The mean within each group is shown. Statistical analysis 
(Mann-Whitney test) was carried out using GraphPad Prism. CLL
IR
 = CLL patient 
(CD4:CD8 ratio <1) CLL
NR
 = CLL patient (CD4:CD8 ratio 1) and HD = Healthy age-
matched donor. 
 
 
3.3.9 CLL
IR 
is not associated with tumour cell phenotype or Binet stage at diagnosis  
 In order to assess the prognostic significance of the inverted CD4:CD8 ratio further, 
CLL
IR
 and CLL
NR 
groups were analysed for their expression of established prognostic 
markers in CLL (Figure 3.18). This study found no significant difference in CD38 (P=0.8), 
ZAP-70 expression (P=0.15), IGHV mutational status (P=0.55) or Binet Stage (P=0.51) 
between the CLL
IR
 and CLL
NR 
groups. There was however a significant association between 
the inversion of the CD4:CD8 ratio and a shorter lymphocyte doubling time (LDT) (P=0.03). 
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      E 
 
 
 
 
 
 
Figure 3.18. Correlation of CD4:CD8 ratio and CD38 expression, ZAP-70 expression, 
IGHV gene mutational status, Binet stage at diagnosis and lymphocyte doubling time. 
(A), percentage of CD38 expression in the CLL
IR
, CLL
NR
 patients. (B), percentage of ZAP-
70 expression in CLL
IR
, CLL
NR
 patients. (C), percentage unmutated and mutated IGHV genes 
in CLL
IR
, CLL
NR
 patients. (D), number of CLL
IR
 and CLL
NR
 patients in stage A, B and C. 
(E), lymphocyte doubling time of CLL
IR
 and CLL
NR
 patients. Statistical analyses were 
performed using a Chi-squared test (3 variables compared between groups) or a Fisher’s 
exact test (2 variables compared between groups).  
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3.4 Discussion 
This study performed immunophenotypic analysis of T-cells from treatment-naїve early 
stage CLL patients with the aim of (A) characterising their dysfunctional status and (B) to 
determine if any T-cell abnormalities in CLL had prognostic significance within the disease.        
General analysis of the lymphocyte population from CLL patients showed a significant 
decrease in T-cells (CD4
+
 and CD8
+
) and NK cells compared to healthy age-matched 
controls. As only percentages of cells were measured it is somewhat unsurprising they were 
decreased given the relative expansion within this population of the leukaemic B-cell clone. 
Previous studies have however shown that whilst the percentage of T-cells and NK cells in 
the peripheral blood decreased, the absolute number of both populations is frequently 
increased in CLL patients (Vuillier et al. 1988). Indeed absolute count data obtained from 50 
CLL patients and 10 healthy donors in this study confirmed the expansion of T-cells in this 
study’s patient cohort (Figure 3.11).  
         The analysis of both CD4
+
 and CD8
+
 T-cells in the cohort of CLL patients revealed 
further abnormalities in T-cell phenotype. This study showed an expansion of CD28
-
CD45R0
+
 CD4
+
 and CD8
+
 T-cells, indicating an expansion of activated T-cells with a 
memory phenotype within CLL patients. This finding supports those of a previous study 
which showed an increased frequency of activated HLA-DR
+
 T-cells in CLL patients 
(Tötterman et al. 1989). Subset analysis revealed reduced percentages of naїve T-cells and a 
trend towards increased EM and EMRA T-cells within the CD8
+
 compartment. Similarly 
there was an expansion in EM and a trend towards a decrease in naїve T-cells within the 
CD4
+ 
compartment. This skewing of T-cells towards a memory phenotype has been reported 
previously in CLL and was found to be more pronounced in progressive patients compared to 
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stable patients (Tinhofer et al. 2009). These results confirm that T-cells are being chronically 
stimulated in CLL patients, which may contribute to the pathogenesis of the disease. 
       Phenotypic analysis of T-cell subsets revealed an increase in CD28
-
 EM T-cells in CLL 
patients. This reduction in CD28 expression may impair the ability of T-cells from CLL 
patients to receive activation signals from antigen presenting cells, including leukaemic B 
cells, which are known to display reduced levels of CD80 and CD86 (Dazzi et al. 1995). The 
study also showed that CD28 negativity was associated with an increase in CD57 expression 
on T-cells in CLL patients. Down regulation of CD28 and an increase in CD57 has been 
reported previously (Brenchley et al. 2003, Serrano et al. 1997, Weekes et al. 1999, Van den 
Hove et al. 1998) where it has been associated with reduced proliferative potential and an 
increased tendency to undergo apoptosis. Subset analysis of CD4
+
 and CD8
+
 T-cells revealed 
that this expansion of CD28
-
 and CD57
+
 cells was predominantly increased in the EM and 
EMRA compartments. CD4
+
CD57
+
 and CD8
+
CD57
+
 T-cells expansions have been reported 
previously in CLL patients where they were shown to have considerable oligoclonality 
(Serrano et al. 1997). The cause of these oligoclonal expansions remains unresolved, however 
several groups have suggested CMV reactivation may play a role in driving CD4
+
 and CD8
+
 
effector memory T-cell expansions in CLL (Mackus et al. 2003, Walton et al. 2010, 
Pourgheysari et al. 2010). Alternatively, other groups have pointed to this expansion as 
evidence for an anti-tumour T-cell response (Goddard et al. 2001, Rezvany et al. 2000). If 
indeed T-cell activation is being regulated by the CLL clone, studying these alterations in T-
cell populations may be important for understanding the pathogenesis of the disease. 
         As part of the comprehensive analysis of T-cells in CLL patients this study showed that 
52% of our patient cohort had a preferential expansion of CD8
+
 T-cells, leading to an 
inversion in the normal CD4:CD8 ratio. Patients with an inverted CD4:CD8 ratio have been 
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reported previously in CLL patients (Platsoucas et al. 1982) but this study showed for the first 
time that patients with an inverted ratio had a shorter time to first treatment conferring an 
inferior prognosis compared to normal ratio patients. This was independent of age and other 
established prognostic markers in CLL including CD38
 
and ZAP-70 expression, IGHV gene 
mutation status and Binet stage at diagnosis. The prognostic significance of CD4:CD8
 
ratios 
have been reported in solid cancers (Hernberg et al. 1997, Sheu et al. 1999) whilst in CLL the 
ratio of naїve to EM CD4+ T-cells has been shown to be an indicator of aggressive disease 
(Tinhofer et al. 2009). A recent study by Gonzalez-Rodriguez et al reported somewhat 
contradictory results to the findings presented here. They suggested that higher CD8 counts 
corresponded with higher medium survival times in CLL patients (Gonzalez-Rodriguez et al. 
2010). These results were however based on the ratio of T-cells to the number of malignant 
B-cells and therefore not directly comparable to results presented in this study. In addition, 
disease progression in CLL is usually associated with an increase in B-cell expansions. 
Therefore it is somewhat unsurprising that patients with a low T-cell to B-cell ratio had a 
poorer prognosis.      
In keeping with other reports this study showed an increase in Tregs in CLL patients 
(Giannopoulos et al. 2008). As Tregs have been showed to increase with disease progression 
and have been associated with decreased T-cell responses in CLL (Giannopoulos et al. 2008), 
the percentage of Tregs was analysed within both the CLL
IR 
and CLL
NR
 groups. This study 
revealed no correlation between Treg percentages and the invertion of the CD4:CD8 ratio 
suggesting Tregs are not responsible for the inferior prognosis of this group. There was 
however a positive correlation between the inversion of the CD4:CD8 ratio and LDT. LDT 
has been recently shown to be the most important determinant of TTFT in Stage A patients 
(Pepper et al. 2012). 
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The reasons behind the inversion of the CD4:CD8 ratio in a subset of CLL patients 
remains unclear; however absolute T-cell count analysis suggests that this inversion is caused 
by the preferential expansion of the CD8
+
 T-cell compartment rather than a relative reduction 
in CD4
+
 T-cells. Several studies have indicated that expansions of T-cells in CLL patients 
might be due to chronic antigen stimulation from persistent viral infections such as CMV 
(Pourgheysari et al. 2010, Walton et al. 2010, Mackus et al. 2003). It is possible that sub-
clinical CMV reactivation in these immunocompromised individuals may drive chronic 
antigen stimulation and exhaustion of the T-cell compartment. However, in this study the 
preferential expansion in CD8
+
 T-cells occurred in both CMV seropositive and seronegative 
CLL patients, indicating that CMV cannot be solely responsible for the inversion of the 
CD4:CD8 ratio or the increase in CD57
+
CD28
-
CD27
-
 EM and EMRA T-cells. These results 
are supported by a previous study that showed CD8
+
 T-cell expansions in CMV seronegative 
CLL patients, with CMV serostatus having no effect on the overall survival of CLL patients 
(Pourgheysari et al. 2010). Further analysis revealed an increase in CD8
+
 T-cells expressing 
PD-1 in the inverted ratio group, a marker associated with replicative senescence. Importantly 
this increase in PD-1 expression was independent of CMV serostatus. A logical extension to 
this work would be to use CMV tetramer technology to determine the number and phenotype 
of CMV-specific CD8
+
 T-cells in CLL patients and healthy donors. This would allow us to 
rule out CMV stimulation as the sole cause of this expanded CD8
+
 T-cell population in the 
CLL
IR 
group including those cells displaying CD57
+
CD27
-
CD28
- 
EM and EMRA 
phenotypes. 
    It is clear that CLL patients’ exhibit increased T-cell numbers compared to healthy age-
matched controls regardless of CMV serostatus. It is possible that other infectious antigens 
may be driving T-cell expansions or possibly that the tumour itself may support T-cell 
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proliferation through the release of cytokines or through the presentation of tumour antigens.  
T-cell responses to autologous CLL cells have been documented in vitro which most likely 
represent responses against multiple tumour antigens rather than a single immunodominant 
epitope (Gitelson et al. 2003). Several candidate tumour antigens have been identified in CLL 
including survivin, fibromodulin and MDM2 which are capable of expanding functional 
autologous tumour specific T-cells (Mayr et al. 2005, Schmidt et al. 2003, Mayr et al. 2006). 
If a tumour-specific response is responsible for the expansion of CD8
+
 T-cells seen in the 
CLL
IR 
group it would seem counter intuitive that these patients would have an inferior 
prognosis when compared to patients with a normal CD4:CD8 ratio. It is however possible 
that these expanded CD8
+
 T-cells are functionally tolerised and thus unable to elicit an anti-
tumour response. Tolerisation of T-cells has been shown to follow an initial period of T-cell 
proliferation (Redmond and Sherman 2005). Furthermore high frequencies of tolerised TAA-
specific CD8
+
 T-cells have been reported in cancer patients with impaired cytokine responses 
to mitogens and an inability to lyse tumour cell targets (Lee et al. 1999). The increased 
number of CD8
+
 T-cells found in the CLL
IR 
group may be due to a loss of immunological 
control in these patients whereby CD8
+
 T-cells are expanding in response to chronic 
stimulation from the tumour but ultimately become anergic. Indeed the increase in antigen 
experienced CD8
+ 
T-cells within the CLL
IR 
group, which are CD28
-
CD27
-
CD57
+
 and PD-1
+ 
indicates that there are a large proportion of effector cells that are highly differentiated and 
have a low proliferative potential in these patients. This may contribute to a reduced ability of 
memory responses to protect against reinfection or for established anti-tumour memory T-cell 
responses to respond to the growth of the tumour. Furthermore the relative reduction in naїve 
T-cells may lead to depletion in the TCR repertoire diversity within the naїve T-cell pool 
making it more difficult to mount immune responses to new infections or novel tumour 
antigens.  
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    Alternatively the poor prognosis of the CLL
IR 
patient group may be explained by the 
presence of CD57
+ 
T-cells. CD8
+
CD57
+ 
T-cells have been shown to secrete a lectin-binding 
soluble factor capable of inhibiting the cytolytic function of CD8
+
CD57
- 
T-cells and 
increasing the risk of infection (Autran et al. 1991). It is also possible that the expanded CD8
+ 
T-cells are capable of driving the growth of tumour cells. CD8
+
CD57
+ 
T-cells can secrete 
high levels of IFN-γ and TNF-α upon activation which has been shown to promote the 
survival of CLL cells in vitro (Chong et al. 2008, Buschle et al. 1993, di Celle et al. 1994).  
 
Given that the poor prognosis of the inverted ratio group is associated with an 
expansion of a potentially tolerised CD8
+ 
T-cells population over expressing PD-1, it would 
be interesting to know if this PD-1 positive population has specificity for the CLL clone. It 
would also be of great interest to evaluate PD-1 signalling blockade as a potential therapeutic 
strategy to break T-cell tolerance within the disease. Blocking antibodies to PD-1 have 
already been shown to reverse the exhaustive phenotype of HIV-specific PD-1
+
 CD8
+
 T-cells 
allowing the recovery of proliferative and cytotoxic responses (Trautmann et al. 2006). In 
addition PD-1-PDL-1 signalling blockade has been shown to provide clinical benefit in phase 
1 clinical trials of patients with solid and haematological malignancies (Berger et al. 2008, 
Brahmer et al. 2010). 
    The results of this chapter show that there is a clear perturbation in the normal 
lymphocyte populations in CLL patients, including a reduction in the percentages of T-cells 
and an increase in the frequency of regulatory T-cells. Within the CLL patient cohort we also 
identified a subset of patients that display an inversion in the CD4:CD8 T-cell ratio. These 
patients had a preferential expansion in CD8
+
 T-cells displaying a highly differentiated and 
replicative senescent phenotype. Importantly this group of patients had shorter lymphocyte 
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doubling times, representing patients with more progressive disease who are likely to require 
earlier treatment. 
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CHAPTER 4 
Investigating the role of immunosuppressive molecules in CLL 
 
Immunosuppressive molecules, including PD-1 and CD200, have been implicated in 
the suppression of T-cell responses during chronic infections as well as in solid and 
haematological malignancies (Zhang, Gajewski and Kline 2009a, Gao et al. 2009). Sustained 
signalling via these molecules can result in T-cell exhaustion including suppression of T-cell 
proliferation, cytokine release and effector function, whilst facilitating immune escape of 
cancer cells (Norde et al. 2012). Furthermore immunosuppressive molecules may reduce the 
efficacy of current therapeutic strategies aimed at promoting T-cell responses in 
haematological malignancies including vaccination, allo-HSCT and adoptive T-cell therapy 
(Berger et al. 2008).  
This study has previously described a cohort of CLL patients with inferior prognosis 
based on their inversion in CD4:CD8 T-cell ratio. Such patients were found to have a 
preferential expansion of CD8
+
 T-cells skewed towards a highly differentiated effector 
memory phenotype with increased expression of PD-1. PD-1 expression has been associated 
with a replicative senescent phenotype and may contribute to T-cell dysfunction in CLL 
patients thereby impairing immune regulation of the leukaemic clone (Grzywnowicz et al. 
2012). The aims of this chapter were to further investigate the expression of 
immunosuppressive molecules including PD-1 and CD200, and to evaluate their functional 
and clinical significance in CLL patients. 
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4.1 Immunosuppressive molecules in CLL 
Immunosuppressive molecules such as CD200 and PD-1 have been shown to be         
upregulated during chronic infections and in cancer (Dorfman and Shahsafaei 2010, Caserta 
et al. 2012, Zhang et al. 2009a, Day et al. 2006). CD200 is a cell surface glycoprotein found 
on B, T and NK cells that is known to play a role in regulating immune responses. As CD200 
does not possess a cytoplasmic domain with signalling motifs, inhibitory signals are believed 
to be delivered to CD200R expressing cells including myeloid cells (macrophages and 
neutrophils) and T-cells upon CD200:CD200R engagement (Gorczynski et al. 1999, Wang et 
al. 2010). CD200 upregulation has already been demonstrated in haematological 
malignancies including AML and MM, where it is associated with inferior prognosis 
(Moreaux et al. 2006). In accordance with previous work (El Desoukey et al. 2012, Wong et 
al. 2010, Dorfman and Shahsafaei 2010, Rawstron et al. 2010) the expression of CD200 was 
analysed on the surface of CLL cells in this study including analysis of T-cells and NK cells. 
The expression of its receptor (CD200R) was measured on T-cells in a smaller cohort of CLL 
patients to demonstrate the potential for CD200-CD200R inhibition of T-cells in CLL.  
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Figure 4.1. Gating strategy for the identification of B, T and NK cells from CLL 
patients and the measurement of CD200 and CD200R expression. Lymphocytes were 
gated based on forward and side scatter and separated on cell surface expression of CD3 (A-
B). Within the CD3 negative population CD19
+
CD5
+
 B-cells (C) and CD16
+
CD56
+ 
NK cells 
(D) were gated. In the CD3 positive population both CD4
+
 and CD8
+
 T-cells were gated (E). 
CD200 was measured within in B, T and NK cells and CD200R in T-cells as a percentage 
above an isotype control antibody (F-G). The numbers of positive cells were determined 
using flow cytometry and analysis was performed using Flowjo software. 
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4.1.1 CD200 and CD200R expression in CLL patients  
CD200 expression was measured on CD19
+
CD5
+
 B-cells, T-cells and NK cells from 
the blood of CLL patients and healthy age-matched donors (Figure 4.1). The percentage of 
CD200
+
CD19
+
CD5
+
 B-cells from CLL patients was significantly higher than healthy controls 
(Mean: 94.9% VS 40.3% P<0.0001). Analysis of T-cells and NK cells showed significant 
increases in the percentages of CD200 expressing CD8
+
 T-cells (28.4% vs. 8.7%, P=0.02), 
CD4
+
 (42.4% vs. 16.8%, P=0.02) and NK cells (Mean 2.0% vs. 0.7%, P=0.001). 
Measurement of the receptor for CD200 (CD200R) on the surface of T-cells from CLL 
patients and healthy donors showed there was no statistically significant difference between 
both groups (Figure 4.2: CD4
+
 18.8% vs. 16.6%, CD8
+
 10.4% vs. 8.7% respectively). 
     Analysis of T-cells revealed a significant correlation between the percentage 
CD4
+
CD200
+
 T-cells and CD8
+
CD200
+
 T-cells in CLL patients (P<0.0001). A similar 
correlation was shown between the percentage of CD4
+
CD200R
+
 T-cells and CD8
+
CD200R
+
 
T-cells in CLL patients (P<0.0001). In addition no significant correlations were observed 
between the percentages of CD200 and CD200R expressing T-cells within the CD4
+
 T-cell 
population (P=0.14) or CD8
+
 T-cell population (P=0.33) in CLL patients. No correlations 
were seen between the percentages of CD4
+
 (P=0.57) or CD8
+
 T-cells (P=0.50) expressing 
CD200 and CLL cells expressing CD200R in CLL patients (Figure 4.3).    
   Collectively the data presented here shows that CD200 is over expressed in CLL 
patients including on B, T and NK cells when compared to healthy donors. Moreover there 
was a strong correlation between the percentage of CD4
+ 
and CD8
+ 
T-cells expressing either 
CD200 or CD200R in CLL patients. There however appeared to be no link between CD200R 
expression on T-cells and CD200 expression on either T cells or CLL cells.  
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Figure 4.2. CD200 (n=44) and CD200R (n=26) expression on lymphocytes from CLL 
patients compared to healthy age-matched controls (n=12). The numbers of positive cells 
were measured using 8-colour flow cytometry (FACS Canto ІІ). Lymphocytes were gated 
based on forward and side scatter profiles. CD200 expression was measured on CD19
+
CD5
+
 
(CLL patients) and CD19
+ 
(Healthy donors) B-cells, CD3
+ 
T-cells (CD4
+
 and CD8
+
) and 
CD56
+
CD16
+
CD3
-
 (NK cells) and CD200R expression was measured on CD4
+ 
and CD8
+ 
T-
cells. Both CD200 and CD200R expression  was measured as a percentage of expressing 
cells above that of an isotype control. The mean within each group is shown. Statistical 
analysis (Mann-Whitney U test) was carried out using GraphPad Prism.  
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Figure 4.3. Analysis of CD200 and CD200R expression on T-cells and tumour cells in 
CLL patients. Linear regression plots comparing the percentage of CD200 (A) or CD200R 
(B) expressing CD8
+
 T-cells against the percentage of CD200 or CD200R expressing CD4
+
 
T-cells for each patient. (C) Linear regression plots comparing the percentage of CD200R vs. 
CD200 expressing CD4
+
 T-cells within the CLL patient cohort. (D) Linear regression plots of 
the percentage of CD200R vs. CD200 expressing CD8
+
 T-cells within the CLL patient 
cohort. Linear regression plot comparing the percentage of CD200
+
 CD4
+
 (E) or CD8
+
 (F) T-
cells vs. CD200 expressing CLL cells within the CLL patient cohort.  
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4.1.2 Programmed death-1 (PD-1) and its ligand (PDL-1)  
PD-1 is a co-inhibitory molecule expressed on activated B and T-cells and has been 
shown to promote immune tolerance including T-cell anergy (Tsushima et al. 2007). 
Interaction of PD-1 with its respective ligand (PDL-1) found on leukocytes and non-
haematopoietic cells have been shown to inhibit TCR signalling (Sheppard et al. 2004).     
PD-1-PDL-1 ligation promotes the recruitment of the phosphatases SHP-1 and SHP-2 to the 
cytoplasmic tail of PD-1 that subsequently interfere with the phosphorylation of ZAP-70 
(Fife et al. 2009). PDL-1 expression on tumour cells has been shown to suppress PD-1 
expressing tumour-reactive T-cells in solid cancers and may suppress T-cells in 
haematological malignancies including CLL and AML (Zhang et al. 2008, Brusa et al. 2013, 
Berthon et al. 2010). In addition, tumour expression of PDL-1 has also been associated with 
inferior clinical outcome in several solid cancers including gastric and ovarian cancer (Hino 
et al. 2010). 
         PDL-1 engagement with PD-1 has not only been shown to interfere with TCR 
signalling but may also deliver signals to PDL-1-expressing cells (Keir et al. 2008). Soluble 
PD-1 has been shown to induce IL-10 production from CD4
+
 T-cells in rheumatoid arthritis 
(Dong et al. 2003). In addition PDL-1 on T-cells is able to bind CD80 on APCs mediating T-
cell inhibition (Park et al. 2010). Here both PD-1 and its ligand PDL-1 were analysed on the 
surface of T-cells and tumour cells from CLL patients and compared to a cohort of healthy 
age-matched controls (Figure 4.4).     
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4.1.3 PD-1 and PDL-1 expression in CLL patients  
PD-1 expression was significantly increased on CD19
+
CD5
+ 
B-cells (15.3 vs. 2.0%, 
P=0.005), CD4
+ 
T-cells (21.7% vs. 6.3%, P=0.0005) and CD8
+ 
T-cells (18.6 vs. 7.5%, 
P=0.04) from CLL patients compared to healthy aged-matched controls (Figure 4.5). 
Analysis of PDL-1 showed it was decreased on CD19
+
CD5
+
 B-cells (53.8% vs. 72.6%, 
P=0.02) but increased on CD4
+ 
T-cells (34.8 vs. 24.2%, P=0.002) and CD8
+ 
T-cells (31.7% 
vs. 24.5%, P=0.01) from CLL patients compared to healthy controls.  
     Analysis of T-cells showed that there was a significant correlation between the 
percentage of CD4
+
PD-1
+
 T-cells and CD8
+
PD-1
+
 T-cells in CLL patients (P<0.0001). A 
similar correlation was seen when comparing CD4
+
PD-L1
+
 and CD8
+
 PDL-1
+
 T-cells 
(P<0.0001). Furthermore significant correlations were observed between the percentages of 
PD-1 and PDL-1 expressing CD4
+
 T-cells (P=0.0004) and CD8
+
 T-cells (P=0.03) in our 
patient cohort. No correlation was seen between the percentages of CD4
+
 (P=0.41) or CD8
+
 
T-cells (P=0.39) expressing PD-1 and CLL cells expressing PDL-1 in CLL patients (Figure 
4.6).    
     These findings show that PD-1 is over expressed on T-cells from CLL patients 
suggesting T-cells may be subject to PD-1-PDL-1 mediated suppression in this disease. In 
addition PDL-1 was upregulated on T-cells from CLL patients demonstrating the potential for 
an alternative mechanism of T-cell inhibition through PDL-1 ligation on T-cells.  
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    A                                                 B                                           C                             
    
     D       HEALTHY DONOR               CLL PATIENT                                                                                     
                  
    E        
  
Figure 4.4. Gating strategy for measurement of PD-1, PDL-1 and BTLA within CD4
+
 
and CD8
+
 T-cell subsets. The numbers of positive cells were measured using 8-colour flow 
cytometry (FACS Canto ІІ). (A) Lymphocytes were gated based on forward and side scatter 
profiles. (B) Separation of T-cells within lymphocyte population based on CD3 positivity. (C) 
Gating of CD4
+
 and CD8
+
 T-cells within CD3
+
 population. (D) Gating of Naїve, Central 
memory (CM), Effector memory (EM) and EMRA T-cells based on CCR7 and CD45RO 
expression within the CD4
+
 T-cell population. (D) Expression of PD-1, PDL-1 and BTLA 
within each subset of T-cells (Naїve, CM, EM and EMRA) was measured as a percentage 
above an isotype control antibody. 
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Figure 4.5. PD-1 (n=52) and PDL-1 (n=37) expression on lymphocytes from CLL 
patients compared to healthy age-matched controls (n=12). The numbers of positive cells 
were quantified using 8-colour flow cytometry (FACS Canto ІІ). Lymphocytes were gated 
based on forward and side scatter profiles. PD-1 and PDL-1 expression was measured on 
CD19
+
CD5
+
 (CLL patients) and CD19
+ 
(Healthy donors) B-cells, CD4
+ 
T-cells and CD8
+ 
T-
cells. The mean within each group is shown. Statistical analysis (Mann-Whitney U test) was 
carried out using GraphPad Prism.  
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Figure 4.6. Analysis of PD-1 and PDL-1 expression on T-cells and tumour cells in CLL 
patients. Linear regression plots comparing the percentage of PD-1 (A) or PDL-1 (B) 
expressing CD8
+
 T-cells against the percentage of PD-1 or PDL-1 expressing CD4
+
 T-cells 
for each patient. (C) Linear regression plots comparing the percentage of PDL-1 vs. PD-1 
expressing CD4
+
 T-cells within the CLL patient cohort. (D) Linear regression plots of the 
percentage of PDL-1 vs. PD-1 expressing CD8
+
 T-cells within the CLL patient cohort. Linear 
regression plot comparing the percentage of PD-1
+
 CD4
+
 (E) or CD8
+
 (F) T-cells vs. PDL-1 
expressing CLL cells within the CLL patient cohort. (A-B (n=52), C-F (n=29)). 
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4.1.4. PD-1 and PDL-1 expression in T-cell memory subsets 
     In order to determine if the increase in PD-1 and PDL-1 expression seen on T-cells 
from CLL patients was due to an increase in expression in a particular subset of T-cells, 
CCR7 and CD45RO were used to subcategorise T-cells into Naїve, CM, EM and EMRA 
phenotypes in a cohort of 10 CLL patients and 10 healthy donors (Figure 4.6). Analysis of 
PD-1 showed it was predominately expressed in the CM and EM T-cell subsets in the CD4
+ 
and CD8
+
 T-cell compartments. In contrast PDL-1 was predominately expressed in the Naïve 
and CM T-cell subsets in both the CD4
+
 and CD8
+
 T-cell compartments. Comparison of CLL 
patients and healthy donors showed that
 
PD-1 positive cells were significantly increased in 
nearly all CD8
+
 T-cell and CD4
+
 T-cell subsets except the CD4
+
 EMRA population in CLL 
patients. Analysis of PDL-1 positive cells showed they were significantly increased on every 
CD4
+
 T-cell subsets, but only on the Naїve and CM subsets of the CD8+ T-cell population in 
CLL patients. PDL-1 positive cells within the CD8
+
 EM and EMRA populations of CLL 
patients were not statistically different to healthy controls (Figure 4.7).  
     These findings show that PD-1 is predominately expressed on previously activated T-
cells displaying an antigen experienced phenotype including CM and EM T-cells. PDL-1 
however is predominately expressed on naïve and CM T-cells. Comparison of CLL patients 
and healthy donors suggest that PD-1 and PDL-1 are upregulated on multiple T-cell subsets, 
suggesting the potential for immunosuppression through these molecules.  
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PD-1 
 
 
 
PDL-1 
 
 
Figure 4.7. The expression of PD-1 and PDL-1 on Naїve, Central memory, Effector 
memory, and Effector (EMRA) CD8
+
 and CD4
+
 T-cells in CLL patients (n=10) 
compared to healthy age-matched controls (n=10). The numbers of positive cells were 
quantified using 8-colour flow cytometry (FACS Canto ІІ). Lymphocytes were gated based 
on forward and side scatter profiles. CD8
+
 and CD4
+
 T-cell subsets were gated based on their 
expression of CCR7 and CD45RO, Naїve (CCR7+CD45RO-), Central memory (CM) 
(CCR7
+
CD45RO
+
), Effector memory (EM) (CCR7
-
CD45RO
+
) and Effector (EMRA) (CCR7
-
CD45RO
-
). PD-1 expression was then measured on CD4
+
 and CD8
+
 T-cells subsets. The 
ligand for PD-1, PDL-1 was also measured on CD4
+
 T-cell subsets and CD8
+
 T-cell subsets. 
The mean within each group is shown. Statistical analysis (Mann-Whitney U test) was carried 
out using GraphPad Prism. CLL=CLL Patients, HD=Healthy donors. 
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4.1.5 B and T lymphocyte attenuater (BTLA) expression on T-cells in CLL 
 
In order to determine if the upregulation of PD-1 seen in T-cell subsets was part of a 
more generalised upregulation of co-inhibitory molecules, the expression of BTLA on T-cells 
from CLL patients was also measured (Figure 4.4). BTLA was identified in 2003 as a co-
inhibitory molecule with similarities to CTLA-4 and PD-1 (Watanabe et al. 2003). Loss of 
PD-1 or BTLA function results in a predisposition to experimentally-induced autoimmune 
encephalomyelitis in mouse models, suggesting that both molecules play a crucial role in 
maintaining T-cell tolerance (Watanabe et al. 2003, Salama et al. 2003). Analysis of  both 
CD4
+
 and CD8
+
 T-cell from CLL patients showed no difference in BTLA expression when 
compared to healthy age-matched donors (Figure 4.8). Separation of T-cells into subsets, 
based on CCR7 and CD45RO expression, revealed no differences in the percentage of BTLA 
expression in naїve, CM or EMRA CD4+ or CD8+ T-cells between both groups. There was 
however a significant increase in BTLA expression in the EM CD4
+
 T-cells compartment 
(P=0.02) and a trend towards an increase in the CD8
+
 T-cell compartment (P=0.07). 
The data presented here suggests unlike PD-1, BTLA is highly expressed on T-cells 
from CLL patients and healthy age-matched controls. In addition no significant differences in 
BTLA expressing T-cells were observed in CLL patients compared to heathy age matched 
controls suggesting it may not have a role in suppression of T-cells in the disease.  
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Figure 4.8. The expression of BTLA on Naїve, Central memory, Effector memory, and 
Effector (EMRA) CD8
+
 and CD4
+
 T-cells in CLL patients (n=10) compared to healthy 
age-matched controls (n=10). The number of positive cells was measured using 8-colour 
flow cytometry (FACS Canto ІІ). Lymphocytes were gated based on forward and side scatter 
profiles. CD8
+
 and CD4
+
 T-cell subsets were gated based on their expression of CCR7 and 
CD45RO, Naїve (CCR7+CD45RO-), Central memory (CM) (CCR7+CD45RO+), Effector 
memory (EM) (CCR7
-
CD45RO
+
) and Effector (EMRA) (CCR7
-
CD45RO
-
). BTLA 
expression was then measured on CD4
+
 and CD8
+
 T-cells subsets. The mean within each 
group is shown. Statistical analysis (Mann-Whitney test) was carried out using GraphPad 
Prism. CLL=CLL Patients, HD=Healthy donors.  
 
4.1.6 PD-1 expression has no effect on TTFT and PFS in CLL patients  
In order to determine if the presence of PD-1 in CLL patients had an effect on 
prognosis, PD-1 expression was measured on T-cell and PDL-1 on CLL cells was analysed 
and compared to time to first treatment and progression free survival. No correlation was 
found between the percentage of CD4
+
 and CD8
+
 T-cells expression PD-1 and either TTFT 
or PFS. Similiarly no correlation was found between the percentage of PDL-1
+
 CLL cells and 
TTFT and PFS (Figure 4.9).  
Overall these results suggest that PD-1-PDL-1 signalling may not have any effect on 
the prognosis of CLL patients. 
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Figure 4.9. Analysis of the percentage of PD-1
+
 T-cells and PDL-1
+
 CLL cells vs time to 
first treatment (TTFT) and progression free survival (PFS) in CLL patients. Linear 
regression plots comparing the percentage of PD-1
+
 T-cells (CD4
+
 (A) and CD8
+
 (B)) and 
PDL-1
+
 CLL cells (C) against TTFT and PFS of CLL patients 
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4.2 PD-1 is upregulated following activation and appears to be a late activation marker 
 Several studies have shown that PD-1 can be induced on T-cells upon activation 
(Hokey et al. 2008, Barber et al. 2006). In order to see whether PD-1 was also upregulated 
upon T-cell activation in CLL, PBMC cultures were stimulated with CD3/CD28 beads and 
measured for PD-1 expression and other activation markers. The expression of HLA-DR, 
CD69 and PD-1 on CD4
+
 and CD8
+
 T-cells were found to be significantly increased in 
PBMC cultures at both Day 1 and Day 3 following CD3/CD28 bead stimulation (Figure 
4.10A). Furthermore, significantly higher percentages of both CD4
+
 and CD8
+
 T-cells were 
found to express CD69 after CD3/CD28 stimulation at day 1 compared to HLA-DR or PD-1 
confirming CD69 as an early activation marker. In contrast, by day 3 the percentages of both 
CD4
+
 and CD8
+
 T-cells expressing HLA-DR were significantly higher than those expressing 
CD69 (CD4: P= 0.02 and CD8: P= 0.04). PD-1 expression was also found to be expressed on 
significantly fewer CD8
+
 T-cells compared to HLA-DR at day 3 (P= 0.01) (Figure 4.10B). 
These findings show that PD-1 expression can be induced upon T-cell activation in 
CLL and is upregulated late in comparison to activation markers including HLA-DR and 
CD69.  
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Figure 4.10. The expression of HLA-DR, CD69 and PD-1 on T-cells following activation 
with CD3/CD28 beads (n=5). The number of positive cells was measured using 8-colour 
flow cytometry (FACS Canto ІІ). Lymphocytes were gated based on forward and side scatter 
profiles. CD4
+
 and CD8
+
 T-cells were measured within the CD3
+
 gate. (A) HLA-DR, CD69 
and PD-1 expression was measured upon both CD4
+
 and CD8
+
 T-cell populations. The mean 
and standard deviation within each group is shown. (B) Comparative analysis of PD-1, HLA-
DR and CD69 expression on CD4
+
 and CD8
+
 T-cells following CD3/CD28 stimulation. 
Activation marker expression was measured at both day 1 and day 3 timepoints. Statistical 
analysis was performed using a paired t-test. *= (P<0.05), **= (P<0.01) and ***= (P<0.001). 
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4.3 CLL cell activation and upregulation of PDL-1 in response to T-cell activation.  
In order to determine if T-cell activation in PBMC cultures had any effect on bystander 
tumour cells, CLL cells were analysed for the expression of activation markers and 
immunosupressive molecules PDL-1 and CD200 in PBMC cultures treated with CD3/CD28 
beads (Figure 4.11). CLL cells showed a significant increase in CD69
+
 expression in PBMC 
cultures treated with CD3/CD28 beads at day 1 and day 3. This was accompanied by a 
significant upregulation of PDL-1 on CLL cells at day 1 and day 3 after CD3/CD28 bead 
treatment. In contrast, no increase in the percentage of CD200 expressing CLL cells was seen 
under the same conditions  
Collectively the data presented here shows that CLL cells are capable of responding to 
T-activation, upregulating both activation markers and PDL-1.  
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Figure 4.11. The expression of CD69, HLA-DR, PDL-1 and CD200 on CLL cells from 
PBMC cultures treated with CD3/CD28 beads.  The number of positive cells was 
measured using 8-colour flow cytometry (FACS Canto ІІ). Lymphocytes were gated based on 
forward and side scatter profiles. Expression of PDL-1, CD200, HLA-DR and CD69 were 
measured on CLL cells defined by expression of CD19 and CD5. The mean and standard 
divation within each group is shown. Statistical analysis was performed using a paired t-test. 
*= (P<0.05), **= (P<0.01) and ***= (P<0.001). Significance was calculated based on values 
from CD3/CD28 treated cultures compared to untreated cultures at each time point 
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4.4 PDL-1 upregulation on CLL cells in response to T-cell activation can be induced by   
      soluble mediators including the cytokines IL-4.  
To determine whether soluble factors were responsible for the upregulation of PDL-1 
on CLL cells, supernatants from cultures previously treated with CD3/CD28 beads were 
added to CLL B cells purified by negative selection (Figure 4.12). Incubation of CLL cells 
with supernatants from CLL PBMC cultures treated with CD3/CD28 beads induced a 
significant upregulation in CLL cell CD69, HLA-DR and PDL-1 expression compared to 
controls.  
  Given that conditioned media was able to induce the expression of PDL-1 on CLL 
cells, further experiments were carried out to establish which cytokines might be responsible 
for the activation and upregulation of PDL-1 on CLL cells (Figure 4.13). Both IL-4 
(P=0.005) and TNF-α (P=0.03) were found to significantly increase the level of the activation 
marker CD69 on the surface of CLL cells. There was also a significant increase in the 
percentage of PDL-1
+
 CLL cells after incubation with IL-4 (5ng/ml) (P=0.05) and a trend 
towards an increase with TNF-α (10ng/ml) (P=0.09) and IFN-γ (10ng/ml) (P=0.09). In 
addition, 4 out of 5 patients showed increased percentages of PDL-1-expressing CLL cells in 
the presence of IL-10 (5ng/ml) but this did not reach significance (P = 0.11). Interestingly, 
there was a significant decrease in PDL-1 expression on CLL cells after the addition of IL-12 
(5ng/ml) (P=0.04). In contrast, no changes in the percentage of PDL-1-expressing CLL cells 
were observed after the addition of  IL-2 (10 IU/ml) or IL-8 (10ng/ml). 
     These findings show that CLL cells can respond to T-cell derived cytokines including 
IL-4 upregulating activation markers and PDL-1 expression.  
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Figure 4.12. Expression of activation markers CD69 and HLA-DR and PDL-1 on CLL 
cells cultured with conditioned media from PBMC cultures treated with CD3/CD28 
beads. Purified B-cells were incubated with conditioned media from PBMC cultures of 5 
patients treated with or without CD3/CD28 beads. Lymphocytes were gated based on forward 
and side scatter profiles. CLL cells were differentiated based on there expression of CD19 
and CD5. The mean and standard deviation within each group is shown. The data shown 
represents one of three independently performed experiments. Statistical analysis was 
performed using a paired t-test. *= (P<0.05), **= (P<0.01) and ***= (P<0.001).    
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Figure 4.13. CLL cell activation and PDL-1 expression in response to cytokine 
stimulation. Purified B-cells were incubated for 24h in the presence of absence of various 
cytokines (IL-4 (5ng/ml), TNF-α (10ng/ml), IFN-γ (10ng/ml), IL-10 (5ng/ml), IL-12 
(5ng/ml), IL-2 (10 IU/ml) and IL-8 (10ng/ml). The percentage of CD69
+
 and PDL-1
+
 CLL 
cells was measured by flow cytometry. CLL cells were gated based on their co-expression of 
CD19 and CD5 expression. PDL-1 and CD69 expression was then measured within the 
CD19
+
CD5
+
 gate by calculating the percentage of positive cells above isotype controls. 
Statistical analysis was performed using a paired t-test. *= (P<0.05), **= (P<0.01) and    
***= (P<0.001).   
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4.5 Increased PDL-1 expression on CLL cells after CD40L stimulation  
The lymph node microenvironment is thought to play a key role in promoting the 
survival and proliferation of CLL cells through tumour cell interactions with accessory cells 
including T-cells and CD14
+
 nurse-like cells (Burger and Gandhi 2009). A recent study 
showed that PD-1
+ 
T-cells locate close to proliferating CLL cells within the lymph node 
suggesting PD-1:PDL-1 signalling may have an important role in promoting CLL cell 
survival and potentially T-cell dysfunction (Yallop et al. 2010). In order to investigate the 
expression and regulation of immunosuppressive molecules in these areas, CLL PBMCs were 
co-cultured in vitro with a CD40L transfected fibroblast cell line. CD40L trasfected fibroblast 
cells provide CLL cells with pro-survival and activation signals thought to be similiar to 
signals received by CLL cells in the lymph node microenvironment. Co-culture of CLL 
PBMCs on CD40L transfected fibroblasts induced an upregulation of activation markers 
CD69 and HLA-DR and immunosuppressive molcules PDL-1 and CD200 on CLL cells when 
compared to liquid culture and non transfected fibroblast controls (Figure 4.14).  
These results suggest that CD40L stimulation can directly upregulate PDL-1 and 
CD200 in vitro. In turn this suggests that CD40L interactions in the lymph node 
microenvironment could contribute to high expression of immunosuppressive molecules on 
CLL cells.       
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Figure 4.14. Expression of CD69, HLA-DR, CD200 and PDL-1 on CLL cells after co-
culture with NTLs or CD40(TL)s. PBMCs from CLL patients were incubated in liquid 
culture (LC) or co-cultured on non-transfected fibroblast cells (NTL) or fibroblast cells 
transfected with CD40L (CD40L(TL)). The expression of CD69, HLA-DR, PDL-1 and 
CD200 on CLL cells was measured after 24h by flow cytometry. CLL cells were gated based 
on their expression of CD19 and CD5 expression. Statistical analysis was performed using a  
paired t-test. *= (P<0.05), **= (P<0.01) and ***= (P<0.001).   
 
 
4.6 Activation of CLL cells does not induce PD-1 or PDL-1 expression on bystander        
      T-cells 
Given that T-cell activation could induce PDL-1 expression on bystander CLL cells, 
this study looked at whether CLL cell activation could promote PD-1 expression on T-cells. 
T-cells from CLL PBMC cultures incubated in the presence of CD40L transfected fibroblast 
cells were analysed for their expression of activation markers CD69 and HLA-DR and 
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immunosuppressive molecules PD-1 and PDL-1 (Figure 4.15). Analysis of T-cells in these 
PBMC cultures showed that there was no increase in CD69
+
 or HLA-DR
+
 CD4
+
 T-cells in 
response to CLL stimulation with CD40L. In contrast, there was a significant increase in the 
percentage CD8
+
 T-cells expressing CD69 and HLA-DR markers (CD69: P = 0.02 and HLA-
DR: P = 0.02 respectively).    
Analysis of both CD4
+ 
and CD8
+
 T-cells showed no increase in PD-1 expression 
following CD40L stimulation of CLL cells in PBMC cultures compared to contols. As PDL-1 
may also play a role in suppressing T-cells in CLL, PDL-1 expression on T-cells was also 
measured following CD40L stimulation of CLL cells. The percentage PDL-1
+ 
 T-cells 
remained relatively unchanged between PBMC incubated in liquid culture and those co-
cultured on CD40L(TL). 
These data demonstrate that CLL cell activation by itself is unable to promote PD-1 or 
PDL-1 expression on T-cells. It does however provide evidence that CD40L stimulated CLL 
cells have an activating effect on CD8
+
 but not CD4
+
 T-cells..  
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Figure 4.15. Expression of activation markers CD69 and HLA-DR and 
immunosuppressive molecules PD-1 and PDL-1 on T-cells from CLL PBMC co-
cultured with a CD40L transfected cell line. PBMCs from CLL patients were incubated in 
liquid culture (LC) or co-cultured on non transfected fibroblast cells (NTL) or fibroblast cells 
transfected with or CD40L (TL(CD40L)). The expression of CD69, HLA-DR, PDL-1 and 
PD-1 on T-cells was measured after 24h by flow cytometry. T-cells were gated based on their 
expression of CD3 and either CD4 or CD8 surface markers. PD-1, HLA-DR, PDL-1 and 
CD69 expression was then measured on CD4
+
 and CD8
+
 T-cells by calculating the 
percentage of positive cells above isotype controls. Statistical analysis was performed using a  
paired t-test. *= (P<0.05), **= (P<0.01) and ***= (P<0.001).   
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4.7 PD-1 and CD200 blockade does not enhance the activation of T-cells from PBMC         
      cultures treated with CD3/CD28 beads  
Based on the immunosuppressive effects of CD200 and PD-1/PDL-1 in other 
experimental systems (Tsushima et al. 2007, Zhang et al. 2009a, Pallasch et al. 2009, Kretz-
Rommel et al. 2008) blocking antibodies against CD200 and PDL-1 were assessed for their 
ability to enhance T-cell responses in CLL PBMC cultures treated with CD3/CD28 beads 
(Figure 4.16). Neither PD-1 or CD200 blockade had any effect on the expression of the 
activation marker CD69 on CD4
+
 and CD8
+
 T-cells following CD3/CD28 stimulation (Figure 
4.16 A-B). Analysis of CD4
+
 and CD8
+
 T-cell intracellular IFN-  expression after CD3/CD28 
stimulation showed no increase after PDL-1 blockade. In contrast, CD200 blockade led to a 
significant reduction in intracellular IFN-γ production in CD8+ T-cells (P=0.05) and a trend 
towards a reduction in CD4
+
 T-cells (P=0.07) when compared to isotype control cultures 
(Figure 4.16 C-D). Surface CD107 expression was investigated as a marker of CD8
+
 T-cell 
cytotoxic granule release. There was no significant change in CD8
+
 T-cell CD107 expression 
following CD3/CD28 stimulation in the presence of PD-1 or CD200 blocking antibodies 
when compared to isotype controls (Figure 4.16 E).  
    These findings suggest that PD-1-PDL-1signalling blockade in CLL PBMC cultures 
does not effect T-cell activation or IFN- γ expression. CD200 blockade however significantly 
inhibited IFN- γ expression in CD8+ T-cells. 
 
 
 
  CHAPTER 4: RESULTS  
138 
 
  
 
Figure 4.16. T-cell responses to CD3/CD28 stimulation in the presence of PDL-1 and 
CD200 blocking antibodies. T-cells from CLL PBMC cultures were stimulated with 
CD3/CD28 beads and incubated in the presence or absence of a PD-1 or CD200 blocking 
antibody for 48h. The expression of the activation marker CD69 (A-B) and intracellular 
expression of IFN-γ (C-D) were measured on CD4+ and CD8+ T-cells. In addition, surface 
expression of CD107 was measured on CD8
+
 T-cells (E). Statistical analysis was performed 
using a paired t-test. *= (P<0.05), **= (P<0.01) and ***= (P<0.001). 
 
A                                                  B
C                                                  D
E           
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Figure 4.17. Proliferation of T-cells in response to CD3/CD28 stimulation in CLL 
PBMC cultures treated with a CD200 or PDL-1 blocking antibody. CFSE labelled CLL 
PBMC were stimulated with CD3/CD28 beads and incubated for 3 or 7 days in the presence 
or absence of CD200 or PDL-1 blocking antibodies. The percentage of proliferating T-cells 
was measured based on the percentage of CFSE dim T-cells in blocking antibody treated 
cultures. 
 
 
4.8 PD-1 blockade and CD200 blockade have differential effects on T-cell proliferation  
To further investigate the effects of PDL-1 and CD200 on T-cells in CLL, T-cell 
proliferation was assessed as a more stringent measure of T-cell activation. CLL PBMC were 
loaded with CFSE, stimulated with CD3/CD28 beads and incubated in the presence of PDL-1 
and CD200 blocking antibodies (Figure 4.17). At day 3 both CD4
+
 or CD8
+
 T-cells show 
reduced proliferative responses to CD3/CD28 beads in the presence of a PDL-1 or CD200 
blocking antibody when compared to an isotype control.  By day 7 no difference in the 
percentage of proliferating CD4
+
 or CD8
+
 T-cells were observed in cultures receiving the 
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PDL-1 blocking antibody compared to the isotype control. In contrast reduced levels of 
proliferating CD4
+
 and CD8
+
 T-cells were seen after 7 days of incubation with a CD200 
blocking antibody in comparison to an isotype control antibody.  
   These data indicates that PD-1-PDL-1 interactions are not involved in regulating T-cell 
proliferative responses or other T-cell functions in this CLL PBMC system. However, 
blockade of CD200-CD200R interactions appears to affect at least two T-cell functions 
(proliferation and IFN-γ secretion) in CD8+ T-cells.  
 
4.9 Discussion  
CLL cells possess multiple mechanisms of escaping T-cell mediated immunity 
including the secretion of immunosuppressive cytokines, recruitment of regulatory T-cells 
and reduced capacity to act as APCs (Riches et al. 2010). In the last decade another 
immunosuppressive mechanism has come to light, the discovery of co-inhibitory molecules. 
Expressed on both tumour cells and immune effector cells, these molecules have the ability to 
suppress anti-tumour immunity and may hamper current immunotherapeutic strategies for the 
treatment of haematological malignancies including transplantation, adoptive T-cell therapy 
and vaccination (Norde et al. 2012). In this study the expression, regulation and function of 
the immunoinhibitory molecules PD-1 and CD200 were investigated in CLL patients.  
       CD200 has been shown to be over expressed in a number of cancers where 
CD200:CD200R signalling is thought to have a role in regulating anti-tumour immunity 
including down regulation of Th1 type immune responses (Moreaux et al. 2006, Coles et al. 
2011). In accordance with other studies CD200 was shown to be over expressed on 
CD19
+
CD5
+ 
B-cells from CLL patients compared to healthy age-matched controls 
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(McWhirter et al. 2006). Furthermore this study showed that CD200 is over expressed on 
other cell types in CLL including T-cells and NK cells. The significance of CD200 on these 
cell types remains to be determined but their presence shows the potential for CD200-
CD200R signalling in CLL, involving multiple immune effector cells. CD200 signalling is 
mediated through the binding to its receptor CD200R found on monocytes/macrophages and 
T-lymphocytes (Rygiel and Meyaard 2012). The expression of CD200R was measured on T-
cells from CLL patients and found to be slightly but not significantly increased in comparison 
to healthy donors. This suggests that CD200 over expression on tumour cells may be the 
main factor driving CD200-CD200R signalling to T-cells in CLL. The CD200-CD200R 
inhibitory pathway may also act through accessory cells such as DC and monocytes shifting 
Th1 to Th2 cytokine profiles and indirectly effecting T-cell effector function (Gorczynski et 
al. 1999). It would be interesting to analyse the expression of CD200R on these cell types in 
CLL patients to determine if CD200-CD200R signalling may be contributing to their 
immunosuppressed state.  
        PD-1 is an immunoinhibitory molecule which, following ligation to its ligand PDL-1, 
negatively regulates T-cell activation (Sheppard et al. 2004). The role of PD-1 in CLL is 
unknown but phenotypic analysis carried out in this study showed that there was a significant 
increase in PD-1 expression on CD19
+
CD5
+ 
B-cells from CLL patients, which confirmed 
results obtained from previous studies (Xerri et al. 2008, Grzywnowicz et al. 2012). This 
study extended these observations by showing that PD-1 is increased on both CD4
+
 and CD8
+
 
T-cells from CLL patients. In depth analysis of T-cell subsets revealed PD-1 expression was 
predominately increased in EM and CM CD4
+ 
and CD8
+
 T-cell compartments. These results 
reveal the existence a large subset of antigen experienced T-cells in CLL patient that may be 
subject to tolerisation involving PD-1-PDL-1 signalling. PD-1 expression has already been 
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associated with exhaustion/tolerisation of T-cells during chronic viral infections (Day et al. 
2006). Increased expression of PD-1 has been observed on virus-specific CD8
+
 T-cells in 
HIV patients and on CD8
+
 TEM/TEMRA during chronic HCV infection where it has been 
shown to correlate with viral load (Trautmann et al. 2006, Shen et al. 2010).  
      As PD-1 signalling is dependent on interactions with its ligand PDL-1, its expression 
was measured on B and T-cells from CLL patients. Interestingly this study showed a 
significant decrease in PDL-1 on CD19
+
CD5
+
 B-cells from CLL patients compared to 
healthy controls. This result was quite unexpected given that PDL-1 has been shown to be   
upregulated in solid tumours including breast cancer when compared to normal tissue (Keir et 
al. 2008). A previous report in 44 CLL patients however documented similar results to this 
study, showing PDL-1 expression on CLL cells was slightly decreased when compared with 
healthy donors albeit not significantly (Grzywnowicz et al. 2012). Despite this, PDL-1 
expression was detected on over 50% of CLL cells from patients in this study and given the 
abundance of CLL cells compared to T-cells in CLL patients, the potential for PDL-1-PD-1 
signalling would appear to be higher in CLL patients than healthy donors.  
          Several studies have reported the potential for bi-directional signalling upon PD-1 and 
PDL-1 interactions. PD-1 engagement with PDL-1 on DCs inhibited DC activation and 
increased IL-10 production (Kuipers et al. 2006). Similarly increased production of IL-10 has 
been reported from CD4
+
 T-cells expressing PDL-1 in the presence of soluble PD-1 (Dong et 
al. 2003). IL-10 is a cytokine that has previously been shown to inhibit T-cell activation and 
proliferation promoting T-cell tolerance (Akdis and Blaser 2001). The observation that PDL-
1 is significantly increased on T-cells derived from CLL patients suggests that this negative 
regulatory pathway may also play a role in T-cell inhibition in CLL. 
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         The PD-1 and CD200 pathways have emerged as potentially important pathway utilised 
by tumour cells to avoid detection by the immune system. Understanding the mechanisms 
that regulate the expression of these immunoinhibitory molecules may reveal effective 
strategies to block such pathways in CLL. PD-1 was shown to be upregulated on CLL patient 
T-cells after activation and appears to be a late activation marker when compared to HLA-DR 
and CD69. These results support the initial finding that PD-1 is predominantly expressed on 
T-cells displaying an antigen-experienced memory phenotype. A previous report suggested 
that T-cell PD-1 expression in response to acute activation is a transient effect and that these 
T-cells may differ from truly tolerised T-cells that continuously express PD-1 (Grosso et al. 
2009). Further characterisation of PD-1
+
 T-cells from CLL patients, including a systematic 
analysis of exhaustion markers and telomere lengths, may help to differentiate between  
recently activated T-cells and truly exhausted T-cells in CLL patients.  
      In CLL PD-1
+
 T-cells are found at higher frequencies in the lymph nodes than 
peripheral blood where they localise close to proliferating CLL cells (Yallop et al. 2010). 
Such interactions may be crucial for mediating the suppression of T-cells at these sites but 
may also play an important role in supporting the survival and proliferation of CLL cells. 
This study investigated the expression of immunosuppressive molecules on CLL cells in a 
co-culture system in order to mimic the pro-survival conditions of a CLL lymph node. CLL 
cells incubated in these pro-survival co-culture conditions upregulated both PDL-1 and 
CD200 expression. These results indicate that PD-1-PDL-1 and CD200-CD200R signalling 
pathways may be highly prevalent in pro-survival microenvironmental niches.   
       Given that lymph node germinal centres represents an important area for T-cell 
recognition and activation in response to antigen, this study further investigated whether T-
cell activation altered the phenotype of bystander CLL cells. CD3/CD28 stimulation of T-
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cells led to an activation of bystander tumour cells and an upregulation of PDL-1 expression 
but not CD200 on the CLL cell surface. Further investigation revealed that CLL activation 
was driven by the T-cell derived cytokines TNF-α and IL-4, whilst PDL-1 expression was 
driven by IL-4 and possibly IFN-γ, TNF-α and IL-10. An interesting additional experiment 
for this study would be to use blocking antibodies for different cytokines or their receptors to 
confirm the ability of these cytokines to activate and upregulate PDL-1 on CLL cells in vitro.  
        Overall these results indicate that CLL cells are capable of reacting to T-cell activation 
by upregulating immunoinhibitory molecules such as PDL-1; possibly to suppress tumour 
specific T-cell recognition, activation and lysis of CLL cells. Indeed, a recent study showed 
that CD200 and PDL-1 may play a key role in synapse dysfunction between leukaemic cells 
and T-cells, impairing CTL effector function (Ramsay et al. 2012). In addition, PD-1-PDL-1 
signalling may play an important role in germinal centre B-cell survival, whereby B-cell 
PDL-1 engagement with PD-1 on follicular helper T-cells promotes IL-4 and IL-21 
production aiding B-cell survival (Good-Jacobson et al. 2010). Increased numbers of IL-4 
producing T-cells have been previously documented in CLL with IL-4 shown to enhance 
CLL cell survival in vitro (Scrivener et al. 2003, Mainou-Fowler and Prentice 1996). 
Collectively, these studies indicate that the PD-1-PDL-1 signalling pathway may have a 
multi-functional role in the pathogenesis of CLL not only aiding T-cell suppression but also 
potentially supporting the survival of the CLL clone.  
       Therapeutic strategies including the use of blocking antibodies and si-RNA knockdown 
of immunoinhibitory molecules are currently under investigation to enhance both anti-viral 
and anti-tumour immunity (Norde et al. 2012). Previous work in chronic viral infections, 
including HIV, have demonstrated the potential for PD-1-PDL-1 signalling blockade to 
enhance the proliferative and cytokine responses of HIV-specific PD-1
+
CD8
+
 T-cells in vitro 
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(Trautmann et al. 2006, Barber et al. 2006). PD-1 blocking antibodies has also shown 
efficacy in murine leukaemia models and in phase 1 clinical trials in solid cancers and 
haematological malignancies (Zhang et al. 2009a, Brahmer et al. 2010, Berger et al. 2008).  
Although CLL patients have increased percentages of PD-1
+
 T-cells this study showed that 
PDL-1 blockade did not enhance T-cell effector function or proliferative responses in CLL 
PBMC cultures stimulated with CD3/CD28 beads. This result is not completely unexpected 
given that a previous study by Salih et al showed no enhancement of allogeneic T-cell 
responses to leukaemia cells after PDL-1 blockade (Salih et al. 2006). In addition a phase 1 
clinical trial of a PD-1 blocking antibody in patients with advanced haematological 
malignancies, including several CLL patients, showed no increase in activated (CD69
+
) 
lymphocytes or serum pro-inflammatory cytokines including IFN-γ and TNF-α following 
PD-1 blockade. This was despite describing clinical benefit in 33% of patients (Berger et al. 
2008). The failure to enhance T-cell responses following PDL-1 blockade in the current in 
vitro system may be due to several factors. Firstly, it is possible that immunosuppression 
mediated through PD-1 signalling may involve multiple immune and non-immune cells 
which may not be represented in the in vitro model. Secondly, success of PDL-1 blockade 
may require prior conditioning regimens to reduce the CLL tumour burden and remove 
suppressive cell populations including Tregs and myeloid-derived suppressor cells. In the 
clinical trial documented above, all CLL patients received lymphodepleting therapy, 
including irradiation and chemotherapy, prior to administering of the PD-1 blocking antibody 
(Berger et al. 2008). Lastly blockade of the PD-1-PDL-1 signalling pathway may not be 
sufficient by itself to break the suppression of T-cell responses in CLL patients. Exhausted T-
cells have been shown to upregulate several different immunoinhibitory molecules, thus the 
efficacy of PD-1 may be improved through combination therapy with other blocking 
antibodies targeting immunosuppressive molecules such as CTLA-4, LAG-3 and TIM-3. 
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Alternatively PDL-1 blocking antibodies may be better utilised to improve the efficacy of 
other treatment modalities aimed at promoting anti-tumour T-cell responses in cancer patients 
including vaccines, bi-specific antibody therapy and adoptive T-cell therapy. 
       When the effect of a CD200 blocking antibody on T-cell responses was assessed in 
CLL PBMC cultures stimulated with CD3/CD28 beads, CD200 blockade inhibited T-cell 
effector function and proliferation. These data may indicate that CD200 is acting as a co-
stimulatory molecule in CLL rather than a co-inhibitory molecule. These results are 
somewhat contradictory to those previously published by Pallash et al which showed an 
enhancement of T-cell proliferation in response to CD40L stimulated CLL cells and an anti-
CD200 blocking antibody (Pallasch et al. 2009). The disparity between these results may be 
due to difference in the ability of each blocking antibody to antagonize CD200-CD200R 
signalling. In addition CD200 is known to be upregulated on activated T-cells, which may 
make them susceptible to ADCC mechanisms in the presence of certain CD200 blocking 
antibodies. A report by Kretz-Rommel et al demonstrated the potential for CD200 blocking 
antibodies to induce ADCC of activated human T-cells in vitro. Interestingly when they 
engineered the C region of the antibody from IgG1 to a hybrid IgG2/G4 to minimise ADCC 
and CDC effector functions, no lysis of activated T-cells was observed (Kretz-Rommel et al. 
2008). Analysis of cell counts from this study’s blocking experiments revealed reduced cell 
numbers in cultures receiving the CD200 blocking antibody compared to those receiving the 
isotype control. Thus it is possible that ADCC of activated T-cells expressing CD200 may be 
occurring in cultures receiving the CD200 blocking antibody in this study. These 
observations suggest that caution should be used when selecting or engineering blocking 
antibodies targeting immunosuppressive molecules, in order to minimise ADCC of T-cells 
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critical for anti-tumour immunity as well as normal cells expressing CD200 including neural 
cells and glomerular cells (Wright et al. 2001).  
 Unfortunately due to time and funding constraints it was impossible to perform a dose 
response with the blocking antibodies or time course experiments. The results of such 
experiments could provide important information as to whether such antibodies could 
enhance T-cell responses in CLL. It may also be interesting to alter the experimental set-up to 
assess the effects of immunosuppressive molecule blockade. It is possible that the PD-L1 
blocking antibody used was not capable of effectively blocking PD-1-PDL-1 signalling in 
this system and therefore other PDL-1 blocking antibodies should be tested. In addition the 
CD3/CD28 stimulus given in this study may be optimal and independent on interactions with 
CLL cells, therefore preventing enhancement of T-cell responses upon blockade of PD-1. 
However, the results obtained in this chapter suggest that T-cell proliferative and IFN-γ 
responses to CD3/CD28 beads can be at least be affected by CD200 blockade. It may be 
better to assess the effects of PD-1 blockade on T-cells sub-optimally activated with an 
agonist anti-CD3 antibody and titrated doses of an anti-CD28 antibody. In addition PD-1 T-
cells from CLL patients could be flow sorted and used in experiments rather than trying to 
activate and block PD-1 using a mixed population of T-cells in CLL PBMC cultures; which 
may mask any enhancement of PD-1
+
 T-cell responses. Ultimately, the effects of PD-1 
blockade on T-cell responses in CLL may be more appropriately tested in vivo, either in an 
animal model or in clinical trials.  
     In summary, this chapter documents the over expression of the immunosuppressive 
molecules PD-1 and CD200 in CLL patients. Furthermore, it demonstrates the potential for 
immunosuppressive molecules and their ligands to be upregulated following activation of 
both T-cells and CLL cells. Blockade of PD-1-PDL-1 signalling however failed to enhance 
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T-cell responses in vitro whilst CD200-CD200R blockade actually suppressed the response 
of T-cells to CD3/CD28 stimulation. Finally this work highlights the need for caution when 
selecting blocking antibodies targeting immunosuppressive molecules for therapeutic use in 
CLL.  
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CHAPTER 5 
Breaking T-cell tolerance in CLL patients using a bi-specific antibody 
targeting CD3 and CD19  
 
CLL cells are known to possess multiple immunosuppressive mechanisms aimed at 
preventing T-cell activation including defects in immune synapse formation, cytokine 
production and abnormal co-stimulatory and co-inhibitory molecule expression (Riches et al. 
2010). These factors have made it a challenging disease for the successful application of T-
cell immunotherapy. Despite this, several therapeutic strategies aimed at promoting tumour-
specific T-cell responses in vivo have been developed including, vaccine therapies with 
dendritic cells pulsed with CLL cell lysates and adoptive T-cell therapy including CD3/CD28 
activated T-cells and T-cells genetically-modified to express chimeric antigen receptors for 
CD19 (Hus et al. 2005, Porter et al. 2011, Foster, Brenner and Dotti 2008). The widespread 
application of such therapies has however been limited due to several factors including 
technical challenges of ex vivo expansion/genetic modification of cells and the cost of 
preparing such ‘personalised’ therapies. Unlike pharmacologically available drugs, which can 
be processed at one site and supplied to many patients, such ‘personalised’ therapy may 
require local production at specialised cell processing facilities and can only be applied to 
individual patients (Kohn et al. 2011).    
        Over the last 20 years monoclonal antibodies such as rituximab, cetuximab and 
trastuzumab have merged as effective therapeutics for the treatment of various cancers 
(Dougan and Dranoff 2009). The relative success of these antibodies has led to a drive 
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towards designing novel antibody therapies including the development of bi-specific 
antibodies. Blinatumomab is a bi-specific single chain antibody construct classified as a bi-
specific T-cell engager (BiTE). It is formed by the fusion of an anti-CD3 single chain 
variable fragment (scFV) to an anti-CD19 scFV via a short peptide linker. These bi-specific 
antibodies can retarget T-cells expressing CD3 towards tumour cells expressing CD19, 
resulting in activation of cytolytic response mechanisms in T-cells (Chames and Baty 2009). 
Blinatumomab has already shown clinical activity in a phase ІІ trial in relapsed acute 
lymphoblastic leukaemia with 80% of patients achieving a complete molecular response 
(Topp et al. 2011) and in a phase І study in non-Hodgkin lymphoma (NHL) with high 
response rates seen in both patients with indolent and aggressive disease (Bargou et al. 2008). 
In addition ongoing phase ІІ clinical trials are assessing the efficacy and safety of 
blinatumomab in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) due for 
completion 2014.  
       The objectives of this chapter are to assess the potential use of blinatumomab as an 
immunotherapeutic agent in CLL. Several flow cytometry based assays will be used to 
determine whether blinatumomab can overcome the tolerance of CLL patients’ T-cells in 
vitro. This will include measuring T-cell activation, proliferation and cytotoxic response to 
blinatumomab treatment in both treatment naїve patients and patients that have relapsed or 
are refractory to current chemoimmunotherapeutic regimens.  
 
5.1 Blinatumomab activates T-cells from CLL patients 
In order to assess whether blinatumomab could activate T-cells from CLL patients, 
CLL PBMCs were incubated in culture with or without the bi-specific antibody. Two 
concentration of blinatumomab (10 and 100ng/ml) were chosen for testing based on  
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pharmacological doses used in clinical trials in NHL and ALL. T-cells from these cultures 
were then analysed for their expression of activation markers at day 3 and day 7. T-cells from 
blinatumomab treated cultures showed an increase in the expression of the activation markers 
CD38 and HLA-DR (CD4
+
: Figure 5.1A-B, CD8
+
: 5.1D-E) by day 3, which further increased 
by day 7. Analysis of surface CD69 expression on T-cells showed it was also increased, 
peaking at day 3 on CD4
+
 (Figure 5.1C) and CD8
+
 T-cells (Figure5.1F).  
 
 
Figure 5.1. Expression of activation markers CD38, HLA-DR and CD69 on CD4
+
 (A-C) 
and CD8
+
 T-cells (D-F) after blinatumomab treatment (n=4). Activation markers were 
measured on T-cells from CLL PBMC cultures after 3 or 7 days by 8-colour flow cytometry 
(FACS Canto ІІ). Statistical analysis was performed using a paired t-test comparing the level 
of activation markers in blinatumomab treated cultures (10 or 100ng/ml) with untreated 
controls. *= (P<0.05), **= (P<0.01) and ***= (P<0.001). 
 
 
E
x
p
re
s
s
io
n
(M
F
I)
A                           B                            C
D                           E                            F
Timepoint
  CHAPTER 5: RESULTS  
152 
 
5.2 Blinatumomab induces T-cell dependent CLL cell activation.  
Given that blinatumomab can activate T-cells from CLL patients, we went on to assess 
whether CLL cells were also being activated in response to blinatumomab treatment of CLL 
PBMCs. CLL cells were found to have an increased expression of the activation marker 
HLA-DR (Figure 5.2A and C) by day 3 in treated PBMC cultures. To determine whether this 
CLL activation was T-cell dependent, purified CLL cells were also incubated with 
blinatumomab and the expression of HLA-DR assessed. No significant increase in CLL cell 
HLA-DR expression was observed after incubation of purified CLL cells with blinatumomab 
(Figure 5.2B).    
Overall these results demonstrate that blinatumomab can activate T-cells and CLL cells 
in PBMC cultures. The activation of CLL cells was subsequently shown to be T-cell 
dependent.  
 
Figure 5.2. Activation of CLL cells in PBMC cultures treated with blinatumomab. 
Expression of HLA-DR on CLL cells taken from (A) PBMC or (B) purified B-cell cultures 
treated for 3 days with blinatumomab (10ng/ml) was measured using 8-colour flow cytometry 
(n=4). (C) Histogram showing HLA-DR expression on CLL cells taken from PBMC cultures 
treated with or without blinatumomab for 3 days. Unt= untreated, BiTE= Blinatumomab. 
Statistical analysis was performed using a paired t-test. 
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5.3 Blinatumomab mediates T-cell proliferation in primary CLL samples 
To establish whether blinatumomab mediated T-activation also resulted in T-cell 
proliferation, T-cells from CLL PBMC cultures were analysed for expression of the Ki-67 
protein after treatment with blinatumomab. Ki-67 is a nuclear protein present in cells in the 
active phases of cell cycle but absence in resting cells (Urruticoechea, Smith and Dowsett 
2005). Intracellular Ki-67 expression in both CD4
+
 and CD8
+
 T-cells was significantly 
increased in cultures treated with blinatumomab after 3 and 7 days compared to untreated 
controls (Figure 5.3A-C). Interestingly blinatumomab treatment induced significantly more 
cycling CD8
+
 T-cells than CD4
+
 T-cells at day 3 (P=0.04). In order to determine if this T-cell 
cycling was maintained, the percentage of Ki-67 expressing T-cells was compared between 
day 3 and day 7. There was a significant increase in the percentage of Ki-67-expressing CD4
+
 
and CD8
+
 T-cells from day 3 to day 7 after blinatumomab treatment (CD4
+
: P=0.0005, CD8
+
: 
P=0.002). As a positive control PBMC cultures were also activated with CD3/CD28 beads to 
determine the highest level of T-cell proliferation possible. Although T-cell proliferation 
induced by blinatumomab treatment was lower than that induced by CD3/CD28 beads at day 
3, similar levels were achieved by day 7.  
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Figure 5.3. T-cell proliferation after incubation with blinatumomab. PBMCs extracted 
from CLL patients were cultured in the presence or absence of blinatumomab (n=7). 
Intracellular Ki-67 was used as a marker for proliferating CD4
+
 and CD8
+
 T-cells. The 
number of positive cells was measured using 8-colour flow cytometry (FACS Canto ІІ). (A) 
FACS analysis showing the gating strategy used to separate Ki-67+/- T-cells (Left plot: 
untreated control, right plot: 10ng/ml blinatumomab treated). The percentage of Ki-67 
expressing CD4
+
 (B) and CD8
+
 (C) T-cells was determined after incubation of PBMCs with 
blinatumomab (10ng/ml) or CD3/CD28 beads for 3 or 7 days in culture. *= (P<0.05), **= 
(P<0.01) and ***= (P<0.001). Statistical analysis was performed using a paired t-test.  
 
 
5.3.1 Blinatumomab promotes the preferential expansion of T-cells displaying an    
         effector memory phenotype 
To identify the phenotype of T-cells cycling in response to blinatumomab treatment, the 
markers CCR7 and CD45RA were used to divide T-cells into Naїve, CM, EM and EMRA 
subsets (Figure 5.4). Analysis of the CD4
+
 T-cell subset in untreated cultures showed they 
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were predominantly an effector memory phenotype followed by Naїve, CM and EMRA. 
After blinatumomab stimulation there was an initial increase in EMRA CD4
+
 T-cells by day 
3 (P=0.01) but by day 7 only CD4
+
 T-cells with an EM phenotype were increased compared 
to untreated controls (P=0.02). In addition was a significant drop in naїve CD4+ T-cells by 
day 7 (P=0.0098). Similar results were obtained from CD3/CD28 stimulated cultures with an 
increase in EM (P=0.004) and decrease in naїve CD4+ T-cells observed at day 7 (P=0.01, 
Figure 5.4A).    
        Analysis of CD8
+
 T-cells in untreated cultures showed that they are of a predominantly 
EM or and EMRA phenotype with few cells displaying either a Naїve or CM phenotype 
(Figure 5.4B). Blinatumomab induced the expansion of EM T-cells at Day 3 (P=0.03) and 
Day 7 (P=0.0002) whilst EMRA T-cells were reduced at the day 7 timepoint (P=0.0003). No 
significant changes in the percentage of naїve or CM CD8+ T-cells were observed at both 
timepoints. CD3/CD28 stimulated cultures also showed an increase in EM CD8
+
 T-cells at 
day 3 (P=0.0006) and day 7 (P<0.0001). The reduction in EMRA CD8
+
 T-cells was however 
observed earlier at day 3 (P=0.0003) continuing until day 7 (P<0.0001). There was no change 
in naїve T-cells with only a slight increase in CM T-cells seen at day 3.  
    These results show that blinatumomab induces a preferential expansion of T-cells 
displaying an effector memory phenotype within the CD4
+
 and CD8
+
 T-cell compartments by 
Day 7. Concomitantly there was a reduction in the percentage of naїve CD4+ T-cells and 
EMRA CD8
+
 T-cells. A similar trend in CD4
+
 and CD8
+
 T-cell expansions was seen 
following CD3/CD28 stimulation by day 7. 
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Figure 5.4 Blinatumomab preferentially induces the expansion of T-cells with an 
effector memory phenotype. T-cells from PBMCs treated with blinatumomab were stained 
with antibodies against CCR7 and CD45RA and analysed by 8-colour flow cytometry (n=7). 
T-cell subsets were defined as naїve (CCR7+CD45RA+), Central memory (CM) 
(CCR7
+
CD45RA
-
), Effector memory (EM) (CCR7
-
CD45RA
-
) and Highly differentiated 
effector memory (EMRA) (CCR7
-
CD45RA
+
). The percentage of naїve, EM, EMRA and CM 
T-cell subsets in (A) CD4
+ 
T-cells and (B) CD8
+
 T-cells were determined at day 3 and day 7 
post incubation with blinatumomab (10ng/ml) or CD3/CD28 beads. Each bar represents the 
combined data from 7 CLL patients. *= (P<0.05), **= (P<0.01) and ***= (P<0.001). 
Statistical analysis was performed using a paired t-test. 
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5.3.2 Cycling of T-cells subsets in response to blinatumomab treatment 
In order to determine whether the increase in T-cells displaying an EM phenotype was 
due to the preferential proliferation of the EM subset, Ki-67 expression was measured in both 
CD4
+
 and CD8
+
 T-cell compartments after blinatumomab treatment. EMRA T-cells within 
the CD4
+
 compartment and naїve and CM T-cells within the CD8+ T-cell compartment were 
not included in the analysis due to their low frequency. Within the CD4
+
 T-cell population T-
cells with an EM phenotype had the highest percentage of cycling cells (Figure 5.5A) 7 days 
after blinatumomab treatment. When the percentage of cycling cells was compared between 
subsets, there was found to be a higher percentage of cycling EM (P=0.01) and CM (P=0.02) 
compared to naїve CD4+ T-cells. There was also a higher percentage of cycling EM CD4+ T-
cells compared to CM but this did not reach significance (P = 0.19). Within the CD8
+
 T-cell 
compartment the predominant T-cell phenotypes are EM and EMRA. By day 7 virtually all 
of the EM cells were cycling (91%) whereas only a minority of the EMRA cells were cycling 
(20%) within the CD8
+
 T-cell compartment (Figure 5.5B; P=0.0001).   
    These results suggest that the expansion of EM T-cells seen within the CD4
+
 and CD8
+
 
T-cell compartments after blinatumomab treatment is due to an increase in EM T-cell 
proliferation in comparison to other subsets. 
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Figure 5.5 The frequency of cycling CD4
+
 (EM, Naїve and CM) and CD8+ (EM and 
EMRA) T-cells after blinatumomab treatment. PBMC from CLL patients were incubated 
for 7 days in the presence or absence or 10ng/ml blinatumomab (n=7). The percentage of 
cycling (Ki-67
+
) cells were measured within T-cells subsets from CD4
+
 (A) and CD8
+
 (B) T-
cell compartments by flow cytometry. T-cell subsets were defined as Naїve 
(CCR7
+
CD45RA
+
), Central memory (CM) (CCR7
+
CD45RA
-
), Effector memory (EM) 
(CCR7
-
CD45RA
-
) and Highly differentiated effector memory (EMRA) (CCR7
-
CD45RA
+
). 
Each bar represents the combined data from 7 CLL patients. Statistical analysis was 
performed using a paired t-test. 
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      patient PBMCs  
Given that blinatumomab could induce T-cell activation, cytokines were measured to 
determine whether activation resulted in Th1 or Th2 type responses. To identify the types of 
cytokines released after blinatumomab treatment, supernatants from PBMC cultures were 
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were found to be significantly increased in the supernatants of cultures treated for 3 days with 
blinatumomab (Figure 5.7). IFN-γ was increased in 9/10 patients (P=0.03) and TNF-α in 
10/10 patient samples (P=0.02). As a positive control CD3/CD28 beads were used to activate 
T-cells from these PBMC cultures and the supernatant analysed for various cytokines. A 
significant increase in IFN-γ, TNF-α, TNF-β and IL-8 levels were also observed in 
CD3/CD28 bead treated cultures similar to those cultures treated with blinatumomab (Figure 
5.7). Analysis of IL-2, IL-5 and IL-10 showed that they were significantly increased in 
supernatants from CLL PBMC cultures treated with CD3/CD28 beads but not blinatumomab 
(Appendix 1). The remaining cytokines IL-1β, IL-12p70 and IL-4 were found at levels below 
the threshold of detection for this assay in untreated, CD3/CD28 bead and blinatumomab 
stimulated cultures.  
  These results show that blinatumomab treatment can promote the release of pro-
inflammatory cytokines in CLL PBMC cultures. 
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Figure 5.6. Gating strategy used to identify the levels of cytokines present in 
supernatant of PBMC cultures treated with blinatumomab. Cytokine levels were 
measured using 8-colour flow cytometry (FACS Canto ІІ). (A+ C) FACS analysis showing 
the levels of cytokines present in untreated PBMC cultures. (B+ D) FACS analysis showing 
the levels of cytokines in PBMC cultures treated with blinatumomab. Cytokines from top to 
bottom: (A-B) TNF-β, TNF-α, IL-1β, IL-5 and IL-4. (C-D) IL-6, IL-8, IL-10, IL-2, IFN-γ and 
IL-12p70.  
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Figure 5.7. Pro-inflammatory cytokine release from CLL patient PBMCs after 
incubation with blinatumomab. Flow cytometric analysis of cytokines in supernatants 
taken from PBMC cultures treated with or without blinatumomab (n=10). Individual 
concentrations of (A) IFN-γ, (B) TNF-α, (C) TNF-β and (D) IL-8 in the supernatants of 
cultures treated with or without 10ng/ml blinatumomab or CD3/CD28 beads. The mean 
within each group is shown. Statistical analysis was performed using a paired t-test. Each dot 
represents 1 CLL patient and statistical analysis was based on 10 individual patient samples. 
BiTE=10ng/ml blinatumomab treated, CD3/CD28= CD3/CD28 bead treated cultures. 
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5.5 T-cells release cytotoxic granules and express high levels of IFN-γ and TNF-α after  
       incubation with blinatumomab 
To elucidate whether T-cells were the source of the pro-inflammatory cytokines found 
in the supernatants from PBMC cultures, T-cells were analysed for the intracellular 
expression of IFN-γ and TNF-α. There were significantly higher percentages of CD4+ and 
CD8
+
 T-cells expressing IFN-γ, TNF-α or both cytokines after treatment with blinatumomab 
(Figure 5.8A-B). The percentage of T-cells expressing IFN-γ was higher than that of TNF-α 
expressing T-cells (CD4
+
: P=0.04, CD8
+
: P=0.04). 
The ability of blinatumomab to activate the cytolytic response mechanisms of T-cells 
was measured by staining for the intracellular expression of granzyme B in both CD4
+
 and 
CD8
+
 T-cell subsets. There was a significant increase in the percentage of CD8
+
 (P=0.03) and 
CD4
+
 (P=0.004) T-cells expressing granzyme B in PBMC cultures treated with 
blinatumomab compared to controls (Figure 5.8C and F). Further analysis revealed there was 
significantly more CD8
+
 T-cells expressing granzyme B post blinatumomab treatment 
compared to CD4
+
 T-cells (P=0.03). In order to assess whether or not T-cells were releasing 
granzyme B, surface expression of the degranulation marker CD107 was measured (Figure 
5.8D and G).The percentage of CD4
+
 (P=0.01) and CD8
+
 (P=0.0004) T-cells expressing both 
granzyme B and surface CD107 increased after blinatumomab treatment. Statistical analysis 
showed that the percentage of CD8
+
 T-cells expressing both granzyme B and CD107 were 
significantly higher than that seen in the CD4
+
 T-cell population (P=0.04). PBMC cultures 
treated with CD3/CD28 beads were included as a positive control for the measurement of T-
cell cytokines (IFN-γ and TNF-α) and markers of cytolytic activity (Granzyme B and 
CD107). CD3/CD28 beads induced similar levels of IFN-γ and TNF-α expression and 
granzyme B release from CD4
+
 and CD8
+ 
T-cells.  
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These findings show that blinatumomab treatment of PBMC cultures increases IFN-γ 
and TNF-α expression and granzyme B release from CD4+ and CD8+ T-cells similar to 
PBMC cultures treated with CD3/CD28 beads.  
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Figure 5.8 Blinatumomab treatment increases Th1 type cytokine expression and 
cytotoxic granule release from T-cells. Multicolour flow cytometric analysis of PBMCs 
from CLL patients treated with blinatumomab (n=4). (A-B) The percentage of CD4
+
 and 
CD8
+
 T-cells expressing IFN-γ, TNF-α or both IFN-γ and TNF-α. (C-F) The percentage of 
CD4
+
 and CD8
+
 T-cells expressing granzyme B or granzyme B and surface CD107 after 
treatment with blinatumomab. Statistical analysis was performed using a paired t-test and 
based on the relative levels of cytokines, CD107 and/or granzyme B expression in treated 
cultures compared to untreated controls. *= (P<0.05), **= (P<0.01) and ***= (P<0.001). 
BiTE=10ng/ml blinatumomab treated, CD3/CD28= CD3/CD28 bead treated cultures.  
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5.6 Blinatumomab induced activation of T-cells is CLL cell dependent 
From an immunotherapeutic perspective it is important that blinatumomab does not 
induce T-cell activation and degranulation in the absence of CLL target cells, which could 
result in damage to healthy tissue. Purified T-cells from CLL patients were therefore 
incubated with blinatumomab in the presence or absence of CLL cell for 3 days. Intracellular 
Ki-67 expression was measured in both CD4
+
 and CD8
+
 T-cells, whilst granzyme B and 
surface CD107 were measured from CD8
+
 T-cells (Figure 5.9A-C). There was no increase in 
the percentage of Ki-67 expressing CD4
+ 
or CD8
+ 
T-cells in T-cell cultures treated with 
blinatumomab compared to untreated controls. In contrast, T-cell cultures containing CLL 
cells and blinatumomab showed increased percentages of Ki-67 expressing T-cells in 3 out of 
3 patients (Figure 5.10A-B). Similarly no increase in granzyme B
+ 
or granzyme B
+
CD107
+
 
CD8
+ 
T-cells were observed in T-cell cultures treated with blinatumomab compared to 
untreated controls. T-cell cultures containing CLL cells however showed increased 
percentages of granzyme B
+ 
or granzyme B
+
CD107
+
 CD8
+ 
T-cells after blinatumomab 
treatment (Fig. 5.10C-D). 
These findings show that T-cell activation, proliferation and CD8
+ 
T-cell cytotoxic 
granule release is strictly dependent on the presence of the tumour cells.  
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Figure 5.9. Gating strategy for measurement of Ki-67
+
 and Granzyme B
+
 CD107
+
 CD4
+
 
and CD8
+
 T-cells. T-cells were treated with blinatumomab (10ng/ml) in the presence or 
absence of CLL cells. Multicolour flow cytometric analysis showing the levels of 
intracellular Ki-67 expression in (A) CD4
+
 and (B) CD8
+
 T-cells after 3 days in culture with 
blinatumomab. Intracellular Granzyme B and surface CD107 expression were also measured 
in CD8
+
 T-cells at Day 3 (C). Culture conditions: left panels T-cells and blinatumomab 
(10ng/ml), right panel T-cells, CLL cells and blinatumomab (10ng/ml).   
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Figure 5.10. Blinatumomab induced activation of T-cells is CLL cell dependent. T-cells 
were treated with blinatumomab (10ng/ml) in the presence or absence of CLL cells. The 
percentage of (A) Ki-67
+
 CD4
+ 
and (B) Ki-67
+
 CD8
+
 T-cells were measured after 3 days in 
culture by flow cytometry. Within the CD8
+
 T-cell compartment the percentage of (C) 
Granzyme B
+
 and (D) Granzyme B
+
 CD107
+
 cells were also measured. Each bar represents 
the results obtained from 1 patient (n=3).  
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5.7 Blinatumomab induces the expansion of T-cells and a concomitant reduction in CLL  
      cells in PBMC cultures 
To assess whether the total number of T-cells and CLL cells were changing in PBMC 
cultures treated with blinatumomab, the absolute number of these cell types were measured 
(Figure 5.11). Cultures treated with blinatumomab had a significantly higher absolute number 
of CD4
+
 (P=0.01) and CD8
+
 (P=0.01) T-cells after 7 days when compared to untreated 
controls (Figure 5.12A-B). Significant increases in CD4
+
 and CD8
+
 T-cells were also seen in 
cultures treated with an agonist anti-CD3 antibody or CD3/CD28 beads. Absolute numbers of 
CLL cells were significantly reduced in cultures treated with blinatumomab when compared 
to untreated controls (P=0.002). In contrast, cultures treated with the anti-CD3 antibody 
showed a significant increase in absolute numbers of CLL cells, whilst cultures treated with 
CD3/CD28 beads showed no significant change compared to untreated controls (Fig. 5.12C).  
Comparison of treatment naїve and previous treated patients within the blinatumomab, anti-
CD3 antibody or CD3/CD28 bead treated groups showed no significant differences in 
absolute CLL cell counts. 
In order to determine if the level of T-cell expansion correlated with the amount of CLL 
cell death in the cultures, the change in absolute numbers of CD4
+
 and CD8
+
 T-cells in each 
culture was plotted against the percentage change in CLL cells in treated cultures compared 
to controls (Figure 5.13). There was a significant correlation between the change in absolute 
numbers of CD4
+
 and CD8
+
 T-cells in blinatumomab treated cultures and the reduction in 
CLL cell numbers (CD4: P=0.05, CD8: P=0.04). In cultures treated with the anti-CD3 
antibody or CD3/CD28 beads no such correlation was observed. 
   These observations show that blinatumomab and not anti-CD3 antibody or CD3/CD28 
bead treatment of CLL PBMCs leads to a decrease in absolute numbers of viable CLL cells in 
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both treatment naїve and previous treated patients. Importantly the levels of T-cell 
proliferation in PBMC cultures treated with blinatumomab positively correlated with reduced 
levels of viable CLL cells.  
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Figure 5.11. Gating strategy for the separation of T-cells (CD4
+
 and CD8
+
) and CLL 
cells for absolute count analysis. The number of positive cells was measured using 8-colour 
flow cytometry (FACS Canto ІІ). (A) The lymphocyte population was gated by firstly 
excluding doublets using forward scatter height vs. area (B) followed by gating of 
lymphocytes and absolute count beads using forward and side scatter profiles. (C) T-cells 
were seperated based on their expression of CD4 and CD8 surface markers. (D) CLL cells 
were then gated based on their lack of surface CD4 and CD8 expression and positive 
expression of CD5. (E) Apoptotic cells were excluded based on the expression of Annexin V 
(left panel untreated, right panel 10ng/ml BiTE treated).  
  CHAPTER 5: RESULTS  
171 
 
 
 
Figure 5.12. CLL PBMC cultures showed an increase in absolute numbers of T-cells 
and a decrease in absolute CLL cell numbers after treatment with blinatumomab.       
Absolute numbers of (A) CD4
+
 T-cells, (B) CD8
+
 T-cells and (C) CLL cells were calculated 
from CLL PBMC cultures after 7 days in the presence or absence of blinatumomab 
(10ng/ml). CD3/CD28 beads and an agonist anti-CD3 antibody were included as positive 
controls. Each bar represents the combined results with BiTE and CD3 Ab (n = 15) and 
CD3/CD38 (n = 7) respectively. The mean within each group is shown. Statistical analysis 
was performed using a paired t-test. For this analysis, patients were divided into treatment 
naïve (●) and previously treated patients (◊) respectively. 
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Figure 5.13. Linear regression plots for the percentage change in CLL cells vs. change 
in absolute numbers of T-cells in cultures treated with BiTE, an anti-CD3 antibody or 
CD3/CD28 beads. Linear regression analysis was used to analyse the effect T-cell 
expansions had on the percentage change in CLL cells in response to (A) BiTE (10ng/ml), 
(B) an agonistic CD3 antibody (27.7ng/ml) or (C) CD3/CD28 bead stimulation. Each dot 
represents data obtained from 1 CLL patient. BiTE and CD3 Ab treated (n = 15), CD3/CD28 
treated (n = 7).  
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5.8 Blinatumomab induces CLL cell death by apoptosis that is enhanced in the presence  
      of CD40L 
As CLL cells readily undergo apoptosis in liquid culture, CLL cells were incubated in 
co-culture with a CD40L transfected fibroblast cell line to promote cell survival. In keeping 
with previous findings, CLL cells were found to be protected from apoptosis in the presence 
of both non-transfected mouse fibroblasts (NTLs) and mouse fibroblasts transfected with 
CD40L (TL(CD40L)) when compared to liquid culture (LC) alone (Figure 5.14A). Despite 
the increased survival of CLL cells conferred by co-culture, blinatumomab treatment 
increased the percentage of apoptotic CLL cells in liquid culture (P=0.04) and in co-culture 
with NTLs (P=0.002) or TL(CD40L) (P=0.02, Figure 5.14B). Furthermore, the percentage of 
apoptotic CLL cells induced by blinatumomab in the TL(CD40L) cultures was similar to that 
observed in LC. Interestingly increased percentages of apoptotic CLL cells were observed in 
blinatumomab treated TL(CD40L) cultures compared to TL cultures (BiTE: 10ng/ml P=0.06, 
100ng/ml P=0.05) suggesting that CLL cell activation following CD40L stimulation may 
enhance the effects of blinatumomab (Figure 5.14C). When purified CLL cells were 
incubated in LC in the presence of blinatumomab (10ng/ml) no increase in the percentage of 
Annexin V
+ 
CLL cells was observed when compared to untreated controls (Figure 5.14D, 
P=0.63).  
These findings show that blinatumomab treatment of CLL PBMC cultures leads to an 
increase in the percentage of apoptotic CLL cells in vitro. Importantly these increases in 
apoptotic CLL cells detected after blinatumomab treatment are maintained even in the 
presence pro survival and activation signals.  
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Figure 5.14. Blinatumomab induces CLL cell death in PBMC cultures, which is 
maintained even in the presence of pro-survival signals. PBMCs from CLL patients were 
incubated for 7 days in liquid culture (LC) or co-cultured on fibroblast cells transfected with 
TL(CD40L) (n=7). (A) The percentage of Annexin V
+
 CLL B-cells after 7 days of incubation 
in LC or on NTL or TL(CD40L) (B) The percentage of Annexin V
+
 CLL cells measured in 
cultures treated with or without blinatumomab (10ng/ml). Each graph shows the combined 
data from 7 CLL patients. (C) The percentage of Annexin V
+
 CLL cells above background 
controls in PBMCs treated with blinatumomab (10ng/ml and 100ng/ml) and co-cultured on 
NTL or TL(CD40L). (D) The percentage of Annexin V
+
 CLL cells measured in purified CLL 
cell cultures incubated for 7 days in the presence or absence of blinatumomab (10ng/ml). 
Each dot represents 1 CLL patient (n=4). The mean within each group is shown. Statistical 
analysis was performed using a paired t-test. 
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5.9 Blinatumomab induces clustering of CLL cells around T-cells  
The ability of blinatumomab to bind both CD3 and CD19 is thought to promote the 
bridging of T-cells and tumour cells. In order to determine if this bridging effect would occur 
in CLL, PBMCs from CLL patients were cultured in the presence of blinatumomab and 
visualised by phase contrast microscopy. Incubation of CLL PBMCs with blinatumomab 
caused the formation of cell clusters after 12 hours in culture. These clusters were not 
observed in cultures treated with an anti-CD3 Ab or CD3/CD28 beads (Figure 5.15). 
Interestingly, the size and number of clusters observed after treatment with 100ng/ml BiTE 
compared to 10ng/ml BiTE is indicative of a dose-dependent relationship. In order to identify 
the cellular composition of these clusters, purified CFSE-labelled T-cells (CFSE Red) and 
CLL cells (CFSE Green) were incubated in culture with blinatumomab (Figure 5.16).  
Fluorescence confocal imaging of these clusters showed a single T-cell (Red) surrounded by 
multiple CLL cells (Green, Figure 5.16B). A computer generated 3-D reconstruction of these 
clusters revealed one T-cell closely interacting in a centralised position with 11 CLL cells 
(Figure 5.16C).    
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Figure 5.15 CLL patient PBMCs treated with blinatumomab, an anti-CD3 antibody or 
CD3/CD28 beads.  Phase contrast images taken using light microscopy after 12hours in 
culture. Each image is labelled with the concentration and treatment added to each culture.            
UNT = untreated, BiTE = blinatumomab (10 or 100ng/ml), CD3 = anti-CD3 Ab (27.7 or 
277.7ng/ml) and CD3/CD28 beads. Data represents one of 3 patients tested.  
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Figure 5.16 Visualisation of CLL and T-cell clustering in the presence of blinatumomab. 
T-cells and CLL cells were stained with CFSE (red and green) and visualised after incubation 
for 12 hours in the presence of blinatumomab (100ng/ml). (A) Phase contrast image showing 
a cell cluster formed in the presence of blinatumomab. (B) Visualisation of CLL cells (Green) 
and T-cell (Red) in clusters by confocal microscopy. (C) 3-D reconstruction of cluster using 
imaris imaging software; T-cells (Red) and CLL cells (Green). Results represent images 
obtained from 1 of 3 CLL patients.   
 
5.10 Mechanism of blinatumomab directed T-cell killing of CLL cells  
Taking into account all the information obtained from the experiments detailed above, a 
mechanistic timeline of blinatumomab-directed T-cell killing of tumour cells was developed 
(Figure 5.17). Firstly, blinatumomab engages both CD19 on CLL cells and CD3 on T-cells, 
bringing both cell types into close proximity allowing the formation of T-cell-CLL cell 
conjugates. The delivery of activation signals to T-cells induces their proliferation and 
differentiation into a predominately effector memory phenotype capable of secreting Th1 
type cytokines. This process can take up to 3 days after which T-cells are capable of 
degranulating as evidenced by increased surface expression of CD107, leading to tumour 
cell-directed killing.  
    Like blinatumomab, CD3/CD28 beads can also induce the proliferation of T-cells with 
a predominately effector memory phenotype that are capable of secreting Th1 type cytokines. 
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CD3/CD28 beads however lack the ability to recruit CLL cells to the T-cell surface resulting 
in the failure of secreted granzyme B to enter the CLL cells and induce apoptosis. CLL cells 
therefore continue to survive in these cultures aided by the release of T-cell derived cytokines 
including IFN-γ, TNF-α and IL-8 which have been shown to promote CLL cell survival 
(Buschle et al. 1993, di Celle et al. 1994, Bojarska-Junak et al. 2002).  
     Overall these result indicate that blinatumomab mediated killing of CLL cells is strictly 
dependent on the bridging effect of the antibody between CLL cells and T-cells. Activation 
of T-cells in the absence of T:CLL cell bridging may result in the failure of T-cell cytotoxic 
mechanisms to successful target CLL cells. 
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Figure 5.17. Proposed mechanism of blinatumomab directed T-cell killing of CLL cells. 
(A) Blinatumomab engages both CD19 on CLL cells and CD3 on T-cells bringing both cells 
into close proximity. Activation signals are then delivered to both cell types. (B) Activated T-
cells proliferate and release pro-inflammatory cytokines including IFN-γ and TNF-α whilst 
also differentiating into an effector memory phenotype. (C) Blinatumomab brings effector 
memory T-cells and multiple CLL cells into close proximity, allowing targeted release of 
cytotoxic granules from both CD4
+
 and CD8
+
 T-cells towards the CLL cell surface. (D) 
Cytolytic granules enter the CLL cell inducing death by apoptosis. Blinatumomab disengages 
and is free to bind other T-cells and CLL cells. 
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Figure 5.18. Proposed mechanism of CD3/CD8 bead promotion of CLL cell survival.  
(A) CD3/CD28 beads bind to CD3 and CD28 on the surface of T-cells inducing activation. 
(B) Activated T-cells proliferate and release pro-inflammatory cytokines including IFN-γ and 
TNF-α whilst also differentiating into an effector memory phenotype. (C) CD3/CD28 beads 
bind to effector memory T-cells inducing the release of cytotoxic granules which fail to enter 
and kill CLL cells due to distance between effector and target cells (D) The pro-inflammatory 
milieu of cytokines released by PBMCs upon incubation with CD3/CD28 beads aids the 
activation and survival of CLL cells.   
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5.11 Discussion 
This chapter provides detailed in vitro evidence showing that blinatumomab, a bi-
specific antibody targeting CD3 and CD19, can activate and induce the proliferation of T-
cells from CLL patients in situ without having to provide additional CD28 stimulation or IL-
2. Analysis of T-cell subsets showed that blinatumomab treatment induced the preferential 
expansion of T-cells with an effector memory phenotype; a phenomenon previously reported 
in NHL patients treated with blinatumomab (Bargou et al. 2008). EM T-cells are known to 
have a low-activation threshold and are capable of vigorous proliferation in response to 
stimulation (Sallusto, Geginat and Lanzavecchia 2004), which may explain their preferential 
expansion in blinatumomab-treated cultures. In addition, EMRA T-cells have been shown to 
have a low proliferation potential in comparison to TCM and TEM which supports the loss of 
EMRA T-cells after blinatumomab stimulation, particularly in the CD8
+
 T-cell compartment 
(Sallusto et al. 2004). EM T-cells have also been reported to carry large amounts of perforin 
and are known to display rapid effector function upon stimulation (Sallusto et al. 2004). The 
generation of increased numbers of T-cells displaying an EM phenotype is likely to be 
important for blinatumomab-mediated cytotoxic T-cell responses against CLL cells. In 
colorectal cancer high densities of tumour infiltrating EM T-cells has been associated with 
increased overall survival (Pagès et al. 2005). Furthermore activation of tumour-associated 
CD8
+
 EM T-cells have also been shown to promote tumour destruction and the production of 
tumour specific CD8
+
 T-effector cells in mouse models (Pagès et al. 2005, Kilinc et al. 2009). 
In this regard, it would be interesting to investigate whether the elevated EM T-cell 
population is maintained in CLL cell cultures even after cessation of blinatumomab 
treatment. 
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CD4
+
 and CD8
+
 T-cells activated in response to blinatumomab treatment were shown 
to have increased expression of granzyme B and the surface degranulation marker CD107. 
These observations indicate that blinatumomab is indeed capable of inducing cytotoxic 
responses from CD4
+
 and CD8
+
 T-cells in CLL patients. Traditionally CD4
+
 T-cells are 
thought to provide cytokine and co-stimulatory support to cytotoxic CD8
+
 T-cells, with 
cytotoxic CD4
+
 T-cell responses being relatively rare in healthy subjects (Man et al. 1990). 
However, an expanded population of cytotoxic
+
 CD4
+
 T-cells have been described during 
CMV infection and also in CLL patients (Walton et al. 2010, Casazza et al. 2006). It would 
be of interest to further characterise both the CD4
+
 and CD8
+
 T-cells post blinatumomab 
treatment, potentially giving further insight into how blinatumomab overcomes T-cell 
tolerance in the disease. This may include a detailed analysis of exhaustion and senescence 
markers, the frequency of regulatory T-cells and the expression levels of immunosuppressive 
molecules.    
      In this chapter, blinatumomab treatment induced CLL cell death in PBMC cultures, 
with the level of cell death shown to positively correlate with the degree of T-cell expansion. 
Interestingly, an agonistic CD3 antibody and CD3/CD28 beads were also capable of inducing 
proliferation of T-cells but unlike blinatumomab they did not cause a decrease in CLL cell 
survival. Indeed incubation with the agonistic CD3 antibody led to a significant enhancement 
of CLL survival in culture. This result is not unprecedented given that Patten et al showed 
that stimulation of T-cells with CD3/CD28 beads could increase the viability of CLL cells in 
vitro (Patten et al. 2005). In keeping with these findings we showed that incubation of CLL 
PBMC with CD3/CD28 led to a release of pro-inflammatory mediators including IFN-γ, 
TNF-α and IL-8 which are known to promote the survival of CLL cells in vitro (Buschle et 
al. 1993, di Celle et al. 1994, Bojarska-Junak et al. 2002). Although similar levels of these 
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cytokines were seen in cultures treated with blinatumomab, increased CLL cell death was 
observed in these cultures suggesting that it is not T-cell activation and cytokine release per 
se that promotes CLL cell killing.  
    The disparagy in CLL cell death detected after blinatumomab and CD3/CD28 or CD3 
treatments indicates that the bridging of CLL cells and T-cells mediated by blinatumomab 
may be crucial for promoting the redirection of cytotoxic granules onto the CLL cell surface. 
Light microscope images from this study showed that blinatumomab could induce the 
clustering of CLL PBMCs in vitro. These clusters were subsequently shown to be composed 
of a centralised T-cell surrounded by CLL target cells. As T-cells express multiple CD3 
molecules on their surface it is possible that blinatumomab facilitates the binding of several 
CLL cells to one T-cell allowing cytotoxic molecules to be delivered to multiple targets. 
Importantly, these clusters were not formed in the presence of CD3 or CD3/CD28 beads 
suggesting this bi-specificity is crucial for this T-cell/tumour cell conjugate formation and the 
subsequent cytotoxicity of the CLL cells. This concept is further supported by the fact that 
CD3/CD28 beads can induce granzyme B release from T-cells, but unlike blinatumomab this 
does not result in CLL cell death. Taken together these observations have important 
implications for adoptive T-cell therapy being trialled in CLL as this data suggests that 
transfer of CD3/CD28 activated T-cells will not be effective in treating CLL patients, without 
the bridging between CLL cells and T-cells (Wierda and O'Brien 2001, Ramsay and Gribben 
2008). 
      The efficacy of blinatumomab in PBMC cultures is all the more remarkable given the 
fact that CLL cells typically outnumbered T-cells by up to 50:1, creating very low effector to 
target ratios. Blinatumomab may therefore represent a potential therapy for patients with high 
tumour burdens. Furthermore therapy with blinatumomab may not require prior 
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lymphodepleting regimes; which can restrict patients’ suitability for treatment. The results of 
this study also suggests blinatumomab could have efficacy in patients where treatment 
options are extremely limited, including those patients that have relapsed from first-line 
therapy and those patients with poor prognostic markers including p53 mutations (Appendix 
2).  
Given the potential for activated T-cells to damage healthy tissue it was important to 
show that blinatumomab-mediated T-cell activation and cytotoxic granule release was only 
induced upon binding of T-cells to CLL cells. This study showed that blinatumomab 
mediated T-cell activation, proliferation and cytotoxic granule release from T-cells was 
strictly dependent on the presence of CLL cell targets. A potential side effect of 
blinatumomab could be the elimination of healthy B-cells in CLL patients leading to reduced 
antibody responses. Hypogammaglobulinemia is however a feature of many CLL patients 
and can be managed with donor antibody infusions. Blinatumomab therefore represents a 
highly targeted therapy which may lack the numerous off target toxicities associated with 
chemotherapeutic agents.      
There is a growing appreciation that conventional chemotherapeutic agents have 
significantly less potency against CLL cells found in microenvironmental niches including 
the lymph nodes and bone marrow (Munk Pedersen and Reed 2004). Drug resistance 
conferred by these microenvironmental niches may be responsible for the residual disease 
seen in patients after conventional therapy, which ultimately aids the repopulation of CLL 
cells in the periphery and the eventual relapse of patients. Microenvironmental signals 
including interactions between CLL cells and CD40L-expressing T-cells, stromal and nurse-
like cells are thought to increase the apoptotic-threshold of CLL cells (Plander et al. 2009, 
Burger et al. 2000, Buggins et al. 2010, Hamilton et al. 2012). Furthermore CD40-CD40L 
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interactions have been shown to augment the antigen presenting capacity of CLL cells due to 
increased surface expression of adhesion molecules (CD54) and co-stimulatory molecules 
such as CD80, CD86 and CD70 leading to CLL cell activation and protection from 
fludarabine-mediated killing (Kitada et al. 1999, Ranheim and Kipps 1993, Romano et al. 
1998). Importantly this study showed that CLL cells receiving activation signals through 
CD40-CD40L interactions in a co-culture model system were still susceptible to 
blinatumomab-mediated killing. Indeed it would appear that CD40L-mediated activation of 
CLL cells may augment blinatumomab-induced T-cell killing of CLL cells, possibly due to 
the upregulation of co-stimulatory molecules such as CD80 and CD86 on the CLL cell 
surface enhancing T-cell activation and targeting of CLL cells (Ranheim and Kipps 1993).      
Given these in vitro findings, it seems likely that blinatumomab promotes the formation 
of T-cell-CLL cell conjugates through the bridging of CD3 and CD19. T-cells are both 
activated and proliferate into predominately an EM phenotype, which are capable of 
producing Th-1 type cytokines. These T-cells have cytolytic potential as they produce and 
release granzyme B as evident by the expressing of surface CD107 leading to tumour cell-
directed killing. Importantly this killing mechanism is undiminished even in the presence of 
pro-survival co-culture conditions. 
    In conclusion the bi-specific antibody platform represents a novel immunotherapeutic 
strategy in CLL. Blinatumomab has the ability to overcome T-cell tolerance of CLL cells in 
situ which does not require the ex vivo separation of T-cells or gene transfer technology 
which can be technically challenging. Furthermore, it induces antigen-independent 
autologous T-cell activation in situ resulting in serial T-cell-mediated CLL cell killing. This 
chapter also demonstrates the efficacy of blinatumomab in variety of patients, including those 
who are treatment naїve and those that have relapsed or are refractory to conventional 
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therapy. Finally the data generated from this study strongly supports the clinical development 
of blinatumomab as a therapeutic agent in CLL.  
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CHAPTER 6  
Final Discussion 
 
6.1 Discussion  
Despite recent advances in the treatment of CLL, it still remains an incurable B-cell 
malignancy with a median overall survival time of approximately 10 years regardless of the 
patient’s age at diagnosis. For a proportion of CLL patients, treatment will never be required 
and they may die from causes unrelated to their disease. However for the majority of patients; 
particularly younger patients and those presenting with aggressive disease, their CLL will 
require treatment and they will invariably die from disease related complications (Dearden 
2008).  
 Chemotherapy has traditionally been the backbone to any therapeutic approach in CLL. 
It does not however, induce long-term disease free survival, and patients are at high risk of 
relapsing and developing chemotherapy-resistant disease. Moreover there are relative few 
effective treatments for those patients that do relapse or are refractory to chemotherapy 
including patients with p53 mutations. Novel therapeutic strategies aimed at improving the 
treatment and survival of these types of patients is therefore warranted. 
     CLL remains an attractive model for immunotherapeutic approaches aimed at 
harnessing the body’s natural immune system to target tumour cells. CLL patients have a 
relatively long natural disease course in comparison to other cancers, potentially allowing the 
development and progression of immune responses to tumour cells. Indeed evidence of 
improved clinical responses after the addition of immunotherapy to current chemotherapeutic 
regimes supports the use of such approaches. In addition the potential curative GVL effect 
observed after allo-HSCT, demonstrates that T-cells can recognise and target CLL cells. 
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There are however several obstacles to the successful implementation of immunotherapy in 
CLL including the profound immunosuppression and immune dysfunction associated with 
the disease. Such immune defects including the ability of CLL cells to induce T-cell tolerance 
compromises tumour vaccine and adoptive T-cell therapy, resulting in poor clinical responses 
(Ramsay and Gribben 2008).  
In this study immunophenotypic analysis of T-cells from CLL patients was performed 
in order to better characterise their dysfunction status within the disease. Conceivably better 
identification and understanding of T-cell defects in CLL, may lead to the development of 
novel targeted therapies aimed at restoring T-cell function. Indeed such therapies may 
improve T-cell responses to vaccination and infection as well as potentially restoring tumour 
immunosurveillance in CLL patients. In-depth analysis of CLL patient in this study revealed 
a skewing of T-cells towards a highly differentiated effector memory phenotype with an 
increase in markers associated with limited ability to proliferate and increased propensity to 
undergo apoptosis (Brenchley et al. 2003, Serrano et al. 1997, Weekes et al. 1999, Van den 
Hove et al. 1998). These results provided evidence that T-cells are not simply bystander cells 
in this B-cell malignancy but are subject to chronic stimulation leading to exhaustion.  
 As part of the immunophenotyping study a novel prognostic marker in CLL patients 
based on patients CD4:CD8 T-cell ratio was identified (Nunes et al. 2012). CLL patients 
found to have an inversion in their CD4:CD8 T-cell ratios were shown to have a shorter time 
to first treatment and thus inferior prognosis when compared to normal ratio patients. T-cells 
from the CLL
IR
 patient group had a preferential expansion of antigen experienced CD8
+
 T-
cells with a CD28
-
CD27
-
CD57
+
 and PD-1
+ 
phenotype when compared to the CLL
NR
 group. 
These observations further support a role for T-cells in the pathogenesis of CLL with chronic 
CD8
+
 T-cell stimulation seemingly a feature of poor prognostic patients. 
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Given that most patients in our cohort were stage A, it would have been interesting to 
assess whether the ratio of CD8:CD4 T-cells increased with disease progression by studying 
patients with stage A, B and C disease. In addition, it would be of interest to assess what 
effect treatment with chemotherapy had on the distribution and phenotype of T-cells in CLL 
patients including the CD4:CD8 ratios. This aside, the identification of inverted CD4:CD8 
ratios as a novel prognostic marker in CLL patients represents a significant finding, 
particularly in an age where therapy is becoming increasingly personalised. Currently the 
decision to initiate treatment of CLL patients is based on clinical symptoms indicative of 
disease progression (Gribben 2010) with prognostic markers somewhat sidelined due to 
several reasons. Firstly the multitude of prognostic markers and the lack of clinical trials 
comparing their individual and combined prognostic values have made it difficult to evaluate 
their true potential in CLL treatment. In addition large clinical trials looking at the clinical 
benefit of different therapeutic regimens on patients separated based on various prognostic 
markers are still lacking (Van Bockstaele et al. 2009). It is therefore hard to fully evaluate the 
prognostic power of CD4:CD8 ratios in CLL. Having said that CD4:CD8 ratios remains the 
only prognostic marker to date that is not based on the tumour cell and this study further 
showed it correlates with LDT, which has recently been shown to be the most important 
determinant of TTFT in stage A patients (Pepper et al. 2012). Completion of clinical trials 
evaluating prognostic markers will hopefully allow clinicians to utilise prognostic markers in 
CLL to better predict the prognosis of patients at diagnosis and direct when and what types of 
treatments are given to patients. Such prognostic markers will likely include immunological 
(CD4:CD8 ratio), tumour (LDT, CD38 positivity, IgVh mutational status) and genetic 
(cytogenetic aberrations e.g. deletion 17p or 13q) markers.   
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  One interesting finding from chapter 3 was the identification of PD-1 as a marker that 
is upregulated on a subset of CD8
+
 T-cells within the CLL
IR
 group. Interaction of PD-1 on T-
cells with its ligand PDL-1 has previously been shown to inhibit TCR signalling (Sheppard et 
al. 2004) and may play an important role in maintaining T-cell tolerance in solid and 
haematological malignancies (Zhang et al. 2008, Berger et al. 2008). Conceivably blockade 
of such interactions in CLL may help overcome T-cell tolerance in the disease and may 
restore normal T-cell function including tumour surveillance. This study showed that PD-1 is 
over expressed on T-cells in CLL patients and the ligand for PD-1(PDL-1) on CLL cells can 
be upregulated in response to T-cell derived cytokines including IL-4 and following CD40L 
stimulation in vitro.  
 Unfortunately one drawback to this study was the expression and regulation of PD-
1/PDL-1 could only be analysed on cells obtained from the peripheral blood of CLL patients 
and not from the lymph nodes. The microenvironment of the peripheral blood varies 
considerably from the lymph node where CLL cells are subject to pro-survival and activation 
signals, with proliferating tumour cells co-localising with activated CD4
+
 T-cells in 
pseudofollicles (Patten et al. 2008). It would be interesting to obtain CLL lymph node 
samples, in order to test whether immunosuppressive molecules are over expressed in 
secondary lymphoid organs as well as the peripheral blood and to investigate their potential 
function at these sites.   
 Antibodies capable of blocking the signalling of immunosuppressive molecules have 
recently come under intense investigation as therapeutic molecules in solid and 
haematological malignancies (Berger et al. 2008, Brahmer et al. 2010). Blockade of 
immunosuppressive molecules may overcome tumour cell suppression of T-cells in CLL 
potentially restoring T-cell function. In this study antibody blockade of PD-L1 and CD200 
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signalling was found not to enhance CLL patient T-cell responses in vitro. However given the 
growing number of immune evasion mechanisms known to be utilised by CLL cells to 
suppress T-cell responses including reduced expression of molecules involved in antigen 
presentation, promotion or Treg production and secretion of immunosuppressive cytokines 
(Riches et al. 2010), it is possible that blockade of a single immunosuppressive molecule is 
insufficient to overcome T-cell tolerance in CLL patients (Kater, van Oers and Kipps 2007). 
Indeed it is possible that certain immune evasion strategies in CLL may play more important 
roles in maintaining T-cell tolerance than others. Future investigations are therefore required 
to evaluate the importance of individual immune evasion mechanisms in CLL so therapeutic 
agents can be designed targeting those mechanisms crucial for suppressing T-cell responses.  
 Due to the failure of blocking antibodies targeting known immunosuppressive 
molecules to enhance T-cell responses from CLL patients, this study investigated a more 
direct approach of promoting T-cell activation. Blinatumomab a bi-specific antibody 
targeting CD19 and CD3 has previously been shown to have clinical activity in ALL and 
NHL (Topp et al. 2011, Bargou et al. 2008) but its potential use in CLL was unknown. 
Despite evidence of T-cell exhaustion and suppression in CLL patients (Serrano et al. 1997, 
Wadhwa and Morrison 2006, Pallasch et al. 2009), this study showed that it is possible to 
induce significant activation of T-cells from CLL patients with blinatumomab in vitro. 
Moreover T-cell activation was shown to be accompanied by T-cell proliferation, production 
of pro-inflammatory cytokines and the release of granzyme B from both CD4
+
 and CD8
+
 T-
cells.  
 From the experimental data collected this study was able to outline a mechanism of 
blinatumomab-mediated killing of CLL cells. Blinatumomab likely promotes the formation 
of T-cell/CLL cell conjugates facilitating the activation and proliferation of T-cells into a 
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predominately effector memory phenotype. Confocal microscope images obtained from this 
study provided evidence of these conjugates with tight clustering of CLL cells around a 
centralised T-cell after blinatumomab treatment; a phenomena not seen after anti-CD3 or 
CD3/CD28 stimulation. The bridging effect mediated by the bi-specific antibody appears to 
help direct T-cell cytolytic mechanisms in the form of granzyme B release towards the CLL 
cell surface inducing tumour cell death by apoptosis. This hypothesis was supported by 
evidence of increased CLL cell death in PBMC cultures treated with blinatumomab, which 
was notably absent in cultures treated with anti-CD3 or CD3/CD28beads. In addition, a study 
by Offner et al showed that bi-specific antibodies can mediate T-cell adhesion to target cells 
inducing T-cell signalling and the formation of regular lytic synapses (Offner et al. 2006). 
These findings support the idea that the bridging effect of blinatumomab is crucial for T-
cell/tumour cell conjugate formation and the subsequent cytotoxicity of the CLL cells. It also 
provides evidence that activation of T-cells in the absence of T cell-CLL cell bridging can 
promote CLL cell survival in vitro, which may help explain the poor clinical responses of 
patients receiving autologous T-cells activated with CD3/CD28 stimulation (Hami et al. 
2004, Ramsay et al. 2008).  
 It is likely that future therapeutic agents will be aimed at providing efficacy in all types 
of CLL, including those patients with chemotherapy refractory disease, the frail and elderly 
and those with pre-existing co-morbidities. This study provides evidence that blinatumomab 
may have efficacy not only in treatment naïve patients but also in those patients who are 
refractory or have relapsed from chemotherapy. In addition, blinatumomab appears to work 
even at high target to effector cell ratios. This suggests that prior lympho-depleting regimens 
designed to reduce tumour burden, but which limit the applicability of treatments in the frail, 
elderly and patients with co-morbidities, may not be necessary with blinatumomab therapy. 
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Lastly, evidence obtained from this study suggests that blinatumomab-mediated T-cell 
activation, proliferation and effector function is strictly dependent on the presence of the 
tumour cell, which may minimise off target toxicities. 
 Resistance mechanisms, the potential for clonal evolution and the emergence of tumour 
variants also remain significant obstacles hampering successful implementation of 
therapeutic agents in CLL. As blinatumomab targets CD19, an important co-receptor 
involved in BCR signalling, it seems unlikely that CD19 negative CLL clones would develop 
post treatment. In addition, drug resistance conferred by microenvironmental niches may play 
a crucial role in maintaining residual CLL cell populations after chemotherapy, allowing the 
repopulation of CLL cells in the periphery and contributing to the relapse of CLL patients 
(Foster et al. 2008). Evidence from this study suggests blinatumomab may maintain efficacy 
in pro-survival microenvironmental niches including lymph nodes and bone marrow. These 
observations are supported by results from a clinical trial in NHL patients showing that 
blinatumomab treatment cleared tumour cells from the blood, lymph nodes, spleen and bone 
marrow (Bargou et al. 2008). Overall these in vitro results suggest blinatumomab therapy 
could be highly effective in a wide variety of CLL patients with limited treatment-related 
toxicities and reduced chance of relapse.  
 The logical step forward would be to utilise data generated from this in vitro study to 
set-up a phase 1 clinical trial with blinatumomab here in Cardiff. Analysis of T-cells and B-
cells from the blood of CLL patients, pre and post blinatumomab treatment would allow us to 
determine whether these in vitro results are translated in vivo. It would also be interesting to 
look at the effects of combining blinatumomab with different therapeutic agents. This study 
did investigate the potential synergistic properties of blinatumomab therapy with blocking 
antibodies against immunosuppressive molecules PD-1 and CD200 but was unable to show 
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any enhancement to T-cell responses in vitro. It would however be interesting to look at CLL 
cell survival as an indicator of synergy between these two therapeutic strategies, especially 
given previous in vivo data which suggested single agent blocking antibodies against PD-1 
can provide clinical benefit in patients with haematological malignancies (Berger et al. 2008). 
In addition, it would be of great interest to investigative the potential synergistic properties of 
blinatumomab with lenalidomide or monoclonal antibody therapy (d'Argouges et al. 2009). 
Lenalidomide has previously been shown to induce CLL cell activation and upregulation of 
the co-stimulatory molecule CD80 (Aue et al. 2009). Given that CLL cell activation is 
observed prior to blinatumomab mediated T-cell killing of CLL cells in this study it would be 
interesting to assess both therapeutic agents for synergistic properties in CLL. It is however 
important to note that this study also demonstrates potent T-cell activation with 
blinatumomab as a single agent. Therefore caution should be used when trying to combine 
this type of therapy with other immunostimulatory agents to prevent over activation of the 
immune system in vivo.   
  Bi-specific antibodies aimed at directing T-cell responses towards tumour cells 
displaying specific antigens represents an interesting and widely applicable therapeutic 
strategy for treating cancers. Bi-specific antibodies have advantages over other types of 
immunotherapy designed to enhance T-cell responses in CLL including tumour vaccines and 
adoptive transfer of CD3/CD28 activated T-cells or TCR modified T-cells. Firstly, bi-specific 
antibodies can recognize and bind antigens presented on the tumour cell surface, without the 
need for MHC presentation, meaning they can be used to treat patients irrespective of HLA-
genotype (Chames and Baty 2009). In addition the ability of bi-specific antibodies to 
recognize native surface antigens may limit the effects of tumour immune escape 
mechanisms including defective antigen processing and reduced MHC expression. Such 
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mechanisms are thought to hamper the generation of effective anti-tumour immune responses 
with vaccines or adoptive T-cell therapy. Secondly bi-specific antibodies can recognise non-
protein antigens including carbohydrates and glycolipids allowing for an expanded range of 
tumour antigens that can be potentially targeted. Finally, bi-specific antibodies unlike 
adoptively T-cell therapy do not require the ex vivo expansion or genetic manipulation of T-
cells with lentivirus/retrovirus technologies required for chimeric T-cells that can be 
technicallychallenging. ACT/CAR therapies also require T-cell preparations for each patient 
usually at onsite GMP labs whereas bi-specific antibodies can be produced offsite and can be 
administered to any patient. 
  B-cell malignancies generally represent a promising group of diseases for bi-specific 
antibody therapeutics due to their expression of CD19. CD19 is expressed on virtually all B-
cell lineage leukaemias and lymphomas making it an excellent tumour-associated antigen. In 
addition, it is not present on haematopoietic stem cells or non B-cell lineages therefore 
limiting the chance of off target toxicities. Expanding the bi-specific antibody platform into 
solid cancers however may represent a more difficult challenge. Although many tumour 
antigens have been defined for solid cancers with respect to T-cells, few antibody targets that 
are applicable to a wide range of tumours have been defined. The few defined antigens that 
can be targeted by antibodies are often not consistently expressed between patients, may only 
be expressed on a proportion of tumour cells and may be present to some degree on healthy 
tissue (Igney and Krammer 2002). Despite this, a number of bi-specific antibodies have been 
developed targeting antigens in solid cancers such as EpCAM and HER2/neu (Baeuerle and 
Reinhardt 2009). Future identification of novel cancer antigens by serological testing e.g. 
SEREX, will no doubt aid the development of bi-specific antibodies with new target 
specificities that can be clinical applied in solid cancers.  
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  In conclusion, the results of this study provided clear evidence of T-cell dysfunction in 
CLL patients, including a skewing of T-cells towards a memory phenotype with increased 
expression of exhaustion/senescence markers and immunosuppressive molecules. Moreover, 
it demonstrated the difficulty of trying to enhance T-cell responses from CLL patients using 
blocking antibodies against immunosuppressive molecules to PD-1 or CD200 in vitro. 
Despite these observations, this research did demonstrate the ability of a bi-specific antibody 
called blinatumomab to overcome T-cell tolerance in CLL allowing retargeting of T-cell 
cytotoxic killing mechanisms towards autologous tumours cells in vitro. Such therapy 
appeared to have efficacy not only in treatment naїve patients but also in patients that have 
relapsed or are refractory to current chemotherapy. Finally this research strongly advocates 
progression of blinatumomab into clinical trials as a novel therapeutic agent in CLL. 
 
6.2 The future of immunotherapeutic agents in CLL 
 Immunotherapeutic agents aimed at harnessing the body’s own immune system to 
target cancer cells remain a particularly appealing strategy for the treatment of CLL. The 
successful application of such approaches designed to enhance T-cell responses to CLL cells 
has however been limited due in part to the suppressive effects mediated by the tumour 
microenvironment (Kater et al. 2007). Future advances in our understanding of the tumour 
microenvironment, including identifying the key mechanisms that are utilised by tumour cells 
to suppress T-cells, will likely aid the development of novel therapeutics capable of blocking 
such pathways. In addition, immunotherapeutic agents are now being developed, which 
include bi-specific antibodies that can promote T-cell directed killing of CLL cells through 
mechanisms that minimise the suppressive effects of tumour cells. 
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 It is likely that novel therapeutic agents, which block the suppressive mechanisms of 
the tumour microenvironment will form a key part of any immunotherapeutic strategy aimed 
at enhance anti-tumour immune responses in vivo. In addition, immunotherapy may be used 
alongside other cytotoxic agents, enabling killing of CLL cells through multiple mechanisms 
in order to avoid clonal evolution, the emergence of tumour escape variants and tumour 
relapse. Currently the ‘gold standard’ of treatment for CLL patients involves chemotherapy 
given alongside the monoclonal anti-CD20 antibody rituximab (FCR) (Robak et al. 2010). In 
the future, toxic chemotherapy will most likely be replaced by more targeted therapies with 
an emphasis on investigating in vitro/in vivo their modes of action and potential synergistic 
properties with immunotherapy. Indeed immunotherapy is already being considered 
alongside antagonists of BCR-associated kinases (Bruton’s tyrosine kinase (BTK) and 
PI3Kδ) which have shown promising results in early phase І/ІІ clinical trials in CLL 
(Woyach et al. 2012).  In addition, new and current prognostic factors will become increasing 
important in the management of CLL, helping to identify those patients at risk of rapid 
disease progression, likely to be refractory to treatment and those that have worse overall 
survival. These ‘high risk’ patients may benefit from early treatment prior to the development 
of symptoms (Figure 6.1). 
 In regard to curing CLL, it is difficult to envision a single-agent being used to treat all 
types of CLL patients without the emergence of drug resistant disease. As such it is likely 
immunotherapy including blinatumomab would form part of a multi-strategy approach. Initial 
therapy may be designed to deplete the lymphoid compartments and peripheral blood of CLL 
cells including chemotherapy and BTK inhibitors. Once CLL cell numbers have reached a 
critical threshold, immunotherapy could be employed to eliminate residual CLL cells whilst 
minimising the potential emergence of tumour escape variants. 
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  Future advances in the understanding of CLL, together with extensive clinical trials 
involving immunotherapeutic agents, will no doubt lead to improvements in clinical care and 
ultimately enhance the quality of life of CLL patients.   
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Figure 6.1 Present and future directions of therapy in CLL. Adapted from (Gribben 
2010).  
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Appendix 1  Concentrations of IL-2, IL-5, IL-6 and IL-10 released from CLL patient     
                    PBMCs after incubation with blinatumomab or CD3/CD28 beads. 
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Appendix 2 Characteristic profiles of CLL patients used in the blinatumomab study  
 
ID AGE Binet Stage LDT % CD38 Genetics IGHV Status IGHV Usage % ZAP-70 Treatment 
001 73 A <12 35.0 N 100.00% Vh 3-11 31.6 U 
002 60 B ND ND 13q- ND ND ND U 
003 67 A >12 8.7  ND ND ND 3.4 U 
004 72 A >12 0.4 N ND ND 5.5 U 
005 69 A >12 2.3 13q- 89.00% Vh 3-7 2 U 
006 58 A <12 5.0 N 90.00% Vh 4-34 34 T 
007 83 A >12 0.9 ND 92.00% Vh 3-23 10.3 U 
008 72 A >12 99.0 ND 91.00% Vh 4-61 66 U 
009 65 A >12 6.9 N 89.00% Vh 3-53 1.4 U 
010 73 A <12 10.1 ND 94.00% Vh 4-39 2.4 T 
011 64 A <12 10.5  ND ND ND 3.1 U 
012 53 A <12 19.4 13q- ND ND 0 U 
013 70 A >12 3.3  ND 84.00% Vh 3-11 0.2 U 
014 79 A >12 6.7 ND  ND  ND 1.5 U 
015 61 A >12 0.4 N 90.00% ND 0.6 T 
016 64 A >12 97.0 13q-  99.00% Vh 3-30 43 U 
017 79 A >12 7.0 13q-/17p- ND ND 4 T 
018 78 A >12 ND ND ND ND ND U 
019 82 A <12 2.7 ND 87.00% Vh 3-74 20 U 
020 58 A >12 0.8 13q- ND  19 U 
021 58 A >12 81.0 N 98.00% Vh 3-48 85 U 
022 73 A <12 50.2 N 96.00% Vh 3-48 0.3 T 
023 61 A ND 7.0 ND ND ND 18 U 
024 65 B ND 10 ND ND ND ND U 
025 53 A ND 8.2 13q- ND ND 0.4 U 
026 72 A >12 ND ND ND ND ND U 
027 54 A >12 3.0 13q- 92.00% Vh 3-23 10.3 U 
028 72 A ND ND ND ND ND ND U 
029 78 A >12 ND 6q- ND ND ND T 
030 64 A ND 16.0 Trisomy 12 100.00% Vh 3-23 81 T 
031 66 A >12 2.3 ND ND ND ND T 
032 57 ND ND ND ND ND ND ND U 
033 42 ND >12 ND N ND ND ND U 
034 73 A >12 5.5 Trisomy 12  91.00% Vh 4-34 0.3 T 
035 40 B ND 6.0 11q- 96.00% Vh 4-34 3.6 T 
 
LDT: lymphocyte doubling time; ND: not determined 
13q- and 17p-: any FISH or karyotypic abnormality of 13q or 17p; N: normal cytogenetics 
IGHV status: <98% sequence homology with the closest germline sequence (mutated); 
>98% sequence homology with the closest germline sequence (unmutated) 
